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ATP  adenosine triphosphate  
TG  triglyceride 
FA  fatty acid 
LD  lipid droplet 
CE  cholesterol ester 
WAT  white adipose tissue  
FFA  free fatty acid  
LSEC  sinusoidal endothelial cell 
HSC  hepatic stellate cells  
FAO  Fatty acid oxidation  
SCFA  Short-chain fatty acid 
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PL  phospholipid 
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GLUT  glucose transporter 
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PKB  protein kinase B 
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GLUT2 glucose transporter 2  
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LDLR  LDL receptor  
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G3P  glycerol-3-phosphate  
GPL  glycerophospholipids  
GPAT  glycerophosphate-O-acyltransferases  
LPA  lysophosphatidic acid  
ER  endoplasmic reticulum  
AGPAT 1-acylglycerol-3-phosphate  
PA  phosphatidic acid  
PAP  phosphatidic acid phosphohydrolases  
DG  diglycerides  
PC  phosphatidylcholine  
PE  phosphatidylethanolamine  
DGAT  diglycerol acyl transferase  
VLDL  very low-density lipoprotein 
ATGL  adipose triglyceride lipase  
MGL  monoglyceride lipase  
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TCA  tricarboxylic acid  
FAD  flavin adenine dinucleotide  
NAD  nicotinamide adenine dinucleotide nicotinamide adenine dinucleotide 
CPT  carnitine palmitoyl transferase  
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LCAD  long-chain acyl-CoA dehydrogenase  
MCAD  medium-chain acyl-CoA dehydrogenase  
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AMP  adenosine monophosphate  
mtDNA mitochondrial DNA  
SLC2A2 solute carrier family 2, member A2  
HKVI   Hexokinase IV  
UDP  uridine diphosphate  
PDH  pyruvate dehydrogenase  
PDK  pyruvate dehydrogenase kinase 
LDL  low-density lipoprotein 
HDL  high-density lipoprotein 
SAA  serum amyloid A  
CRP  C-reactive protein  
Hp  haptoglobin  
NF-ĸB  Nuclear factor kappa-light-chain-enhancer of activated B cells  
TNF-α  tumour necrosis factor α 
IL-1ß  Interleukin ß 
ROS  reactive oxygen species  
UV  ultraviolet  
LPS  lipopolysaccharide 
RHD  Rel homology domain  
IKK  Iĸβ kinase  
NEMO  NF-ĸB essential modulator  
PRR  pattern recognition receptors  
TNFR  tumour necrosis factor-receptors  
TLR  Toll-like receptor  
TCR  T-cell receptor  
BCR  B-cell receptor  
LTβR  lymphotoxin ß receptor  
BAFFR B-cell activating factor receptor  
CD40  cluster of differentiation 40 
RANK  receptor activator of nuclear factor κ B  
NIK  NF­ĸB inducing kinase  
HCC  hepatocellular carcinoma  
GSH  glutathione  
C/EBP-β CCAAT-box/enhancer–binding protein-β  
LTB4  dihydroxy leukotriene B4  
PGC-1a peroxisome proliferator activated receptor coactivator 1a  
IL-17  Interleukin-17  
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The metabolic syndrome and obesity are currently reaching pandemic dimensions worldwide. 
The hepatic consequence is an imbalance in fatty acid (FA) homeostasis, which results in 
hepatic lipid accumulation, a critical characteristic of non-alcoholic fatty liver disease (NAFLD), 
the most common chronic liver disease. NAFLD is a highly heterogeneous liver disease that 
ranges from simple steatosis (non-alcoholic fatty liver, NAFL), to non-alcoholic steatohepatitis 
(NASH), which is associated with inflammation and liver injury, and can ultimately lead to 
NASH-driven hepatocellular carcinoma (HCC). Pro-inflammatory cytokines, derived from 
activated immune cells, strongly affect hepatic FA metabolism, and are implicated in NASH 
and NASH-derived HCC. However, underlying molecular mechanisms and signalling 
pathways are not known in detail yet. 
To investigate the influence of NASH-derived inflammatory cytokines on hepatic FA 
metabolism and to study molecular mechanisms as well as involved signalling pathways, I 
established an in vitro NASH model to recapitulate the transition from steatosis to 
steatohepatitis in mouse and human hepatocytes. I used several in vitro and ex vivo 
experimental set-ups including fluorescence and radioactive labelling of lipids, to study 
changes in FA- uptake, de novo synthesis, storage, oxidation, and secretion. In addition, I 
performed fluorescence-based assays to focus on regulations affecting mitochondrial function, 
cell viability, proliferation and associated replication stress, and DNA damage. By using 
CRISPR-Cas based knock out cell models and si-RNA mediated knock downs in hepatocytes, 
as well as treatment of cells with different inhibitors, antagonists, and agonists, I studied 
involved inflammatory and metabolic pathways. To disentangle molecular mechanisms 
induced by FAs and pro-inflammatory cytokines, I performed a multi omics approach including 
lipidome, transcriptome, proteome, phosphoproteome, and thermal proteome profiling.   
I demonstrated that inflammatory cytokines increase FA storage in a NF-ĸB dependent manner 
by interference with catabolic processes. Exacerbated lipid accumulation in hepatocytes 
subsequently promoted mitochondrial dysfunction, apoptotic cell death and compensatory 
proliferation. In addition, inflammatory cytokines induced an inflammatory stress response, 
replication stress, and DNA damage. Importantly, the exposure to inflammatory cytokines 
alone and in combination with FAs lead to the downregulation of genes and proteins involved 
in essential metabolic processes in hepatocytes, not only specific for FA metabolism.  
The understanding of the effect of inflammatory cytokines on metabolic dysregulation and 
transcriptional control of metabolic genes in hepatocytes will help to find possible treatment 






Fettleibigkeit und das metabolische Syndrom, erreichen derzeit weltweit pandemische 
Dimensionen. Die hepatische Manifestation ist ein Ungleichgewicht in der Lipid Homöostase 
welche zu einer Ansammlung von Neutrallipiden in Lipidtröpfchen führt, und ein Hauptmerkmal 
der am häufigsten vorkommende chronischen Lebererkrankung, der nichtalkoholischen 
Fettlebererkrankung (engl.: non-alcoholic fatty liver disease, NAFLD) ist. NAFLD ist eine 
heterogene Lebererkrankung, die von einfacher Steatose bis zu einer Steatohepatitis, (engl.: 
non-alcoholic fatty liver disease, NASH) reicht, die mit Entzündungen und Leberschäden 
verbunden ist und letztendlich zur Entstehung des NASH-induzierten hepatozellulärem 
Karzinoms führen kann. Proinflammatorische Zytokine, die von aktivierten Immunzellen 
stammen, beeinflussen den Fettsäure Metabolismus in Hepatozyten und sind an der 
Entstehung und der Progression zu NASH und NASH-induzierten HCC beteiligt. Die diesen 
Pathologien zugrunde liegenden molekularen Mechanismen und Signalwege, als auch als 
auch die zellulären Grundlagen sind jedoch noch nicht im Detail bekannt. 
Um den Einfluss von entzündlichen Zytokinen auf den Fettsäure Metabolismus in der Leber 
zu untersuchen und molekulare Mechanismen und Signalwege, die daran beteiligt sind, zu 
identifizieren, habe ich ein in-vitro NASH-Modell etabliert, um den Fortschritt von einer 
Steatose zu einer Steatohepatitis in Maus und Humanen Hepatozyten zu rekapitulieren. Ich 
habe verschiedene in-vitro- und ex-vivo-Versuche darunter Fluoreszenz- und radioaktive 
Markierung von Lipiden, um Änderungen in der Fettsäure Aufnahme, der de-novo-Synthese, 
der Speicherung, der Oxidation und der Sekretion zu untersuchen, durchgeführt. Zusätzlich 
führte ich fluoreszenzbasierte Experimente durch, um Regulationen zu untersuchen, die die 
Mitochondrien Funktion, die Lebensfähigkeit der Zellen, die Proliferation und den damit 
verbundenen Replikationsstress sowie die DNA-Schädigung beeinflussen. Unter Verwendung 
von CRISPR-Cas-basierten knock-out-Zellmodellen und si-RNA-basierten Knock-downs 
sowie durch Behandlung der Zellen mit verschiedenen Inhibitoren, Antagonisten und 
Agonisten, untersuchte ich die Beteiligung von verschiedenen Entzündungs- und 
Stoffwechselwegen. Um die durch Fettsäure und proinflammatorische Zytokin-induzierten 
molekularen Mechanismen zu untersuchen, führte ich einen Multi-Omics-Ansatz durch, der 
das Lipidom, das Transkriptom, das Proteom, das Phosphoproteom und das thermische 
Proteom-Profiling umfasste. 
In der hier vorgelegten Doktorarbeit konnte ich zeigen, dass entzündliche Zytokine die 
Fettsäurespeicherung in NF-ĸB-abhängiger Weise erhöhen indem sie katabolische Prozesse 
wie die Oxidation von Fettsäuren inhibierten. Eine verstärkte Lipidakkumulation in Hepatozyten 
induzierte eine mitochondriale Dysfunktion, apoptotischen Zelltod und eine kompensatorische 
Proliferation. Darüber hinaus aktivierten entzündliche Zytokine eine 
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Entzündungsstressreaktion, Replikationsstress und DNA-Schäden. Entzündliche Zytokine 
allein und in Kombination mit Fettsäuren führte zu einer herab Regulierung von Genen und 
Proteinen, die an essenziellen Stoffwechselprozessen in Hepatozyten beteiligt sind, und 
welche nicht nur spezifisch für den Fettsäuremetabolismus sind.  
Die Untersuchung der Wirkung von entzündlichen Zytokinen auf die metabolische 
Dysregulation und Transkriptionskontrolle von metabolischen Genen in Hepatozyten,  trägt 






2.1. Metabolic energy storage 
 
Energy metabolism is the conversion of nutrients into energy, such as adenosine triphosphate 
(ATP), and is essential for virtually all processes related to life and biological systems. Changes 
in energy availability impel organisms to generate storage depots. In times of energy excess 
these storage depots are filled up and are decomposed during times of energy demand 1,2. 
The most common used molecules for metabolic energy storage are triglycerides (TGs), 
consisting of fatty acids (FAs) and glycerol 3. Almost all cells can synthesise and store TGs in 
lipid droplets (LDs) within their cytosol 4. LDs are lipid-rich organelles involved in various 
cellular processes including lipid (TGs and sterols/cholesterol esters (CE)) storage, transport, 
hydrolysis, as well as membrane trafficking and signalling 5,6. Mammals have specialized 
tissues (white adipose tissue (WAT)) and cells (adipocytes) (Figure 1I) for long-term lipid 
storage 1. In times of excess FA availability (Figure 1II), adipocytes store them by esterification 
in form of TGs in LDs. Sustained FA excess leads to increased TG storage resulting in 
adipocyte hypertrophy and thereby to an extension of the storage and fat depot (Figure 1III). 
TG catabolic processes are tightly controlled by adipocyte regulated lipolysis and insulin 
signalling 7. Insulin is a peptide hormone that regulates carbohydrate, fat, and protein 
metabolism by facilitating the uptake and absorption of glucose from blood to adipocytes, 
hepatocytes, and muscle cells. Under homeostatic conditions, insulin inhibits lipolysis in WAT. 
During starvation or energy demand, TGs are destructed leading to free fatty acid (FFA) 
release into the blood stream (Figure 1IV). FFAs in the blood are delivered to peripheral 




Figure 1: Illustration of energy metabolism  
(I) FAs are stored in adipocytes in TGs for long-term storage. (II) Sustained energy excess promotes increased 
storage and leads to the (III) expansion of the fat mass. (VI) In times of energy demand TGs are destructed which 
results in FA release into the bloodstream, and delivery to peripheral organs such as the (V) liver where they are 
used as energy source. 
 
2.2. The liver as central organ of metabolism 
 
The liver is a central metabolic organ that regulates whole body energy and metabolically 
connects several tissues including adipose tissue and skeletal muscle. Main functions of the 
liver include detoxification of metabolites, bile acid production, and the regulation of lipid-, 
carbohydrate-, and protein metabolism. The metabolic activity and function of the liver is tightly 
controlled by nutrients, hormones, and neuronal signals 113. The liver is composed of 
parenchymal cells, hepatocytes, and non-parenchymal cells including hepatic stellate cells 
(HSCs), liver sinusoidal endothelial cells (LSECs), biliary cells (cholangiocytes), and immune 
cells such as Kupffer cells (liver resident macrophages) and intrahepatic lymphocytes 12. 
 
2.2.1. Hepatocyte lipid metabolism 
 
Hepatocytes constitute about 60% of the whole cell mass of in the liver and control critical 
processes such as FA metabolism 12. FAs are essential energy sources, can act as signalling 
molecules and are critical structural components of cellular membranes 4,13,14. They consist of 
a carboxyl group (R-COOH) (Figure 2I) at one end, with an aliphatic chain (hydrocarbons, C-
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H) in between and a methyl group (-CH3) (Figure 2II) at the other end.  The carbon atoms of 
the aliphatic chains following the carboxyl group are labelled according to the Greek alphabet, 
e.g. the first carbon of the aliphatic chain is the α carbon and the second is the ß carbon (Figure 
2I). Fatty acid oxidation (FAO) is also known as ß-oxidation due to the oxidative processes 
taking place at the ß carbon. The last carbon is labelled as ω carbon independent on the length 
of the aliphatic chain (Figure 2II). FAs can be either saturated (contain exclusively C-C bonds) 
(Figure 2A) or unsaturated (contain at least one C=C double bond) (Figure 2B) 9. FAs are 
categorized by their length.  Short-chain fatty acids (SCFA) have aliphatic cains of 6 or less 
carbons, medium-chain fatty acids (MCFA) contain aliphatic chains of 7 to 12 carbons, long-
chain fatty acids (LCFA) consists of aliphatic chains of 13 to 21 carbons and very long chain 
fatty acids (VLCFA) have aliphatic chains of 22 or more carbons 15. Number and position of 
carbon bonds can affect the biological activity of FAs 16. The most common saturated fatty acid 
is the LCFA palmitic acid (C16:0) (Figure 2A) which is the first FA generated by de novo 
synthesis and can be used as precursor for synthesis of other FAs 16,17. Palmitic acid makes 
up about 20-30% of the fat depot in humans and is a major component of TGs in palm oil. It is 
also found in soap, cosmetics, and in food including meat and dairy products 17. Oleic acid 
(C18:1) (Figure 2B) is the most common naturally occurring monounsaturated FA and the 
main component of TGs in olive oil. Oleic acid is primarily found in vegetable oils and fats 18,19. 
 
Figure 2: Illustration of saturated and unsaturated fatty acids  
FAs are composed of a (I) carboxyl group (R-COOH) and a (II) methyl group (-CH3) at each end of an aliphatic 
chain of hydrocarbons, C-H. The carbon atoms of the aliphatic chain are labelled with numbers displaying the length 
of FAs and according to the Greek alphabet, the first carbon of the aliphatic chain is the α carbon, the second is the 
ß carbon and the last is the ω carbon. (A) Saturated FA, palmitic acid contains exclusively C-C bonds and is a LCFA 
that with 16 C atoms, C16:0 (16 is the number of carbon atoms and the 0 is indicating without double bonds). (B) 
unsaturated FA, oleic acid contains (III) one C=C double bond within the aliphatic chain and is also a LCFA with 




Hepatocytes can take up FAs from the circulation (e.g. derived from adipose tissue or dietary 
sources) or can generate them by FA de novo synthesis 20. Once in the cell, FAs are either 
stored, most commonly in form of TGs in LDs but also in phospholipids (PLs) and CEs, or are 
used as energy source and catabolized by mitochondrial FAO (ß-oxidation) 21,22. 
 
2.2.2. Fatty acid uptake and transport 
 
FAs are lipophilic molecules and can potentially diffuse passively through plasma membranes, 
however, this mechanism is concentration dependent, slow, and not efficient. Thus, FA uptake 
is mediated by specific transmembrane proteins e.g. by the scavenger receptor CD36 23, fatty 
acid transport proteins (FATPs), and by plasma membrane (pm) located FA binding proteins 
(FABPpm) (Figure 3I) 242. Intracellular FAs are bound by transport proteins including FABPs 
(Figure 3I) 25. FABPs can influence whole lipid metabolism by shuttling FAs between 
membranes, organelles, and other proteins and enzymes. FABPs can regulate FA binding to 
nuclear receptors such as peroxisome proliferator-activated receptor alpha (PPAR-α) leading 
to its activation. In adipocytes they can also interact with hormone sensitive lipase (HSL), 
involved in TG catabolism, to remove and channel released FAs from TGs 14. 
 
2.2.3. Fatty acid de novo synthesis 
 
FA de novo synthesis is dependent on the nutritional status of the cell, substrate availability, 
and is primarily regulated by transcription 26. Acetyl-coenzyme A (acetyl-CoA) generated by  
glucose catabolism (glycolysis) is the main substrate used for lipogenesis (Figure 3) 16. The 
uptake of glucose is mediated by glucose transporters (GLUT). Once in the cell, glucose is 
phosphorylated by glucokinase (GK) to form glucose-6-phosphate (G6P), and through 
glycolysis, pyruvate is generated (Figure 3II, III). In the mitochondria pyruvate is converted to 
acetyl-CoA by pyruvate dehydrogenase (PDH). Acetyl-CoA is then shuttled into the cytoplasm 
were malonyl-CoA is generated by the acetyl-CoA-carboxylase (ACC). Malonyl-CoA is the 
substrate for FA synthase (FAS) to generate new FAs (Figure 3IV). To adapt to nutrient and 
energy availability, lipid metabolic pathways are tightly regulated, e.g. malonyl-CoA promotes 
lipogenesis and at the same time inhibits FA catabolic processes such as mitochondrial FA 
uptake and oxidation. Palmitic acid can inhibit ACC function and thereby FA de novo synthesis 
13,2727. 
FA de novo synthesis is transcriptionally regulated by glucose and insulin which can act 
synergistically to induce gene expression of lipogenic enzymes 26. The expression of enzymes 
necessary for FA de novo synthesis is controlled by the two transcription factors, carbohydrate 
response element binding protein (ChREBP) and sterol regulatory element binding protein 1c 
(SREBP1c). The transcription factor ChREBP is activated by intermediate and final products 
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of glycolysis, thus induced by elevated glucose levels. ChREBP target genes include ACC, 
FAS, and GLUT 26,28. SREBP1c target genes include FAS and also cholesterol synthesis 
associated genes including HMG-CoA reductase (HMGR) and LDL receptor (LDLR) 29. Insulin 
signalling regulates the activity of SREBP1c 29. SREBP1c activation is dependent on insulin 
receptor signalling induced phosphoinositide-3 kinase (PI3K) and protein kinase B (PKB) 
pathway 30, or by Liver X receptor (LXR) pathway 31,32. 
FAs need to be activated by conversion into acyl-CoA esters by FA activating enzymes to 
enable FA metabolic processes such as TG synthesis and FAO (Figure 3V). FA activating 
enzymes include acyl-CoA synthase (ACS) proteins and FATPs 33 
 
Figure 3: Fatty acid- uptake, transport, de novo synthesis, and activation 
(I) FA uptake by transmembrane proteins, scavenger receptor CD36, FATPs or FABPpm. Within the cell, FAs are 
bound and shuttled by FABPs. (II) Glucose uptake is facilitated by GLUTs. GK phosphorylates (P) glucose to 
generate G6P. (III) By glycolysis pyruvate is generated, transferred into the mitochondria, and converted into acetyl-
CoA by PDH. Acetyl-CoA is transported into the cytoplasm were ACC synthesizes malonyl-CoA the substrate for 
(IV) FAS. (V) FAs are activated by ACS proteins to generate acyl-CoAs. 
 
2.2.4. Fatty acid storage 
 
Activated FAs can be stored in form of TGs by the glycerol-3-phosphate pathway (Figure 4). 
The glycerol-3-phosphate pathway uses glycerol-3-phosphate (G3P) from glycolysis to 
generate either TGs or glycerophospholipids (GPLs) by addition of acyl-CoA 34,35. 
Intermediate substrates that are generated during FA storage can serve as second 
messengers or can be used for phospholipid synthesis to build up cellular membranes 20,34,36. 
The initial step in TG synthesis is catalysed by glycerophosphate-O-acyltransferases 
(GPATs) in which lysophosphatidic acid (LPA) is formed by acetylation of G3P (Figure 4I). 
There are four GPAT isoforms known in mammals. GPAT1 and GPAT2 are highly expressed 
in the liver and localized at the mitochondrial membrane 4,34. Subsequently, 1-acylglycerol-3-
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phosphate (AGPAT) which is located at the ER converts LPA into phosphatidic acid (PA) by 
addition of acyl-CoA. PA can serve as second messenger or as substrate for phospholipid 
synthesis to generate phosphatidylinositol, phosphatidylglycerol, and cardiolipin. PA is 
dephosphorylated by phosphatidic acid phosphohydrolases (PAPs also known as Lipins) to 
generate diglyceride (DG) 34,36. DG can be used as substrate for phospholipid synthesis for 
e.g. phosphatidylcholine (PC), phosphatidylethanolamine (PE), and phosphatidylserine or 
can be used as second messenger 34. In the final step diglycerol acyl transferase (DGAT) 
catalyses the condensation of a DG with a FA acyl-CoA to form a TG (Figure 4I). In 
mammals, two DGAT isoforms are known, DGAT1 is localized at the outer ER membrane.  
DGAT2 is localised at the ER membrane and at LDs 4,37,38. Synthesised TGs are either 
stored in form of LDs in the cytoplasm of hepatocytes or they are packed into very low-
density lipoproteins (VLDLs) and exported into the bloodstream and can be subsequently 
stored in adipose tissue 20. 
 
Figure 4: Triglyceride metabolism 
(I) For FA storage in form of TGs, GPAT adds an acyl-CoA to glycerol-3-phosphat to generate LPA. Then AGPAT 
adds an acyl-CoA to LPA to synthesizes PA which is subsequently dephosphorylated by PAP to generate DG. 
DGAT adds another acyl-CoA to DG for TG synthesis. (II) TGs are catabolized by lipolysis, facilitated by ATGL, 
HSL, and MGL, that subsequently remove the three FAs from the glycerol backbone. 
2.2.5. Lipid droplet metabolism 
 
LDs are composed of TGs and CEs that form the neutral lipid core which is coated by a PL 
monolayer (Figure 5) 5. The PL monolayer contains specific LD proteins such as perilipin 
proteins and adipose triglyceride lipase (ATGL) with critical metabolic functions during LD 
formation, lipolysis, endo-, and exocytosis 4,20,39 . The LD size and composition, including lipid 
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species and proteins, greatly varies also within one cell 1. The size of LDs is dependent on the 
cell type. In hepatocytes LD size can range from 0.1µm to 5µm, in adipocytes LDs can range 
from 20µm to 100µm and can constitute most of the cell 5. FFA availability can induce LD 
formation within hours and some LDs can increase their volume up to 3-fold 40. TGs are 
generated at the ER were most enzymes required for synthesis are located. Due to the close 
vicinity of LDs to the ER, the most prominent model for LD biosynthesis describes LD formation 
by budding off the ER 41. LD growth is mediated by LD fusion or LDs can grow by addition of 
TGs to the LD core and PLs to the monolayer 4,40,42,43. 
 
Figure 5: Lipid droplet composition 
LDs consists of a neutral lipid core containing TGs, DGs, and CEs surrounded by a monolayer of PLs with LD 
proteins embedded. 
 
LD catabolism is regulated by two distinct mechanism, lipolysis and lipophagy 44. Lipolysis is 
mediated by specific lipases located in the cytoplasm or at the LD surface including ATGL, 
HSL, and monoglyceride lipase (MGL), that consecutively catalyse the removal of all three FAs 
from the TG (Figure 4II) 5,45,46. FFAs can then serve as energy source by mitochondrial FAO 
or as signalling molecules involved in several cellular processes 47,48. Lipophagy is a specific 
autophagic mechanism used to mobilize and catabolize LDs. Various proteins tightly regulate 
autophagic processes to transport and sequester intracellular components into 
autophagosomes that are composed of double membraned layers. During lipophagy, the 
autophagosome containing LD fuses with the lysosome, leading to the generation of an 
autolysosome where acid lipases facilitate LD breakdown. The rate-limiting lipase ATGL 





2.2.6. Mitochondrial fatty acid oxidation 
 
During energy demand FAs can be used as energy source by mitochondrial or peroxisomal ß-
oxidation that differ in substrate specificity, transport, energy production, and final products 3. 
Mitochondrial FAO is the most common pathway for LCFA breakdown 50. FAO products such 
as acetyl-CoA fuel the tricarboxylic acid (TCA) cycle and ketogenesis 51. Oxidative 
phosphorylation is fuelled by energetic molecules via reduction of nicotinamide adenine 
dinucleotide (NAD) to NADH and flavin adenine dinucleotide (FAD) to FADH2 which drives 
ATP synthesis 50. 
Mitochondrial FAO requires the import of acyl-CoA into the mitochondria which is 
accomplished by the carnitine palmitoyl transferase (CPT) system (Figure 6). The 
mitochondrial membrane consists of an outer and an inner membrane with an intermembrane 
space surrounding the mitochondrial matrix. The CPT system comprises the acyltransferases, 
CPT1 and CPT2, the carnitine acylcarnitine translocase (CACT also known as SLC25A20) and 
requires L-carnitine (Figure 6I). CPT1 is located at the outer mitochondrial membrane and by 
transesterification catalyses the conversion of acyl-CoA to acylcarnitine. Acylcarnitine is then 
transported by CACT across the inner mitochondrial membrane by substitution of free carnitine 
from the mitochondria. CPT2 is located at the inner mitochondrial membrane and reconverts 
acylcarnitine to acyl-CoA 9,50 which can be oxidized by β-oxidation (Figure 6II). Carnitine can 
be generated by carnitine biosynthesis in hepatocytes or can derive from dietary sources such 
as meat and dairy products and is transported by organic cation transporter (OCTN2 also 




Figure 6: Mitochondrial fatty acid oxidation, fatty acid (Acyl-CoA) import into the mitochondrial 
matrix  
(I) CPT1, located at the mitochondrial outer membrane (OM), converts activated fatty acids (FA-Acyl-CoA) to acyl-
carnitine by transesterification. CACT shuttles acyl-carnitine across the inner mitochondrial membrane (IM) into the 
mitochondrial matrix by carnitine exchange. CPT2 reconverts acyl-carnitine into acyl-CoA the substrate for (II) ß-
oxidation where acetyl-CoA, NADH and FADH2 is generated. 
 
2.2.6.1 Mitochondrial ß-Oxidation 
 
FA acyl-CoA is degraded by ß-oxidation inside the mitochondria in four enzymatic reactions 
(Figure 7). The initial step is catalysed by acyl-CoA dehydrogenase converting acyl-CoA to 
trans-2-enoyl-CoA. Subsequent enoyl-CoA hydratase is generating (S)-3-hydroxyacyl-CoA by 
hydration. Then (S)-3-hydroxyacyl-CoA dehydrogenase converts (S)-3-hydroxyacyl-CoA to 3-
ketoacyl-CoA which is cleaved by the enzyme thiolase into acetyl-CoA and two acyl-CoAs with 
shortened carbon chains (Figure 7I-V). FA degradation requires specific enzymes for distinct 
chain-length. Three Acyl-CoA dehydrogenases regulate the catabolism of long- to medium- to 
short-chain acyl-CoAs including very long chain acyl-CoA dehydrogenase (VLCD), long-chain 
acyl-CoA dehydrogenase (LCAD), medium-chain acyl-CoA dehydrogenase (MCAD), and 
short-chain dehydrogenase (SCAD) 9,50. Deficiencies in the CPT system interferes with FAO, 
reduces the generation of acetyl-CoA and mitochondrial energy production 51. Mitochondrial 
FAO is a key metabolic pathway in mammalian organisms for aerobic ATP generation. Several 
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Figure 7: Mitochondrial fatty acid oxidation, ß-oxidation  
(I) Acyl-CoA within the mitochondria is oxidized by acyl-CoA dehydrogenase to (II) trans-2-enoyl-CoA. FAD is 
reduced to FADH2 which is used by mitochondrial respiratory chain for ATP production. Then enoyl-CoA 
hydratase is catalysing the conversion of trans-2-enoyl-CoA to (III) (S)-3-hydroxyacyl-CoA which is subsequently 
converted to (IV) 3-ketoacyl-CoA by (S)-3-hydroxyacyl-CoA dehydrogenase. NAD+ is reduced to NADH that fuels 
the mitochondrial respiratory chain. The enzyme thiolase cleaves 3-ketoacyl-CoA into acetyl-CoA and two acyl-
CoAs with shortened carbon chains that can enter the next ß-oxidation cycle. 
 
FAO is primarily regulated by transcriptional and posttranscriptional mechanisms. PPARs are 
essential transcriptional regulators of metabolic pathways to maintain energy homeostasis 50,54. 
PPARs are nuclear receptors that are activated in response to fasting, by FAs and their 
derivatives. The activation of PPARs leads to nuclear translocation and heterodimer formation 
with the retinoid X receptor (RXR), which allows for binding to peroxisome proliferator response 
elements (PPREs); located in the promoter sites of target genes leading to PPAR-target gene 
transcription. PPARs consist of three family members, PPAR-α (NR1C1), PPAR-β/δ (NR1C2), 
and PPAR-γ (NR1C3) 55. Their expression is heterogeneous and tissue dependent. PPAR-α 
is mainly expressed in tissues with FAO capability including the liver, skeletal muscle, and 
heart. In the liver, PPARα is an essential regulator of mitochondrial, peroxisomal, and 
microsomal FAO 56–58. Overall, lipid metabolic processes in hepatocytes are primarily regulated 
by PPARα 58. The expression of genes involved in FA- uptake, transport, oxidation, and 
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ketogenesis are regulated by PPAR-α activity 59–61. PPAR-α is primarily activated by direct 
ligand binding including FAs, FA derived derivates, and synthetic ligands such as fibrates 
(compounds to treat hyperlipidaemia) 61. PPAR-α target gene transcription is regulated by 
transcription factor hepatocyte nuclear factor 4 alpha (HNF4-α) binding to the PPARα promoter 
in human hepatocytes 62–64. PPARγ is highly expressed in adipose tissues and regulates key 
functions in adipocytes such as cell differentiation and energy storage 65. In skeletal muscle, 
adipose tissue and the heart FAO is controlled by PPARα and PPARβ/δ. In skeletal muscle 
PPARß/δ is involved in the response to exercise 50,66 
An essential post transcriptional regulation of FAO is the inhibition of CPT1A (mainly 
expressed in the liver) and CPT1B (expressed in the muscle and the heart) by cellular malonyl-
CoA levels 2,67. Malonyl-CoA concentration is dependent on the synthesis induced by ACC and 
degradation regulated by malonyl-CoA decarboxylase (MCD). PPAR activation induces MCD 
transcription, thus promoting FAO by reducing malonyl-CoA levels. AMP-activated protein 
kinase (AMPK) is activated by elevated adenosine monophosphate (AMP) levels, to restore 
decreased ATP levels. Activated AMPK inhibits ACC enzymatic activity by phosphorylation 
and is thereby also stimulating FAO 50. 
 
2.2.7. Mitochondrial energy production 
 
Mitochondria are essential for energy production in form of ATP by aerobic respiration, 
biosynthesis of phospholipids, and regulation of calcium signalling, cell growth, proliferation, 
and apoptotic cell death 68. Mitochondria are double membraned bound organelles originated 
by engulfment of an α-proteobacterium by a precursor of an eukaryotic cell 69. Thus, they 
comprise a residual genome, mitochondrial DNA (mtDNA), encoding for proteins involved in 
the regulation of the respiratory chain. An essential function of mitochondria is the oxidation of 
lipids, carbohydrates, and proteins for ATP synthesis 68. Acetyl-CoA generated from pyruvate 
(derived from glycolysis or amino acid catabolism) or FAO within the mitochondria can enter 
the TCA cycle where it is converted to energy molecules such as NADH, GTP, and FADH2. 
NADH is shuttled to the mitochondrial respiratory chain which consists of protein complexes 
(complex I-V) embedded at the inner membrane. The complex I (NADH dehydrogenase) of 
the mitochondrial respiratory chain converts NADH to NAD+, inducing oxidative 
phosphorylation by the electron transfer chain 9. The electron transfer along the respiratory 
chain is regulated by generation of a mitochondrial membrane potential (ΔΨm) through 
pumping protons (H+) from the mitochondrial matrix to the intermembrane space 70. In the final 
step of oxidative phosphorylation, ATP is generated via complex V (ATP synthase) 
phosphorylation of ADP. Changes in the membrane potential caused by cell stress (e.g. 
oxidative stress or ER stress) results in mitochondrial membrane permeabilization which 
promotes cell death 68. 
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2.2.8. Glucose metabolism 
 
Glucose is the primary carbon source used for energy production by glycolysis and the pentose 
phosphate pathway. Carbohydrates derived from dietary sources circulate in the bloodstream. 
Specific transport proteins are required for glucose uptake, export, and trafficking between cell 
membranes and organelles 11,27. In the liver, hepatocytes take up glucose by the glucose 
transporter GLUT2 also known as solute carrier family 2, member A2 (SLC2A2) 11,71. Once in 
the cell, glucose is phosphorylated by GK (Hexokinase IV, HKVI) to generate G6P. In contrast 
to other cells G6P in hepatocytes can be dephosphorylated by glucose-6-phosphatase to 
glucose to ensure availability, if required to maintain blood glucose levels 11,72. In fed state, 
G6P can be stored in form of glycogen by synthesis of glucose 1-phosphate and uridine 
diphosphate glucose (UDP)–glucose. G6P can also generate NADPH and ribose 5-phosphate 
via the pentose phosphate pathway. High intracellular glucose levels lead to glucose catabolic 
processes by glycolysis and synthesis of acetyl-coA from pyruvate in the mitochondria 
promoting FA de novo synthesis. Glucose can be synthesised in hepatocytes by 
gluconeogenesis where amino acids (alanine), lactate or glycerol can serve as substrate and 
by glycogen degradation. Generated glucose can be released from the liver and used as 
energy source by peripheral tissues 27,72. Intermediate substrates from glucose metabolism 
can be used for protein glycosylation, a post-translational protein and lipid modification that 
impacts their activity 11,73. 
 
2.2.9. Glucose and fatty acid catabolism 
 
The liver regulates key metabolic processes by responding to nutrients and hormones. The 
nutritional status regulates hormone secretion and affects anabolic and catabolic processes 
11. Metabolic adaptions are necessary to adjust to physiological changes 74. In times of nutrient 
availability, which leads to elevated glucose levels in the blood, insulin secretion is increased, 
which in turn triggers anabolic processes such as de novo lipogenesis and glycogen synthesis. 
During energy demand, catabolic processes, such as FAO, are induced. FAO induces ketone 
body synthesis to generate an energy source for the brain during times of energy requirement 
11,74. 
The PDH complex is critically involved in the accommodation to nutrient demand and supply 
by regulating FA- and glucose oxidation to maintain blood glucose and ATP levels 74,75. The 
PDH complex converts pyruvate (CoA and NAD+), derived from glycolysis, to acetyl-CoA 
(NADH and CO2). Acetyl-CoA can further enter the TCA and can be used as energy source 
for ATP production or it can be transported into the cytoplasm as substrate for ACC to generate 
malonyl-CoA for FA synthesis. Thus, PDH complex activity promotes glucose catabolism for 
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energy generation. PDH function is inhibited by phosphorylation through pyruvate 
dehydrogenase (PDH) kinases (PDKs) 76. 
PDKs consist of four PDK isozymes (PDK1-4) and their expression is tissue depended. PDK2 
and PDK4 are both expressed in liver 77, and PDK4 is located in the mitochondrial matrix and 
functions as histidine kinase. By PDH phosphorylation, PDK4 interferes with glucose 
catabolism by reducing the conversion of glucose or pyruvate to acetyl-CoA promoting a 
metabolic shift from glucose to FA oxidation. A mechanism to preserve pyruvate for 
gluconeogenesis when glucose is limited 76,78. PDK4 levels are regulated by several 
mechanisms including starvation 79, and activation of PPARs to promote FAO 80. Elevated 
mitochondrial acetyl-CoA levels, NADH from TCA, and ATP from oxidative phosphorylation, 
positively regulate PDK expression and activity. In contrast, PDK4 expression is 
downregulated by e.g. insulin and PI3K/Akt signalling activation, and by the presence of 
pyruvate from glycolysis (or lactate) 74,77. 
 
2.3. Acute and chronic liver inflammation 
 
The liver maintains and restores physiological homeostasis during systemic and local 
inflammation 81. Inflammation can be triggered by physiological disturbances induced by 
pathogens, tissue injury, and tumour growth leading to the activation of immune cells, 
inflammatory cytokine and chemokine secretion, and inflammatory mediator circulation in the 
bloodstream 81–84. Inflammatory cytokines bind to cytokine receptors on several target cells 
which can intensify the inflammatory response and impacts immunological and metabolic 
regulations. Inflammation affects whole body and liver metabolism by decreasing hormone 
secretion, levels of low and high-density (LDL and HDL), and serum levels of calcium, iron, 
zinc, and retinol / vitamin A 85. Inflammatory cytokines affect gene expression and proteins 
levels in the liver within hours, leading to increased expression of acute phase proteins 
including C-reactive protein (CRP), serum amyloid A (SAA), and haptoglobin (Hp) which are 
released by hepatocytes 82,84,86,87. Inflammation in the liver can be acute or chronic, depending 
on the persistence of the pro-inflammatory stimulus as well as the efficacy of cellular and 
molecular mechanisms that actively contribute to the resolution of hepatocyte inflammation 88–
90. In general, chronic liver inflammation causes necro-inflammation, constitutive liver 




2.3.1 NF-κB pathway 
 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB) is a protein family of 
inducible transcription factors that are essential regulators of inflammation, immune responses, 
cell survival, apoptosis, proliferation, angiogenesis, cell migration, and invasion 91,92. The NF-
κB pathway is a highly conserved pathway that controls the cellular response to pro-
inflammatory cytokines (e.g. tumour necrosis factor α (TNF-α), Interleukin 1 ß (IL-1ß)), 
intracellular stress (DNA damage), reactive oxygen species (ROS), ultraviolet (UV) irradiation, 
and different pathogen derived antigens (lipopolysaccharide (LPS) and bacterial or viral nucleic 
acids) 93–95. The NF-ĸB protein family consist of five members, RelA /p65 (RELA), RelB (RELB), 
c-Rel (REL), p105, precursor of p50 (NFĸB1) and p100, precursor of p52 (NFĸB2) that can 
form homo- and heterodimers which enables distinct responses to specific stimuli 91,9691,96. 
Individual dimers show different DNA binding specificity for target gene regulation 97,98. All NF-
ĸB proteins share a conserved domain for DNA binding and dimerization, the Rel homology 
domain (RHD), and comprise C-terminal activation domains 99–102. The activation of NF-ĸB 
transcription factors is tightly controlled by interaction with inhibitory IĸB proteins including 
IĸBα, IĸBβ, IĸBγ, and IĸBε 103,104. IĸB proteins have diverse affinities for distinct NF-ĸB dimers. 
The NF-ĸB family precursors p105 and p100 can also serve as IκB-like proteins, due to their 
C-terminal domain resembling the structure of inhibitory IκB proteins 105,106.  
NF-ĸB proteins are part of primary “fast acting” transcription factors. The translocation of NF-
ĸB proteins into the nucleus is rapid and can take place within minutes after stimulation 107. 
In most cells, NF-ĸB is present in an inactive state in the cytoplasm bound to inhibitory IĸB 
proteins 104. There are two prominent pathways leading to the activation of NF-ĸB, the 
canonical (classical) pathway and the non-canonical (alternative) pathway (Figure 8) 108. In 
both pathways NF-ĸB activation is regulated by Iĸβ kinase (IKK) complex. The IKK complex 
comprises the catalytic kinase subunits IKKα and / or IKKβ, and in case of the canonical 
pathway, the regulatory subunit and the scaffold protein NF-ĸB essential modulator (NEMO) 
109. Activation of the IKK complex leads to phosphorylation and degradation of inhibitory IĸB 
proteins, NF-ĸB dimer release, translocation into the nucleus, and target gene transcription 91. 
In the presence of a sustained trigger, the activation of NF-ĸB is cyclic and transient, as a result 
of repeating IĸB protein synthesis and subsequent degradation 103,110,111. 
The canonical NF-ĸβ pathway can be induced by diverse stimuli such as inflammatory 
cytokines, mitogens, growth factors, cellular stress, and microbial components 109. Signalling 
pathway activation of pattern recognition receptors (PRRs), several cytokine receptors such 
as tumour necrosis factor-receptors (TNFRs), Toll-like receptor (TLR), T-cell receptor (TCR) 
and B-cell receptor (BCR), leads to the recruitment of adapter proteins to the cytoplasmic 
receptor domains (Figure 8I) 94,95,112. These adapter proteins can subsequently recruit the IKK 
complex (consisting of IKKα, IKKβ, and NEMO) via NEMO K63-ubiquitin binding affinity, 
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leading to IKK complex activation. The activated IKK complex phosphorylates inhibitory IĸBα 
and results in (K48) ubiquitination, proteasomal degradation, NF-ĸB protein release and 
translocation to the nucleus for target gene transcription 103,109,113,114. NF-ĸB members of the 
canonical pathway are predominantly p50/RelA (or p50/c-Rel) dimers that are sequestered in 
the cytoplasm bound to the inhibitory IĸB protein IĸBα 104,114,115.  
In the non-canonical NF-ĸβ pathway, the NF-ĸβ dimers p100/RelB are activated by specific 
stimuli such as ligands of the TNFR superfamily including lymphotoxin ß receptor (LTßR), B-
cell activating factor receptor (BAFFR), cluster of differentiation 40 (CD40), and receptor 
activator of nuclear factor κ B (RANK), that signal via IKK complexes comprising two IKKα 
subunits (Figure 8II) 116–120. The activation of the non-canonical pathway is slower, due to the 
required de novo synthesis of NF­ĸB inducing kinase (NIK) 121. Receptor binding activates NIK 
that subsequently activates an IKKα complex by phosphorylation. The activated IKKα complex 
then phosphorylates the IĸB domain of p100 which results in partial p100 proteolysis, the 
release of the p52/RelB dimer, translocation to the nucleus and target gene transcription 
108,120,122. 
NF-ĸB signalling pathway is associated with several liver diseases including hepatitis, 




Figure 8: NF-ĸB signalling pathway 
(I) Canonical NF-ĸB pathway activation via TNFR leads to the recruitment of adapter proteins that subsequently 
recruit and activate the IKK complex consisting of IKKα, IKKβ, and NEMO. The IKK complex then phosphorylates 
inhibitory Iĸβ proteins resulting in proteasomal degradation, and NF-ĸB dimer release consisting of p50/p65. Free 
NF-ĸB dimers can translocate into the nucleus where target gene transcription takes place. (II) Non-canonical NF-
ĸB pathway activation through LTßR activates NIK that phosphorylates the Iĸβ domain of p100, leading to partial 
proteolytic degradation, and NF-ĸB dimer release consisting of p52/RelB. Released NF-ĸB dimers translocate into 
the nucleus leading to target gene transcription. 
 
2.4. Metabolism control and the NF-κB signalling pathway 
 
Inflammatory and metabolic regulation are tightly connected 124,125. PDK4 can influence NF-ĸB 
signalling by direct interaction with the NF-ĸB protein RelA/p65. Loss of PDK4 switches NF-
ĸB-driven survival to pro-apoptotic signalling facilitated by the release and subsequent binding 
of p65 to the TNFR. Apoptotic pathway activation increases the number of dysfunctional 
mitochondria, reduces glutathione (GSH) levels, and elevates ROS production 126. High PDK 
levels are associated with increased cell proliferation in different cancer entities 127. Cancer 
cells can control PDK levels on transcriptional and post transcriptional levels to sustain 
proliferation by inactivation of PDH complex function and mitochondrial oxidation of glucose / 
pyruvate which stimulates anabolic processes (gluconeogenesis) and promotes cancer cell 
growth 128. PPAR-α can affect inflammatory responses in the liver. During inflammation, 
elevated IL-1ß levels promote the secretion of CRP by formation of nuclear CCAAT-
box/enhancer–binding protein-β (C/EBP-β)-p50-NF-ĸB complexes, enhancing CRP promoter 
activity in hepatocytes. PPAR-α activation decreases CRP secretion by promoting the 
expression of inhibitory IĸBα protein, thus inhibiting the canonical NF-ĸB pathway by reducing 
levels of C/EBP-β and p50-NF-ĸB and interfering with their complex formation 129. The 
dihydroxy leukotriene B4 (LTB4) is involved in the regulation, initiation, maintenance, and 
intensity of inflammation. LTB4 can bind and activate PPAR-α and thereby control inflammatory 
regulations 130. Kupffer cell-derived TNF-α or IL-1ß can interfere with PPAR-α expression via 
NF-ĸB activation, and contributes to TG accumulation in liver 131. In cardiac cells, TNF-α 
induced NF-ĸB activation can directly impact FAO by downregulation of peroxisome 
proliferator activated receptor coactivator 1a (PGC-1a) which elevates glucose oxidation and 
inhibits FAO. Transcriptional mechanisms are regulated by the interference with DNA-binding 
activity of PPAR β/δ leading to reduced PDK4 levels 132. In addition, the NF-ĸB protein p65 can 
directly interact with PPARß/δ which results in a reduction in FAO through decreased PDK4 
expression 133.  
The pro-inflammatory cytokine, Interleukin-17 (IL-17) is critically involved in regulating 
inflammatory cell response and can activates NF-ĸB pathway via NF-κB activator 1 (ACT1) 
and TNFR associated factor 6 (TRAF6) 134–136. Increased IL-17A expression, triggered by 
excess nutrients, increases TG accumulation in the liver by reduction of FAO 137. Obesity is 
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associated with elevated IL-17A levels which promotes the development of fatty liver disease 
138,139.  
 
2.5. Non-alcoholic fatty liver disease, NAFLD, and non-alcoholic steatohepatitis, NASH 
 
Surplus metabolic energy, due to high caloric intake, in combination with reduced energy 
expenditure, through a sedentary lifestyle, resulted in a worldwide epidemic of obesity and the 
metabolic syndrome 140. In 2016, about 1.9 billion adults were overweight and about 650 million 
of them were obese (World Health Organization, WHO). Obesity is defined by a body mass 
index (BMI) greater than 30 kg/m2 (weight to height ratio) 141. Obesity and the metabolic 
syndrome highly increase the risk to develop cardiovascular disease and type 2 diabetes 
mellitus (T2DM) 10,142.  
Obesity is also associated with inflammation 143. Nutrient excess and exacerbated lipid storage 
in adipocytes can lead to immune cell infiltration into WAT and the liver 8. Activated immune 
cells generate an inflammatory environment by secretion of inflammatory cytokines which, in 
combination with surplus nutrients, is driving metabolic changes 144. Inflammation can impair 
insulin signalling and promotes insulin resistance (IR). IR is a pathological condition in which 
cells are unable to respond to insulin, causes lipolysis in adipocytes, and thereby promotes 
dysregulation of lipid metabolism (dyslipidaemia) 7. Thus, nutrient excess in combination with 
inflammation triggers increased lipolysis in adipocytes and results in excess FFA release into 
the bloodstream. Elevated FFAs in the circulation are stored in the liver and promote the 
development of steatosis and non-alcoholic fatty liver disease (NAFLD) 145,146. NAFLD is the 
most common chronic liver disease which affects about 25% of the adult population globally 
147–149. NAFLD is defined by the development of hepatic steatosis with an alcohol uptake less 
than 30g per day (for male). In contrast to NAFLD, alcohol fatty liver disease (AFLD) is induced 
by excess alcohol consumption but displays a similar disease development and progression 
150,151. NAFLD is a highly heterogenous disease with distinct clinical manifestations and 
progression rates, which is dependent on overall metabolism, environmental factors, the 
microbiome, and genetic risk factors 10. NAFLD ranges from simple hepatic steatosis (NAFL), 
characterized by intensified accumulation of lipids in the liver, to steatohepatitis (NASH), 
associated with exacerbated lipid storage, inflammation, cell stress, hepatocyte damage, 
apoptosis, and compensatory proliferation. About 3-5% of NAFLD patients can develop NASH 
which can be associated with fibrosis, cirrhosis, and can lead to NASH-derived HCC 10,16,152. 
HCC is the fastest rising cancer in Europe and the United States and the third most common 
cause for cancer related death worldwide 153–155.  
Up to date there are no drugs approved for NASH treatment 156. Thus, weight loss is currently 
the best “treatment option” for NAFLD and / or NASH by alleviating the risk factors associated 
with fatty liver disease (American Liver Foundation, https://liverfoundation.org/). NAFLD is the 
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hepatic manifestation of the metabolic syndrome, thus targeting associated metabolic risk 
factors e.g., T2D and hyperlipidaemia are possible treatment strategies 157. Metabolic 
associated treatment options include (i) administration of vitamin A / retinol to reduce oxidative 
stress caused by inflammation, (ii) targeting nuclear receptors 158,159, such as PPARs by 
fibrates / PPAR-α agonists that act anti-hyperlipidaemic and anti-inflammatory 129,130,160, 
thiazolidinediones / PPAR-γ agonists that are insulin sensitising agents and act anti-
inflammatory 161,162, and (iii) farnesoid X receptor (FXR) agonists that regulates bile acid, lipid, 
and glucose metabolism 163,164. Chronic inflammation is a key factor for NAFLD progression 
and interference with molecular mechanisms driving intrahepatic immune cell infiltration, 
cytokine secretion, and subsequent intensified steatosis and liver damage provides an 
attractive therapeutic strategy 165. Currently, liver biopsy is the clinical standard for diagnosis. 
Most NASH patients are asymptomatic for decades, only a few patients rapidly progress 
NASH. The recognition of NAFLD and progression to NASH is critical to prevent, potentially 
revert and limit disease severity 10,166. 
Risk factors for NASH development include the metabolic syndrome which is associated with 
obesity, T2DM, hypertension, dyslipidaemia, and hyperglycaemia 90,167. The essential step in 
NAFLD development is the progression from simple steatosis to inflammation-induced 
steatohepatitis, which is dependent on the response of cells to external stressors and stimuli 
in the microenvironment 10,147,152. The first and most prominent model describing NAFLD 
development is the “two hit” hypothesis 168. In this model, excess lipid accumulation is 
described as “first hit” which makes hepatocytes susceptible to subsequent stressors, so called 
“second hits” such as oxidative stress, inflammatory cytokines, xenobiotics, and hypoxia that 
promotes inflammation and development of NASH 88. 
Inflammation is critically involved in the NAFLD to NASH transition and NASH-derived HCC 
development 139,144. A preclinical mouse model demonstrated that immune cell–hepatocyte 
interaction drives NASH and HCC development. Liver infiltration of metabolic activated 
immune cells, particularly CD8+T cells and NKT cells, induces inflammatory cytokine release 
and promotes metabolic reprogramming in hepatocytes. The expression of inflammatory 
cytokines such as tumour necrosis factor superfamily member 14 (TNFSF14 also known as 
LIGHT) and Lymphotoxin-alpha and beta (LT-α and LTβ), which both signal via LTßR, and 
subsequently non-canonical NF-ĸB, is highly increased during NASH. Also, other inflammatory 
signalling pathways such as the canonical NF-ĸB pathway are activated. NASH derived 
inflammation interferes with lipid metabolism by downregulation of genes involved in 
mitochondrial ß-oxidation (e.g. CPT1, acyl-CoA dehydrogenase family, member 10 (ACAD10), 
cholesterol metabolism (e.g. ATP-binding cassette transporter (ABCA1)), and triglyceride 
catabolism (e.g. lipoprotein lipase (LPL), HSL). The inflammatory cytokine LIGHT, mainly 
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expressed by activated immune cells and natural killer T (NKT) cells, induces intensified lipid 
storage in hepatocytes and thereby promotes NASH and NASH to HCC progression 144.  
Excess nutrients can induce unconventional prefoldin RPB5 interactor (URI)-dependent DNA 
damage in hepatocytes which promotes inflammation by T helper 17 (Th17) cell infiltration into 
the liver. The pro-inflammatory Th17 cells secrete IL-17A, which triggers IR in WAT and leads 
to FFA release into the blood stream and delivery to the liver. Interference with Th17 cell 
differentiation or inhibition of IL-17A signalling has been shown to prevent NASH and NASH-
induced HCC 139.  
Cell-cell communication between immune cells, platelets, and hepatocytes is essential for 
NASH pathology 165. Platelets are critically involved in inflammation and liver disease by 
contributing to the activation of the immune system 169–171. The number of activated platelets 
in the liver is increased in NASH and inhibition of platelet accumulation in the liver results in 
less immune cell recruitment and inflammatory cytokine secretion, thereby prevents aberrant 
hepatocyte lipid metabolism 165. Also Kupffer cells are critically involved in NAFLD 
development and progression to NASH 165,172,173. TLR4 induced TNF-α secretion by Kupffer 
cells promotes lipid accumulation and liver injury during NAFLD progression 172172 . Activated 
Kupffer cells interfere with lipid catabolism by reducing the expression of PPAR-α target genes 
involved in FAO which results in the upregulation of the NF-ĸB pathway in hepatocytes. 
Inflammatory cytokine induced NF-ĸB activation interferes with PPAR-α promoter activity 
leading to target gene downregulation 131, displaying the impact of aberrant metabolism 




A pre-requisite for NASH development is intensified lipid accumulation in hepatocytes 168. 
Elevated lipid storage can induce toxicity in cells also known as lipotoxicity. Lipotoxicity can 
trigger a cellular stress response, ROS production, inflammasome activation, and affects 
mitochondria and ER function which in turn induces cell damage and apoptosis by activation 
of death receptor signalling pathways 16.  
Lipid induced toxic cell response is not only dependent on the lipid amount but also on the lipid 
species and composition. Specific lipid classes that induce lipotoxicity are not known in detail 
so far. However, FFAs, free cholesterol (FC), and several other lipids and metabolites have 
been shown to induce lipotoxicity in hepatocytes 10,16.  
One underlying mechanism in hepatocyte lipotoxicity includes elevated ROS generation in the 
liver, promoted by pro-oxidant lipid classes such as saturated FFAs, palmitic acid, and stearic 
acid 16,174. FFA storage in form of TGs in LDs was reported as protective mechanism 4,175.  
Intensified ROS production affects redox-sensitive signalling pathways and triggers damage 
of DNA, enzymes, and proteins, which promotes NAFLD pathogenesis 176,177. This mechanism 
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is partly regulated by oxidative stress induced downregulation of genes involved in lipid 
catabolic processes, removal of toxic intermediates, oxidative phosphorylation, detoxification, 
protein and DNA repair mechanisms, and the cellular component recycling mechanisms (i.e. 
mitophagy and autophagy) 16. In addition, lipotoxicity promotes expression of inflammatory 
stress response genes including activator protein 1 (AP-1), nuclear factor erythroid 2–related 
factor 2 (Nrf2), and NF-ĸB target genes 16,178–180. Lipotoxicity induced NF-ĸB activation 
interferes with mitochondrial morphology and function by promoting mitochondrial 
fragmentation and reducing mitochondrial respiratory capacity 181. 
 
2.5.2 Mitochondria during NAFLD 
 
Mitochondria are critically involved in NAFLD pathogenesis and their function and activity 
change during disease development and progression. NASH is associated with mitochondrial 
dysfunction and impaired FA oxidation 182,183.  
Lipid excess constrains the mitochondria to accommodate by increasing FAO which is linked 
with elevated acetyl-CoA generation. Aberrant acetyl-CoA production can uncouple the TCA 
from mitochondrial respiration as protective mechanism. Dysregulated TCA increases ROS 
production and interferes with the function of the electron transport chain and ATP synthesis 
16,184. Reduced function of the respiratory chain results in incomplete FAO and thereby 
promotes generation of toxic lipid intermediates 185. The accumulation of toxic lipids further 
affects mitochondrial function, which, in combination with elevated ROS, promotes cellular 
stress response, lipotoxicity, and cell death 186,187.  
Intracellular calcium levels are indicative for cellular energy levels and cellular stress. Energy 
demand or cellular stress response is leading to increased calcium levels in the cytosol and 
uptake by a mitochondrial calcium uniporter embedded at the inner mitochondrial membrane 
68,188. Elevated calcium in the mitochondrial matrix activates key enzymes of the TCA and ATP-
synthase of the respiratory chain for NADH generation, respiration activation, and ATP 
production. Calcium overload due to oxidative stress interferes with mitochondrial function and 
morphology and induces apoptotic cell death 9,188. Apoptosis can be activated by two distinct 
pathways, the intrinsic and the extrinsic pathway. The intrinsic mitochondria linked pathway is 
induced by cellular stress, ROS, hypoxia, and DNA damaging signals 189. Apoptotic cell death 
induced by the intrinsic pathway induces mitochondrial outer membrane permeabilization, 
associated with decreased membrane potential and release of pro apoptotic factors into the 
cytosol. In contrast, TNF-α binding to the TNFR can trigger the extrinsic pathway by the 
activation of cell death effectors such as. pro-caspase 8 and 10  that initiate the apoptotic 





2.6. Hypothesis and Aims of the Thesis 
 
Activated immune cells induce aberrant FA metabolism in hepatocytes by the secretion of pro-
inflammatory cytokines and thereby can contribute to NASH and NASH-derived HCC. 
However, the underlying mechanism remain elusive. 
The main aim of this project was to study and understand the impact of proinflammatory 
cytokines on lipid homeostasis in hepatocytes and to identify underlying mechanisms and 
signalling pathways in order to identify possible treatment targets for NAFDL and NASH.  
 
My major hypothesis have been: 
- Key metabolic processes in hepatocytes such as FA- uptake, de novo synthesis, 
storage, oxidation, and export are directly affected by pro inflammatory cytokines. 
- The activation of an inflammatory signalling pathways, such as NF-ĸB, in hepatocytes 
affect major metabolic regulations which induces aberrant lipid metabolism. 
- NASH-derived inflammation, caused by proinflammatory cytokines, directly influences 
the transcriptional and translational machinery of metabolic genes and proteins via 
activation of inflammatory signalling pathways such as NF-ĸB. 
- Increased intracellular lipid levels can induce liptoxicity and affects mitochondrial 
function, cellular apoptosis, and proliferation. 
 
My major aims have been: 
- The establishment of an in vitro NASH model to study the impact of proinflammatory 
cytokines on hepatic lipid metabolism. 
- Investigating changes in FA-metabolism pathways by performing experiments with 
fluorescence and radioactive labelled lipids 
- Describing the role of the NF-ĸB signalling pathway in inflammation induced altered 
lipid metabolism by the use of genetically modified cells and specific inhibitors.  
- To study the consequence of inflammation and increased lipid accumulation on cellular 
stress, mitochondrial polarization, cell viability, and proliferation by fluorescence-based 
assays.  
- To address how inflammation influences the lipid concentration and composition in 
hepatocytes, regulates gene and protein expression and controls signalling pathways 
by using multi omics approaches including lipidome, transcriptome, proteome, 







3. Material and Methods 
 
3.1. Material  
 
Table 1: List of Material and Resources 
Product Company / Supplier Article Number 
Media and Supplements  






William’s E Medium, w.o. Phenol 
red,  
PAN Biotech P04-29510S 
Fetal Clone II Serum (FCS) VWR International HYCLSH30066.03 
Penicillin-Streptomycin (10,000 
U/mL) 
Life Technologies 15140122 
Hydrocortison (Pfitzer) Atzelhof Apotheke PZN1877030 
Human Insulin   
PBS Life Technologies 10010056 
Trypsin-EDTA Solution  Sigma Aldrich T3924 
Versene (EDTA)  VWR International  LONZ17-711E 
Dimethyl sulfoxide (DMSO) Sigma Aldrich D4540 
Chemicals, Buffers and Solutions 
Acetic acid Sigma Aldrich 45731 
Sodium acetate Sigma Aldrich S2889 
EGTA AppliChem A0878,0025 
CaCl2 Sigma Aldrich C8106 
Fetal Bovine Serum (BSA) Sigma Aldrich F7524 
Trizma® base (Tris) Sigma Aldrich T1503 
Sodium Cloride (NaCl) Sigma Aldrich 12781 
Perchloric acid Sigma Aldrich 1090651000 
Methanol Sigma Aldrich 322415 
Chloroform Sigma Aldrich 288306 
Roti®-Histofix 4 % Roth - Carl Roth P087.3 
HBSS Life Technologies 14175129 
Collagenase Sigma Aldrich C5138 
Collagen, Type I solution from rat tail Sigma Aldrich C3867 
Ketamin Atzelhof Apotheke Ketamin Inresa  
Rompun  Bayer 770-081 
RIPA Buffer Cell Signalling Technology 9806S 
PhosSTOP™ Sigma Aldrich 4906837001 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific 23225 
Whatman filter paper Sigma Aldrich WHA1001325 
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cOmplete™ Protease Inhibitor 
Cocktail 
Sigma Aldrich 11697498001 
Clarity™ Western ECL Substrate Bio Rad 1705060 
Precast gels Bio Rad 3450010 
Ethanol absolute VWR International 20821330 
Triton™ X-100 Sigma Aldrich 1086431000 
Sodium hydroxide (NaOH) Sigma Aldrich  S0899 
Tween® 20 Sigma Aldrich  P9416 
Fatty acids 
Oleic acid Sigma Aldrich O1383 
Palmitic acid Sigma Aldrich P5585 
Fluorescence and radioactive labelled fatty acids 
BODIPY™ FL C16                                     Thermo Fisher Scientific D3821 
R-2-bromopalmitic acid  
[1-14C] (0.1mCi/ml) 
Hartmann Analytic                                                   ARC3623
Acetic acid [1-14C] sodium salt, 
50µCi                                                                             
Hartmann Analytic                                                   ARC0101
Palmitic acid [1-14C], 50µCi                              Hartmann Analytic                                                   ARC0172A
Cytokines and inflammatory mediators 
Recombinant Human IL-17A  R&D Systems 317-ILB-050 
Recombinant Human TNF-alpha  R&D Systems 210-TA-020 
Recombinant Human LIGHT  R&D Systems 664-LI-025 
BS1 Genentech N/A 
Recombinant Human IL-4  R&D Systems 204-IL-020 
Recombinant Human IFN-γ  Thermo Fisher Scientific PHC4031 
Recombinant Mouse IL-17A R&D Systems 421-ML-025 
Recombinant Mouse TNF-α R&D Systems 410-MT-010 
Recombinant Mouse LIGHT R&D Systems 1794-LT-025 
Inhibitors, Agonists, and Antagonists 
GW6471  Tocris 4618 
CP775146  Tocris 4190 
TPCA-1  Sigma Aldrich T1452 
Pan Caspase Inhibitor Z-VAD-FMK    R&D Systems FMK001 
N-Acetyl-L-cysteine Sigma Aldrich     A7250 
Primers 
Name                                       Sequence                                                  Company/Supplier 
NFκB2   Fwd: GGGCCGAAAGACCTATCCC 
Rev: CAGCTCCGAGCATTGCTTG 
Sigma Aldrich 
PPARA Fwd: GACAGAAACACACGCGGAA 
Rev: CCCCACCAGGAGAGAGGTAT 
Sigma Aldrich 
PDK4 Fwd: CCGTATTTCTACTCGGATGCTG 
Rev: TGGCTTGGGTTTCCTGTC 
Sigma Aldrich 
siRNA transfection reagents and siRNAs  
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Product Company / Supplier Article Number 
DharmaFECT4, 
Transfection Reagent 
Horizon Discovery T-2004-03 
Opti-MEM™ Thermo Fisher Scientific 31985062 
Silencer Select Negative Control No. 
1 siRNA-5 nmol 
Invitrogen 4390843 
Silencer Select PPARA Pre-
Designed siRNA-5 nmol 
Invitrogen AM16708A 
Silencer®Select, PDK4 Life Technologies 0007128168 
Primary Antibodies  
Western blot antibodies 
Name Species Dilution Company Article Number 
GAPDH Rabbit   1:1000 Cell Signalling 
Technology 
2118  
P-p65 Rabbit 1:1000 Cell Signalling 
Technology 
3033  
p65   Rabbit 1:1000 Cell Signalling 
Technology 
8242 




PPAR-α      Rabbit   1:500 Abcam   ab227074 





(phospho S293)  
Rabbit 5 µg/ml Abcam ab92696 
Cleaved 
caspase 3   






Alexa Fluor 594 
Donkey anti-
Rabbit 





Alexa Fluor 488 
Donkey anti-
Rabbit 
2 drops / ml Thermo Fisher 
Scientific 
R37118 
IgG (H+L) HRP Anti-Rabbit 1:5000 Promega W4011 
Staining Solutions and Kits 
Product Company / Supplier Article Number 
HCS LipidTOX™ Green Neutral 
Lipid Stain 
Thermo Fisher Scientific H34475 
LD540 Dr. Christopher Thiele (Spandl, 
White, Peychl, & Thiele, 2009) 
N/A 
Hoechst 33342 Thermo Fisher Scientific H1399 
MitoTracker®Red CMXRos Cell Signalling Technology 9082 
MitoSOX™Red mitochondrial 
superoxide indicator 
Life Technologies M36008 




and Detection Kit I 
Sigma Aldrich, Roche 11 296 736 001 
PE Annexin V Apoptosis Detection 
Kit I 
BD Pharmingen 559763 
Kits and other Material 
Triglyceride Quantification 
Colorimetric Kit 
Sigma Aldrich MAK266-1KT 
Triglyceride Reagent Sigma Aldrich T2449 
RNeasy Mini Kit Qiagen 74104 
QIAshredder  Qiagen 79656 
Mix SYBR® Green PCR Master Mix Life Technologies 4309155 
QuantiTect Rev. Transcription Kit Qiagen 205314 
ChamberSlides, Lab-Tek II, CC2 Thermo Fisher Scientific 10092371 
Scintillation vials Sigma-Aldrich  Z376825 
Cell Scraper                                                      Sarstedt      83.1830 
Menzel™ Mikroskop- 
Deckelgläschen (coverslides)                                        
Thermo Fisher Scientific                                      BBAD02400240 
26Gx1/2 Needles Medsitis 305111 
BD Falcon Cell Strainer, 70 μm BD Bioscience 352350 
Fluorescence Mounting Medium Dako, Cytomation   S302380 
Eppendorf tubes Eppendorf 0030 120.086 
0030 120.094 
PDVF membrane Thermo Fisher Scientific 88025 
Software  
Software Manufacturer Version 
GraphPad                                                 GraphPad Prism Software 8.0 
QuantStudio™ Real-Time PCR  Applied Biosystem                                   Software V1.2 
Image J / FIJI  64-bit Java 1.8.0_112 
Image Lab  Bio Rad 6.0.1 
Zen  Carl Zeiss 3.1 
FlowJo BD Bioscience V8 
Hardware and Equipment 
Zeiss Cell Observer 
motorised, inverted microscope 
Carl Zeiss Observer.Z1 
Liquid Scintillation counter N/A Packard 1900 TR 
SpeedVac™ Vakuumconcentrator Thermo Fisher Scientific SPD120 
NanoDrop™ 2000 Thermo Fisher Scientific ND-2000 
ChemiDoc Imaging Systems Bio Rad N/A 
Heracell 150i CO2 Incubator Thermo Fisher Scientific 51026281 
PerkinElmer Plate Reader Perkin Elmer N/A 
QuantStudio 5 Real-Time-PCR-
System 
Thermo Fisher Scientific 5 





3.2.1. Cell culture 
 
Culture Medium, for non-differentiated HepaRG Culture Medium, for differentiated 
HepaRG and primary mouse hepatocytes
                          
-Williams E Medium      -Williams E Medium 
-10% FCS      -10% FCS 
-1% Penicillin/Streptomycin (10.000 U/ml)  -1% Penicillin/Streptomycin (10.000 U/ml) 
-Human Insulin (5 µg/ml)    -Human Insulin (5 µg/ml) 
-Hydrocortison hemisuccinate (5X10-5M)  -Hydrocortison hemisuccinate (5X10-5M) 
       -1.8% DMSO  
Assay Medium               
-Williams E Medium, w.o. Phenole red                    
-2%FCS                                                                  
-1% Penicillin/Streptomycin (10.000 U/ml)                        
                                      
3.2.1.1. Cells 
 
Primary mouse hepatocytes were isolated from 8 week old C57BL/6J mice, purchased from 
Charles River, IKKßΔhep mice were obtained from the laboratory of Prof. Mathias Heikenwälder 
191. HepaRG cells were obtained from Philippe Gripon, PhD 192, and were isolated in the 
laboratory of Prof.Christian Trepo and Prof Fabien Zoulim. CRISPR-Cas mediated HepaRG 
cells, HepaRG-sgCtrl, HepaRGsgIKKβ, HepaRG-sgNIK and HepaRGsgIKKβ+sgNIK were 
generated in the laboratory of Prof. Mathias Heikenwälder by Tobias Riedl, MSc. All cells were 
cultured in William E Medium and incubated at 37°C in a humidified atmosphere containing 
5% CO2, in the incubator.  
 
HepaRG cell culture 
HepaRG cell culture and differentiation was performed as described previously by Gripon and 
colleagues 192. In brief, undifferentiated HepaRG were seeded in T.75 flasks and were 
maintained for 2 weeks in Williams E (culture medium for non-differentiated HepaRG), with a 
medium change twice a week. For HepaRG differentiation, DMSO (1.8%) was added and cells 
were cultured in Williams E (culture medium for differentiated HepaRG (dHepaRG)), for 




3.2.1.2. Primary mouse hepatocyte isolation 
 
Perfusion buffer              Digestion buffer  
-HBSS (1X)     -HBSS (1X)  
-EGTA (1 mM)                  -CaCl2 (1 mM) 
     - Collagenase D (working conc. 0.18 U/mg) 
 
Preparations 
For culturing of primary mouse hepatocytes 6 well-plates were coated with collagen I from rat 
tail, diluted in autoclaved sterile filtered distilled H2O (dH2O) to a final concentration of 0,1 
mg/ml. 500 µl of the collagen solution was added per well and plates were incubated for 30 
min. in the incubator. Then the collagen solution was removed, and wells were washed with 
PBS. Coated dishes were stored at 4°C in the fridge and were treated with UV light before 
usage. 
All buffers and solutions were freshly prepared and were stored at 4°C until use. The water 
bath was pre-warmed at 42°C (the digestion buffer should have 37°C during perfusion). 
For anaesthesia of mice a Ketamine / Rompun solution (mixed 1:1) was intraperitoneal 
injected. 
 
Liver perfusion and digestion 
Mice were fixed and the abdomen was cut, all organs were moved to access the liver. Then 
the cannula was inserted into the vena porta, the vena cava was cut (to avoid pressure 
increase within the liver), and the liver was perfused with the perfusion buffer for 3-5 min. At 
the beginning of the perfusion the flow rate should be around 8 ml/min and can be increased 
up to 24 ml/min during perfusion / digestion. To avoid dehydration of the liver perfusion buffer 
was added on the organ. After perfusion, the liver was digested by digestion buffer for 5-10 
min.  
 
Primary hepatocyte cell culture 
The digested liver was transferred into a 50 ml tube, containing prewarmed culture medium 
and by using a tweezer the liver was agitated to liberate the cells. The cell suspension was 
then transferred, by filtering through a 70 µm strainer, into a new 50 ml tube, filled up to 40 ml 
with culture medium, and was centrifuged for 3 min. at 300 g. After pelleting the cells, the 
supernatant was removed, and culture medium was added, and the centrifugation step was 
repeated. Isolated hepatocytes were counted and 3.5x105 cells were seeded per well of a 6-
well plate in culture medium and were incubated in the incubator. After attachment, (after about 
4 h) cells were used for further experiments. 
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3.2.2. Fatty acid metabolism experiments 
     
3.2.2.1. Fatty acid uptake 
 
Radioactive (14C) labelled bromo-palmitic acid uptake 
To quantify FA uptake dHepaRG cells were subjected to 14C-labelled bromo-palmitic acid. 
1.2x105 cells were seeded per well of a 12-well plate in 1 ml assay medium. After attachment, 
cells were left untreated (as blank control), were treated with FAs, palmitic acid (33 µM) and 
oleic acid (66 µM) alone, and in combination with inflammatory mediators, including BS1 (0.5 
µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml), for 21 h in the 
incubator. The assay medium was removed and tracer medium was added which contained 
FAs, palmitic acid (33 µM) and oleic acid (66 µM), and 0.1 µl/ml 14C R-2-bromopalmitic acid 
(with an activity of 0.1 mCi/ml) alone, and in combination with inflammatory mediators including 
BS1  (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml). Cells 
were incubated for 3 h in the incubator. Then the medium was removed, and cells were washed 
twice with PBS, then they were lysed in radioimmunoprecipitation assay (RIPA) buffer (300 µl 
per well). Cell lysates were used to determine protein concentration by Bicinchoninic acid 
(BCA) assay, according to the manufacturer’s manual, for normalization. Radioactivity was 
quantified by using 250 µl of each cell lysate, by scintillation counting. 
 
Fluorescence (BODIPY) labelled palmitic acid uptake 
To study FA uptake over time, BODIPY-labelled palmitic acid was used. 1.2x105 cells were 
seeded per well of a 12-well plate in 1 ml assay medium. After attachment, the assay medium 
was removed, and cells were left untreated, were treated with FAs, palmitic acid (33 µM), oleic 
acid (66 µM) and BODIPY-C16 (33 µM) alone, and together with the cytokine combination 
including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml), 
for 1 h, 3 h and 24 h, in the incubator. After incubation, the cells were washed with PBS, were 
trypsinized and pelleted by centrifugation at 300 g for 3 min. Cell pellets were resuspended in 
300 µl of PBS plus 3% FCS. Cells were analysed by flow cytometry, by using BD 
FACSFortessa, Sony spectral analyser, SP6800, and data were analysed using FlowJo.  
 
3.2.2.2. Fatty acid de novo synthesis 
 
De novo synthesis, radioactive (14C) labelled acetic acid 
For FA de novo synthesis experiments, 1.2x105 cells were seeded per well of a 12-well plate 
in 1 ml assay medium. After attachment, the cells were left untreated (as blank control), were 
treated with FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination with 
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inflammatory mediators, including (BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
and rhTNF-α (50 ng/ml), for 21 h in the incubator. Then the assay medium was removed, and 
tracer medium was added containing 100 µM sodium acetate and 1 µl/ml of acetic acid [1-14C] 
sodium salt alone, and in combination with inflammatory mediators including BS1 (0.5 µg/ml), 
rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml), for 3 h in the incubator. The 
tracer medium was removed, and cells were washed twice with PBS and were lysed in 300 µl 
of RIPA buffer per well. 50 µl were stored for determination of the protein concentration by 
BCA protein assay for normalization, and 200 µl of the cell lysates were used for lipid 
extraction.  
For lipid extraction, 800 µl of chloroform: methanol, in a ratio of 2:1 (533.3 µl chloroform and 
266.6 µl methanol) was added per 200 µl of cell lysate (total volume 1 ml) and centrifuged at 
14.000 g, for 30 min. The bottom phase (700 µl) was collected and 150 µl of 50% TritonX was 
added per sample, then samples were SpeedVac dried by a vacuum concentrator, overnight. 
Cell lipid extracts were resuspended in 700 µl dH2O, and 600 µl were used for scintillation 
counting. 
 
3.2.2.3. Fatty acid storage  
 
Neutral lipid stain by LD540 or LipidTOX green, analysed by fluorescence microscopy and flow 
cytometry  
For neutral lipid quantification by LD540 or LipidTOX green fluorescence microscopy, 5.5x104 
cells were seeded per well of a 4-well chamber slide in 500 µl of assay medium. After 
attachment, the cells were left untreated, were treated with FAs, palmitic acid (33 µM) and oleic 
acid (66 µM) alone, and in combination with inflammatory mediators, including (BS1 (0.5 
µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml), IL-4 (50 ng/ml), IFN- (3 
ng/ml, specific activity: 3.3 x 105 units/mg) and the combination of all cytokines with the same 
final concentrations, for 24 h in the incubator. In addition to investigate the influence of NF-ĸB 
signalling, apoptosis, or ROS production, on neutral lipid accumulation cells were 
simultaneously stimulated with, the IKKß inhibitor TPCA-1 (25 nM), with the Pan caspase 
inhibitor Z-VAD-FMK (100 µM), and the anti ROS agent N-acetyl-cystein (5 mM). After 
incubation, the assay medium was removed, and cells were washed with PBS and were fixed 
for 15-20 min in 4% paraformaldehyde. After washing twice with PBS cells were stained with 
1µg/ml Hoechst (for nuclear staining) and 0.1 µg/ml with LD540 193 or LipidTOX green with a 
final concentration of 1:1000 in PBS, for 30 min. in the dark. After washing twice with PBS, 1 
drop of mounting medium per well was added and samples were covered with cover slides. 
After drying, they were immediately analysed by fluorescence microscopy and analysed by 
ImageJ. Pictures were taken with an inverted Zeiss Cell Observer microscope. 
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For neutral lipid quantification by flow cytometry, cells were stained alive in the incubator. 
Therefore, after 24 h of cell treatment (see above), the assay medium was removed and 
staining solution was added which contained 0.1 µg/ml LD540 or LipidTOX green with a final 
concentration of 1:1000 in assay medium, for 30 min. in the incubator. Then the medium was 
removed and after washing, cells were trypsinized and centrifuged at 300 g for 3 min. for 
pelleting. Cell pellets were washed once with PBS and then 300 µl of PBS plus 3% FCS was 
added per sample and cells were immediately analysed by flow cytometry by using BD 
FACSFortessa, Sony spectral analyser, SP6800, and data were analysed using FlowJo. 
 
3.2.2.4. Fatty acid oxidation (FAO)  
 
Radioactive (14C) labelled palmitic acid oxidation to CO2 
FAO was determined as previously described in 194. In brief, 1.2x105 cells were seeded per 
well of a 12-well plate in 1 ml assay medium. After attachment, the cells were left untreated 
(as blank control), were treated with FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, 
and in combination with inflammatory mediators, including BS1 (0.5 µg/ml), rhLIGHT (500 
ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml), for 21 h in the incubator. Then the assay 
medium was removed and the tracer medium was added which contained FAs, palmitic acid 
(33 µM) and oleic acid (66 µM), and 1 µl/ml of 14C palmitic acid (with an activity of 0.5 mCi/ml) 
for 3 h in the incubator. 1.5 ml Eppendorf tubes were prepared for 14C-CO2 trapping, therefore 
round discs of Whatman filter paper were cut and the paper was stuffed inside the cap of an 
Eppendorf tube. After incubation, cell supernatant was collected (900 µl) and transferred into 
1.5 ml Eppendorf tubes. In addition, cells were washed with PBS and lysed by RIPA Buffer for 
normalization by BCA protein assay, according to manufacturer’s protocol. 200 µl of 1 M 
perchloric acid was added per 14C-CO2 trapping Eppendorf tube and 20 µl of 1 M NaOH was 
added on the paper disc in the cap. Then the cell supernatant was added, and the tube was 
immediately closed. Samples were incubated at room temperature (RT) for 1 h, then the 14C-
CO2 trapped paper discs were used for scintillation counting. 
 
3.2.2.5. Fatty acid export  
 
TG determination in cell supernatant  
To quantify FA export in form of TGs a TG determination Kit was performed according to the 
manufacturer’s protocol. In brief, 1.2x105 cells were seeded per well of a 12-well plate in 1 ml 
assay medium. After attachment, the cells were left untreated, were treated with FAs, palmitic 
acid (33 µM) and oleic acid (66 µM) alone, and in combination with inflammatory mediators, 
including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml), 
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for 24 h in the incubator. Then the assay medium was removed, and cells were washed twice 
with PBS. Cells were lysed with RIPA buffer, 300 µl per well. A 96-well plate (flat bottom) was 
used and 100 µl of cell lysate was added per well. Then a solution was added that contained 
a mixture of Free glycerol (FG) and triglycerides (TG) in a ratio 4:1. As blank control 100 µl 
RIPA buffer was used, and for TG quantification a glycerol standard was used, therefore 5 µl 
of glycerol standard (2.5 mg/ml) plus 95 µl H2O was added per well. After 15 min. at 37°C the 
colorimetric reaction was measured with a plate reader. 
 
3.2.3. Cell preparation for liquid chromatography mass spectrometry (LC-MS)  
 
For lipidomic analysis, 1x106 cells were seeded per 60 mm dish in 2.5 ml of assay medium. 
After attachment, the cells were left untreated, were treated with rhTNF-α (50 ng/ml) alone, 
were treated with FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination 
with inflammatory mediators including BS1 (0.5 µl/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 
ng/ml) and rhTNF-α (50 ng/ml), for 24 h in the incubator. For lipid extraction, cells were put on 
ice and were washed one time with ice cold PBS, then 200 µl of ice-cold methanol was added 
per plate, and cells were scraped and transferred into 1.5 ml Eppendorf tubes. A blank control 
sample was prepared by performing same procedures without biological sample. The samples 
were vortexed for protein precipitation and 500 µl of chloroform was added. After vortexing, 
samples were kept on ice for 10 min., then 200 µl of dH20 was added for phase separation. 
Samples were again vortexed and kept on ice for 10 min. and were then centrifuged at 600 
rpm for 5 min. The bottom layer (300 µl of chloroform layer) was carefully transferred into a 
new tube and samples were SpeedVac dried by a vacuum concentrator, overnight. Dried 
samples were shipped on dry ice for analysis to the EMBL Metabolomics Core Facility 
(Heidelberg, Germany). 
 
3.2.4. Fluorescence stainings 
 
3.2.4.1. Immunofluorescence staining  
 
For immunofluorescence staining, 5.5x104 cells were seeded per well of a 4-well chamber slide 
in 500 µl of assay medium. After attachment, the cells were left untreated, were treated with 
FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination with all 
inflammatory mediators including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
and rhTNF-α (50 ng/ml), for 24 h in the incubator. Then the assay medium was removed, and 
the cells were washed with PBS and were fixed for 15-20 min in 4% paraformaldehyde. 
Samples were washed with PBS and the primary antibody (see Table 1. Immunofluorescence 
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antibodies), diluted in PBS, 1% BSA was added either for 1 h at RT, or at 4°C overnight. Then 
the cells were washed three times with PBS and secondary antibody, diluted in PBS, 1% BSA 
(see Table 1. secondary antibodies) for 30 min. at RT. After washing with PBS, Hoechst 
staining solution (1 µg/ml Hoechst in PBS) was added for 15 min. at RT. Samples were washed 
once with PBS and 1 drop mounting medium was added per well and slides were covered with 
cover slides. After drying, samples were immediately analysed by fluorescence microscopy 
and analysed by ImageJ. Pictures were taken with an inverted Zeiss Cell Observer 
microscope. 
 
3.2.4.2. Mitochondrial staining by MitoTrackerRed 
 
To visualize mitochondria, cells were stained with Mitotracker red staining according to the 
manufacturer’s manual. Briefly, 5.5x104 cells were seeded per well of a 4-well chamber slide 
in 500 µl of assay medium. After attachment, the cells were left untreated, were treated with 
FAs, palmitic acid (33 µM) and oleic acid (66µ M) alone, and in combination with all 
inflammatory mediators, including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
and rhTNF-α (50 ng/ml), for 24 h in the incubator. The assay medium was removed and the 
Mitotracker red staining solution, containing 200 nM MitoTrackerRed in assay media, was 
added for 30 min. in the incubator. After incubation cells were fixed in ice-cold methanol for 15 
min. at -20°C. Then the cells were washed with PBS and mitochondrial staining was analysed 
by fluorescence microscopy. Pictures were taken with an inverted Zeiss Cell Observer 
microscope. 
 
3.2.4.3. JC-1 staining to monitor mitochondrial membrane potential 
 
To determine mitochondrial membrane potential cells were stained with JC-1 dye according to 
manufacturer’s protocol. In brief, 1.2x105 cells were seeded per well of a 12-well plate in 1 ml 
assay medium. After attachment, cells were left untreated, were treated with inflammatory 
mediators, including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 
ng/ml), and the combination of all cytokines alone, were treated with FAs, palmitic acid (33 µM) 
and oleic acid (66 µM) alone, and in combination with inflammatory mediators, including BS1 
(0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml), IL-4 (50 ng/ml) and 
the combination of all cytokines with the same final concentrations, for 24h in the incubator. In 
addition, to investigate the influence of NF-ĸB signalling on mitochondrial polarization, cells 
were simultaneously stimulated with, the IKKß inhibitor TPCA-1 (25 nM). After incubation, the 
assay medium was removed and JC-1 staining solution (10 µl JC-1 in 1 ml Assay Medium, 
final concentration 2 µM) was added and cells were incubated for 30 min. in the incubator. As 
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positive control for mitochondrial depolarization 3 µl of the mitochondrial uncoupler CCCP was 
added. After staining, cells were washed with PBS, were trypsinized, and centrifuged for 3 min. 
at 300 g for pelleting. Cell pellets were resuspended in PBS plus 3% FCS and analysed by 
flow cytometry by using BD FACSFortessa, Sony spectral analyser, SP6800, and data were 
analysed using FlowJo. The ratio of the JC-1 red to JC-1 green mean area was determined.  
 
3.2.4.4. Mitochondrial superoxide production determination by MitoSOXRed 
 
Mitochondrial superoxide production was visualized by MitoSOXRed staining which was 
performed according to manufacturer’s manual. In brief, 5.5x104 cells were seeded per well of 
a 4-well chamber slide in 500 µl of assay medium. After attachment, cells were left untreated, 
were treated with FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and together with 
the cytokine combination including BS1 (0.5 µg/m), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
and rhTNF-α (50 ng/ml), with and without the IKKß inhibitor TPCA1 (25 nM), for 24 h in the 
incubator. The assay medium was removed and MitoSOXRed staining solution was added 
(containing 5 µM MitoSOX reagent in assay medium) for 10 min. in the incubator. Then cells 
were washed with assay medium and were imaged alive by fluorescence microscopy. Pictures 
were taken with an inverted Zeiss Cell Observer microscope. 
 
3.2.4.5. Immunofluorescence assay for the detection of 5-bromo-2´-deoxy-uridine (BrdU) 
incorporation into DNA 
 
To quantify cell proliferation the 5-Bromo-2´-deoxy-uridine Labeling and Detection Kit I was 
used according to manufacturer’s manual. Briefly, for quantification by fluorescence 
microscopy, 5.5x104 cells were seeded per well of a 4-well chamber slide in 500 µl of assay 
medium. For analysis by flow cytometry, 1.2x105 cells were seeded per well of a 12-well plate 
in 1 ml assay medium. After attachment, cells were left untreated, were treated with FAs, 
palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination with all inflammatory 
mediators, including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 
ng/ml), for 24 h in the incubator. To investigate the effect of NF-ĸB signalling on cell 
proliferation FA pus IL-17A stimulated cells were additionally treated with the IKKß inhibitor 
TPCA-1 (25 nM). After incubation, the assay medium was removed and BrdU labelling medium 
(containing BrdU which can be incorporated into DNA in place of thymidine in proliferating 
cells) was added and incubated for 1 h in the incubator. For analysis by flow cytometry, cells 
were washed, trypsinized and pelleted, and all following procedures were performed in 1 ml 
Eppendorf tubes. The BrdU labelling medium was removed and samples were washed three 
times with washing buffer, then samples were fixed in ice cold Ethanol fixative (containing 50 
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mM glycine solution in dH2O and 70% absolute EtOH, pH 2.0.) for 20 min. at -20°C. Samples 
were washed again three times with washing buffer and were covered with Anti-BrdU working 
solution (containing a monoclonal antibody against BrdU) and incubated for 30 min. at 37°C. 
After washing three times with washing buffer the samples were covered with anti-mouse-Ig-
fluorescein working solution (containing fluorochrome-conjugated second antibody) for 30 min. 
at 37°C. Then samples were washed three times with washing buffer and for evaluation by 
fluorescence microscope mounting medium was added and samples were covered with cover 
slides. Pictures were taken with an inverted Zeiss Cell Observer microscope. For analysis by 
flow cytometry cells were resuspended in PBS plus 3% FCS and were analysed by using BD 
FACSFortessa, Sony spectral analyser, SP6800, and data were analysed using FlowJo. 
 
3.2.4.6. Determination of apoptosis by Annexin V staining  
 
To quantify cell apoptosis the Annexin V Kit was performed according to manufacturer’s 
manual. In brief, 1.2x105 cells were seeded per well of a 12-well plate in 1 ml assay medium. 
After attachment, cells were left untreated, were treated with FAs, palmitic acid (33 µM) and 
oleic acid (66 µM) alone, and in combination with all inflammatory mediators, including BS1 
(0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml), in presence and 
absence of the pan-caspase inhibitor Z-VAD-FMK (100 µM) for 24 h in the incubator. After 
treatment cells were washed with PBS, were detached by Versene and were pelleted by 
centrifugation at 300 g for 3 min. Then cells were transferred into 2 ml Eppendorf tubes and 
were stained in 100 µl of 1x Binding Buffer with 5 µl of PE Annexin and 5 µl of 7-AAD. After 
mixing, the cells were incubated for 15 min. at in the dark. After incubation, 200 µl of 1x Binding 
Buffer was added per sample and cells were immediately analysed by flow cytometry, by using 
BD FACSFortessa, Sony spectral analyser, SP6800, and data were analysed using FlowJo. 
 
3.2.5. siRNA mediated knock down 
 
For si-RNA mediated knock down, 1.2x105 cells were seeded per well of a 12-well plate in 1 
ml assay medium. After attachment, the medium was removed and culture medium without 
antibiotics was added (800 µl per well). Then 5 µl of siRNA (see in Table 1. in siRNA reagents 
and siRNAs) was added to 95 µl of OptiMEM per transfection, after mixing the solution was 
incubated for 5 min. at RT. During incubation, 3 µl of Dharmafect and 97 µl of OptiMEM were 
mixed per sample and incubated for 5 min. at RT. Then 100 µl of the si-RNA OptiMEM solution 
was added to the Dharmafect OptiMEM solution and were incubated for 20 min. at RT. Then 
200 µl of the si-RNA containing solution was added per well, with a final siRNA concentration 
of 25 nM. After 1 day the medium was changed to culture medium. After 2 days cells were left 
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untreated, were treated with all inflammatory mediators, including BS1 (0.5 µg/ml), rhLIGHT 
(500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml) alone, were treated with FAs, palmitic 
acid (33 µM) and oleic acid (66 µM) alone, and in combination with all inflammatory mediators, 
including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), for 24 h in the incubator. 
Then cells were stained with LipidTOX green and neutral lipid accumulation was analysed by 
flow cytometry (see above). 
 
3.2.6. Immunoblot analysis 
 
Buffers and Solutions 
4x Sample buffer    10x SDS running buffer Semidry transfer buffer 
-222.24 mM Tris (pH 6.8)   -30.3 g Tris   -48 mM Tris  
-3.52% SDS     -144g  Glycine  -39 mM Glycine 
-35.2% Glycerol    -10 g SDS   -1.3 mM SDS  
-0.016% Bromophenol blue -  ad. 1 L ddH2O  -20 % Methanol  
-10% β-mercaptoethanol     -pH 9-9.4 
 
Wash buffer          TBS-T 
-1xPBS                 -10 mM TRIS 
-0.1% Tween20    -0.1% Tween20     
                             -150 mM NaCl 
 
For immunoblot analysis dHepaRG cells were seeded into 6-well plates in 2 ml assay medium. 
After attachment, the cells were left untreated, or were treated with FAs, palmitic acid (33 µM) 
and oleic acid (66 µM) alone, and in combination with inflammatory mediators including BS1 
(0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), and rhTNF-α (50 ng/ml), for 24 h in the 
incubator. For protein extraction cells were put on ice, and were washed with ice cold PBS, for 
cell lysis 300 µl RIPA buffer supplemented, according to the manufacturer’s manual with 
complete protease inhibitor cocktail and phosphatase inhibitor was added and cells were 
scraped and transferred into 1.5 ml Eppendorf tubes. Cell lysates were either stored at -80°C 
or protein concentration was determined by BCA assay, according to the manufacturer’s 
manual. Briefly, 5 µl of cell lysate was added per well of a 96-well plate, flat bottom. As blank 
control 5 µl of RIPA Buffer was used, and 5 µl of a BSA serial dilution was used for the 
generation of a standard curve. Copper(II)sulphate and BCA were mixed in a ratio 1:50, and 
195 µl of this solution was added per sample. After 5-10min. the protein concentration was 




Semidry western blot 
 
For immunoblot analysis 20 µg of protein were diluted in 4X sample buffer, dH2O and ß-
Mercaptoethanol. For protein denaturation, samples were boiled at 95°C in the thermomixer 
for 5 min. Precast gels from BioRad were used and the running chamber was assembled and 
was filled up with 1x SDS running buffer in the inner and the outer chamber. Then 4 µl of the 
BioRad Protein marker and 15 µl of the protein samples were loaded per lane. The gels run at 
90 V for 60 min. 20% methanol was added to the 1X transfer buffer, and the PDVF membrane 
was activated for at least 1 min. in 100% methanol. Then the gels were assembled and 
transferred into a transfer chamber and set at 150 mA for 1 h. 
After protein transfer, membranes were blocked in in TBS-T plus 5% BSA, for 1 h. After 
blocking the primary antibody (see in Table 1. Western blot antibodies) was added in TBS-T 
plus 5% BSA and incubated overnight, at 4°C. On the next day membranes were washed three 
times in washing buffer for each 10 min. Then the secondary antibody (see in Table 1. 
Secondary antibodies) was added diluted in TBS-T, and membranes were incubated for 1 h. 
Then the membranes were washed with TBS-T three times for 10 min. For development, the 
remaining liquid was removed and ECL substrate was mixed 1:1 and added on the 
membranes, which were then covered in clingfilm and analyzed by a ChemiDoc imaging 
system. 
 
3.2.7. RNA isolation for RNA sequencing analysis and reverse transcription into cDNA for RT-
PCR 
 
For gene expression analysis, 1.2x105 cells were seeded per well of a 12-well plate in 1 ml 
assay medium. After attachment, cells were left untreated, were treated with inflammatory 
mediators alone, including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-
α (50 ng/ml), and the combination of all cytokines with the same final concentrations, were 
treated with FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination with 
inflammatory mediators, including (BS1(0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
rhTNF-α (50 ng/ml), and the combination of all cytokines with the same final concentrations, 
for 24 h in the incubator. To address the effect of NF-ĸB signalling on cell proliferation FA pus 
IL-17A stimulated cells were additionally treated with the IKKß inhibitor TPCA-1 (25 nM). After 
incubation, the assay medium was removed and cells were washed with PBS, and 300 µl of 
lysis, RLT Buffer (from RNeasy Kit) was added. Samples were either stored at -80°C or RNA 
was extracted according to manufacturer’s protocol. 
In brief, cell lysates were put on ice for 2 min. and were then transferred onto a Qiashredder 
spin column, which was placed in a 2 ml collection tube, and centrifuged for 2 min, at 14.000 
g. 300 µl of 70% EtOH were then added per homogenate into the collection tube and 
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transferred to a RNeasy Spin Column, which was placed in a 2 ml collection. After 
centrifugation for 2 min., at 14.000 g, the flow through was discarded and 300 µl of RW1 buffer 
was added onto the membrane in the RNeasy Spin Column. After centrifugation for 2 min. at 
14.000 g, the flow through was discarded and 500 µl of RPE buffer was added, and samples 
were again centrifuged for 2 min. at 14.000 g, and the flow through was discarded. The last 
step was repeated once, and the RNeasy Spin Columns were placed into new collection tubes, 
and for drying the samples they were centrifuged for 2 min, at 14.000 g, to remove any left 
liquids. The dried RNeasy Spin Columns were then placed into 1.5 ml collection tubes and 20 
µl of RNAse-free water was added. RNA concentration and quality were determined by 
Nanodrop analyzer. Isolated RNA was either stored at -80°C or was reverse transcribed for 
cDNA synthesis. 
For RNA sequencing 25 ng RNA (per sample) was delivered to Klinikum rechts der Isar, were 
RNA sequencing analysis was performed by Dr.Rupert Öllinger, from AG Prof. Roland Rad. 
For cDNA synthesis the Quantitect Reverse Transcription Kit was used according to the 
manufacturer’s protocol. In brief, all reagents were thawed, and isolated RNA was kept on ice. 
12 µl of 500 ng RNA, diluted in RNAse-free dH2O, was used for reverse transcription. To 
remove genomic DNA, a DNA wipe out step was performed, by adding 2 µl DNA wipe out 
solution per sample, which were then put on 42°C for 2 min. A master mix (MM) was prepared 
containing, 4 µl of reverse transcriptase (RT) buffer, 1 µl primers, and 1 µl of RT, thus 6 µl of 
the MM were added per sample, which were then incubated at 42°C for 20 min for reverse 
transcription. The reaction was stopped by incubation at 95°C for 3 min. and 180 µl RNAse-
free H2O was added and cDNA was stored at -20°C (for long term storage at -80°C). 
Real-Time (RT) PCR was performed in triplicates in a in 384-well plate using Fast Start SYBR 
Green Master Rox with custom made primers (see in Table 1. Primers). In brief, a MM was 
prepared containing, 6 µl of SYBR Mix, 0.06 µl forward and 0.06 µl reverse primer, and 0.88 
µl nuclease-free H20, then 7 µl of this MM was added per well of a plate and 5 µl of synthesised 
cDNA was added.  
 
3.2.8. Cell preparation for Proteomics and Phosphoproteomics 
 
For proteomics and phosphoproteomics dHepaRG cells were directly treated in T 75 were they 
were differentiated. The culture medium was removed and cells were left untreated, were 
treated with all inflammatory mediators alone, including (BS1(0.5 µg/ml), rhLIGHT (500 ng/ml), 
rhIL-17A (50 ng/ml) and rhTNF-α (50 ng/ml), were treated with FAs, palmitic acid (33 µM) and 
oleic acid (66 µM) alone, and in combination with all inflammatory mediators, including 
(BS1(0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), rhTNF-α (50 ng/ml), for 24 h in the 
incubator. After incubation, the cells were put on ice, washed once with ice cold PBS, and were 
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scraped in PBS, transferred into 2 ml Eppendorf tubes, and centrifuged for 3 min. at 300 g. For 
cell lysis 350 µl of RIPA Buffer (1 volume pellet: 5 volumes lysis buffer) containing 
phosphoSTOP phosphatase inhibitors (25X stock in dH2O) and complete mini EDTA free 
phosphatase inhibitors (1 tab in 10ml d H2O) was added. Cells were incubated on ice for 10 
min. and were then sonicated with the standard program. After sonication samples were 
centrifuged for 1 h at 4°C at 14.000 g. The lysates were transferred into a new 1.5 ml Eppendorf 
tube and protein concentrations were determined by BCA Assay. Samples were delivered to 
the German Cancer Research Center (DKFZ) MS-Based Protein Analysis Core Facility (GPCF 
- Protein Analysis Unit (W120) were proteomics and phophoproteomics analysis was 
performed. 
 
3.2.9. Cell preparation for Proteome-based complex analysis 
 
For thermal protein profiling dHepaRG cells were directly treated in T75 flasks, used for cell 
differentiation. At the day before the experiment the culture medium was removed and cells 
were left untreated, were treated with all inflammatory mediators alone including BS1 (0.5 
µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml) and rhTNF-α (50 ng/ml), were treated with 
FAs, palmitic acid (33 µM) and oleic acid (66 µM) alone, and in combination with all 
inflammatory mediators including BS1 (0.5 µg/ml), rhLIGHT (500 ng/ml), rhIL-17A (50 ng/ml), 
rhTNF-α (50 ng/ml), for 24h in the incubator. After treatment, cells were delivered to EMBL and 
experimental procedures were performed by Isabel Becher from the group of Dr. Michael 
Savitski. Data were analysed by and Mathias Kalxdorf, PhD. 
 
3.2.10. Statistical analysis 
 
Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; 
****: p < 0.001; ns: not significant. For RNA sequencing based differential expression (DE) 
analysis, genes were ranked based on their log2foldchange (log2FC≥1) and adjusted p value 
(padj<0.05), and normalized counts of all genes, raw counts (count < 2), were used. 
For DE analysis of proteomics, all proteins were ranked by log 2 fold change (log2FC≥1, and 
p value adjusted (padj<0.05), for phospho proteomics, phosphoproteins were ranked by p 









4.1. Fatty acid metabolism in hepatocytes 
 
4.1.1. In vitro experimental set-up to study the influence of inflammatory mediators on hepatic 
fatty acid metabolism 
I developed an in vitro NASH model to investigate molecular mechanisms underlying the 
transition from simple steatosis (NAFLD) to steatohepatitis (NASH). Mouse and human 
hepatocytes were used to mimic different stages during NAFLD to NASH transition (Figure 9).  
Hepatocytes were either untreated (normal hepatocytes), stimulated with FAs alone (steatotic 
hepatocytes), and in combination with inflammatory mediators (changed hepatocytes), known 
to contribute to NASH pathology including LIGHT and IL-17A 139,144. 
 
 
Figure 9: Illustration of the in vitro experimental set-up to mimic NAFLD to NASH development 
in hepatocytes.  
FAs induce a steatotic phenotype (LD accumulation, yellow circles) in hepatocytes, to recapitulate NAFLD. FAs 
together with pro-inflammatory cytokines trigger metabolic changes in hepatocytes and mimic NASH development. 
NASH can progress towards NASH-derived HCC. As in vitro experimental set-up, hepatocytes, dHepaRG cells or 
primary mouse hepatocytes were, untreated (normal), stimulated with FAs, palmitic and oleic acid, alone, and in 
combination with inflammatory mediators, LTßR agonist BS1, LIGHT, IL-17A, TNF-α, and a combination of all listed 
cytokines (Cytokine Combination), (FA + BS1, FA+ LIGHT, FA + IL-17A, FA + TNF-α, FA + Cytokine Combination) 




4.1.2. Fatty acid storage into neutral lipids is intensified by NASH-derived inflammatory 
cytokines 
Primary mouse hepatocytes were exposed to FAs alone and in combination with pro-
inflammatory cytokines. Consistent with published data 144, treatment with inflammatory 
cytokines increased lipid accumulation (Figure 10A, B), and promoted the development of 
macrovesicular steatosis, displayed by an increase of large (1-1.5um) and very large (1.5-2um) 
LDs (Figure 10C). This demonstrated that inflammatory cytokines not only influence LD 
number but also size in hepatocytes. 
To investigate whether inflammation-induced increased lipid accumulation is a mechanism 
also affecting human hepatocytes, dHepaRG cells were exposed to FAs and inflammatory 
mediators. In line with the observations in primary mouse hepatocytes, human dHepaRG cells 
that were subjected to FAs in combination with inflammatory mediators displayed intensified 
LD accumulation when compared to FA treated cells (Figure 10D, E). The LD number and the 
LD size were increased in dHepaRG cells that were exposure to an inflammatory, lipid-rich 
microenvironment (Figure 10F). However, the macrovesicular phenotype in dHepaRG cells 
was less pronounced when compared to primary mouse hepatocytes (Figure 10C, F).  
Treatment with a combination of all inflammatory mediators (BS1, LIGHT, IL-17A, TNF-α: 
Cytokine Combination), which more closely recapitulates the inflammatory microenvironment 
in vivo, most significantly increased neutral lipid storage in human hepatocytes (Figure 10G). 
In contrast, hepatocyte stimulation with IL-4 (promoting an anti-inflammatory immune 
response) or IFN-γ (associated with an anti-viral immune response) did not promote aberrant 





















Figure 10: FA storage into neutral lipids in hepatocytes, determined by LD540 / Hoechst and 
LipidTOX green / Hoechst staining. 
(A, B, C) Primary mouse hepatocytes and (D, E, F) dHepaRG cells  were left untreated (CTRL), or were treated 
with FAs and with FAs together with cytokines (FA + LIGHT, FA + IL-17A, FA + TNF-α) for 24h. LDs were visualized 
by staining with LD540 (neutral lipid stain) and Hoechst (nuclear stain). (A, D) Representative fluorescent pictures. 
(B, E) Neutral lipid accumulation (pixel area (LD540+area) in microns per hepatocyte), and (C, F) number and size 
of LDs were analyzed by ImageJ, for (B, C) primary mouse hepatocytes and (E, F) dHepaRG cells. (G-I) dHepaRG 
cells were left untreated, or were treated with FA alone, and in combination with one or all cytokines (FA + BS1, FA 
+ LIGHT, FA + IL-17A, FA + TNF-α, FA + Cytokine Combination, FA + IL-4, FA + IFN-γ) for 24h. LDs were visualized 
by staining with LD540 (neutral lipid stain) + Hoechst (nuclear stain). (G) Lipid accumulation of LipidTOX green 
stained dHepaRG was analyzed by flow cytometry. FA storage was quantified by determination of the LipidTOX 
green mean area. (H) Neutral lipid droplet accumulation (pixel area (LD540+area) in microns per hepatocyte), was 
analyzed by ImageJ. (I) Representative fluorescent pictures. Statistical analysis was performed by one-way 
ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant.  
 
4.1.3. Inflammation promotes fatty acid storage in form of triglycerides 
Inflammatory cytokines affect intracellular lipid levels, to investigate their influence on lipid 
composition, the lipidome of dHepaRG cells under normal conditions, in a lipid-rich and 
inflammatory microenvironment was determined by liquid chromatography mass spectrometry 
(LC-MS). Several lipid classes were detected including DGs, TG, PLs, and GPLs (Figure 11A). 
FAs were mainly incorporated into TGs, shown by high relative ion intensities (ion counts) 
when compared to other lipid classes (Figure 11A, B). FA storage into TGs was significantly 
increased by additional inflammatory cytokine stimulation (Figure 11B, C, D) including 
TG(16:0/18:0/18:1), TG(18:0/18:1/18:1), and TG(18:0/18:1/20:2). Only few DGs were 
identified by lipidomic analysis (Figure 11A). FA incorporation into the DGs, including DG 
(16:0/18:0/0:0) and DG (18:1/18:2/0:0), was significantly elevated by additional inflammatory 
mediator stimulation (Figure 11E). FA storage into PLs was markedly lower (Figure 11A), 
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inflammatory cytokine stimulation intensified relative PL level of PE (P-16:0/20:4) (Figure 11F). 
The relative ethanolamine glycerophospholipid (GPEtn) levels were also significantly 
increased by inflammatory cytokine treatment (Figure 11G).  
Lipidomic analysis showed that inflammation intensifies the incorporation of FAs into TGs, 
revealing that inflammatory cytokines affect primarily lipid concentration and not composition 




Figure 11: Liquid chromatography-mass spectrometry (LC-MS) analysis of dHepaRG cells under 
normal conditions, and in an inflammatory microenvironment in presence and absence of lipids. 
Lipid composition of dHepaRG cells determined by LC-MS. Cell lipid extracts were analyzed from dHepaRGs that 
were either untreated, treated with the inflammatory cytokine TNF-α, stimulated with FAs alone and in combination 
with inflammatory cytokines (FA + BS1, FA + LIGHT, FA + IL-17A, FA + TNF-α, FA + Cytokine Combination) for 
24h. (A) Heatmap displays relative ion intensities (ion counts) of detected lipids. (B, C) Relative ion intensities (ion 
counts) of TGs normalized to CTRL. (D-G) Relative ion intensities (ion counts) of detected lipids, TGs, DGs, PLs, 
and GPEtn. LC-MS data were not normalized to biological sample amounts. Lipid identification was done by 
accurate MS1 (< 5 ppm) and in-silico MS/MS match (> 10% score). Peak area was quantified for 4 replicates per 
condition. LipidBlast and Waters Library hits from Progenesis was used as Metabolite ID library. Xcalibur Quan 
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software was used for analysis. The instrument Vanquish-UHPLC_Q-exactive plus_2 was used. Statistical analysis 
was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
4.1.4. Catabolic deficiencies induced by inflammatory mediators promote aberrant lipid storage 
To discover metabolic mechanisms of intensified FA storage, upon inflammatory cytokine 
stimulation, their influence on essential lipid metabolic pathways was determined. Radioactive 
labelled lipids were used to trace FA- uptake, de novo synthesis, and oxidation. To address 
lipid export, TG concentration was determined in the cell supernatant. 
Of note, FA uptake (Figure 12A) and FAO (Figure 12B) was markedly lower in cells that were 
exposed to inflammatory cytokines. In contrast, inflammatory mediators showed a negligible 
effect on FA de novo synthesis (Figure 12C) and FA / TG export (Figure 12D). The molecular 
regulation of increased FA storage and at the same time reduced FA uptake remained unclear. 
However, these results showed that downregulation of lipid catabolic processes such as FAO 
are likely the key mechanism that induces aberrant lipid accumulation in hepatocytes. 
Figure 12: Radioactive labelling of lipids to trace FA- uptake, de novo synthesis and oxidation. 
Lipid export was quantified by secreted TGs. 
dHepaRG cells, were treated with FAs alone and in combination with inflammatory cytokines (FA + BS1, FA + 
LIGHT, FA + IL-17A, FA + TNF-α) for 21h. Radioactive labelled lipids, (A)14C-Bromo-palmititic acid for FA uptake, 
(B)14C-Palmitic acid for FAO, and (C) 14C-Acetic acid (AA) for FA de novo synthesis, were additionally added for 
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another 3h. Radioactivity was measure in (A, C) lipid extracts of cell lysates and (B) cell supernatant by scintillation 
counting. (D) TG concentration was determined in cell supernatant. All measurements were normalized to biological 
sample amount, based on the protein concentration, per mg protein. Statistical analysis was performed by one-way 
ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
4.1.5. Inflammation rapidly affects fatty acid metabolism in hepatocytes 
To further address the influence of inflammatory mediators, known to affect extent and severity 
of NASH 88, on FA- uptake, storage, and oxidation over time, dHepaRG cells were subjected 
to fluorescence (BODIPY) and radioactive labelled (3H) palmitic acid for different time points. 
FA uptake by hepatocytes was already visible after 1h of treatment. Additional exposure to 
BS1, IL-17A, TNF-α, and the cytokine combination significantly reduced FA uptake (Figure 
13A). After 3h of treatment, lipid concentrations were similar between all FA containing 
conditions without an additional effect induced by inflammatory cytokines. Exposure to 
inflammatory cytokines decreased FAO after 3h (Figure 13B), however not significantly. 24h 
of treatment with FAs intensified FA concentration which was further increased by 
simultaneous exposure to the cytokine combination (Figure 13A). FAO was significantly 
reduced after 24h of FA and cytokine stimulation (Figure 13B).  
These results show that within 1h, a cytokine induced intrahepatic signalling affects / 
downregulates FA metabolism (FA uptake) in dHepaRG cells. 3h of exposure to lipids and 
inflammatory mediators showed similar lipid levels, likely due to deficiencies in catabolic 
processes, such as FAO, which is leading to lipid accumulation. After 24h of inflammatory 
cytokine treatment, FA storage was further elevated, indicating that intensified catabolic 
deficiencies over time induce exacerbated lipid accumulation in dHepaRG cells. 
 
Figure 13: Fluorescence and radioactive labelling of lipids to study FA- uptake, storage, and 
oxidation in dHepaRG cells. 
(A) dHepaRG cells were either untreated, stimulated with FAs plus C16-BODIPY, and with FAs plus C16-BODIPY, 
together with all cytokines (FA + Cytokine Combination) for 1h, 3h, and 24h. C16-BODIPY uptake and storage was 
determined by flow cytometry analysis and quantified by BODIPY (fluorescence) mean area. (B) dHepaRG cells 
were treated with FAs, and with FAs in combination with inflammatory cytokines (FA + LIGHT, FA + IL-17A), and 
the radioactive labelled FA (3H-palmitic acid), either immediately, for 3h, or after 21h of pre-treatment, with FA, FA 
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+ LIGHT, and FA + IL-17A), for 3h. Radioactivity was measured in cell supernatant, by scintillation counting. 
Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: 
not significant. 
 
4.1.6. NF-ĸB-driven inflammation affects lipid metabolism in dHepaRG cells 
Intensified lipid accumulation was observed upon exposure to pro-inflammatory mediators. 
Thus, I studied the involved signalling pathways, and how they affect the lipid accumulation in 
hepatocytes. NASH-derived, pro-inflammatory cytokines, LIGHT, IL-17A, and TNF-α, can 
activate the canonical (Figure 14A) and BS1/LIGHT, TNF-α, the non-canonical NF-ĸB 
signalling (Figure 14B). To examine whether increased lipid accumulation was triggered by 
canonical NF-κB activation, primary mouse hepatocytes with a hepatocyte specific IKKß knock 
out (IKKßΔhep), CRISPR-Cas mediated IKKß knock out (IKKß KO) dHepaRG cells, and 
dHepRG cells treated with the selective inhibitor of human IκB kinase-2 (IKK-2/ß), TPCA-1, 
were used.  
In line with previous results, inflammatory cytokine stimulation intensified neutral lipid storage 
(Figure 14C, D). Loss of IKKß in primary mouse hepatocytes and in dHepaRG cells interfered 
with increased FA storage. Simultaneous exposure to TPCA-1 prevented elevated lipid 
accumulation induced by inflammatory cytokines (Figure 14E, F, G). 
These results clearly demonstrate that canonical NF-κB signalling affects lipid metabolism in 





Figure 14: FA storage into neutral lipids in hepatocytes with deficiencies in canonical NF-ĸB 
signalling, determined by LD540 / Hoechst and LipidTOX green staining.  
dHepaRG cells were either untreated, stimulated with FAs alone and in combination with inflammatory mediators 
(FA + BS1, FA + LIGHT, FA + TNF-α) for 24h. (A, B) Immunoblot analysis of dHepaRG cells, showing activation of 
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(A) canonical NF-ĸB pathway, by phosphorylation of p65 (P-p65) and (B) non-canonical NF-ĸB pathway, by 
degradation of p100 to p52.  
(C, D) Primary mouse hepatocytes, control cells, and cells with a hepatocyte specific IKKß KO (IKKßΔhep) and (E, 
F) dHepaRG cells  in presence and absence of the IKKß inhibitor, TPCA-1, were left untreated, or were treated with 
FAs alone and together with cytokines (FA + BS1, FA + LIGHT, FA + IL-17A, FA + TNF-α, FA + Cytokine 
Combination) for 24h. LDs were visualized by staining with LD540 (neutral lipid stain) + Hoechst (nuclear stain). (C, 
E) Representative fluorescent pictures. (D, F) Neutral lipid droplet accumulation (pixel area (LD540+area) in 
microns per hepatocyte), analyzed with Image J. (G) dHepaRG cells in presence and absence of TPCA-1, and 
CRISPR Cas-mediated IKKß knock out (IKKß KO) dHepaRG cells, were untreated, FA treated and stimulated with 
FAs plus cytokines (FA + BS1, FA + LIGHT, FA + IL-17A, FA + TNF-α, FA + Cytokine Combination) for 24h. (G) 
Neutral lipid accumulation, was determined by LipidTOX green staining. LipidTOX green mean area was quantified 
by flow cytometry analysis. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p 
< 0.001; ****: p < 0.001; ns: not significant. 
 
4.1.7. Activation of the canonical- and non-canonical NF-ĸB pathway drives neutral lipid 
accumulation in hepatocytes 
To further investigate the role of canonical and non-canonical NF-κB signalling on lipid 
metabolic processes, human hepatocytes with deficiencies in NF-ĸβ signalling (CRISPR-Cas 
mediated IKKß KO (canonical) and NIK KO (non-canonical) dHepaRG cells) were generated 
and used thereafter.  
FA treatment induced FA storage into neutral lipids, and additional inflammatory cytokine 
stimulation further intensified this effect in non-targeting control (NTC) dHepaRG (Figure 15A, 
B, C). Deficiencies in NF-ĸB signalling induced by CRISPR-Cas mediated IKKß KO, NIK KO, 
and IKKß-NIK double KO inhibited intensified FA storage (Figure 15A, B, C), revealing that 
interference with inflammatory cytokine dependent activation of the canonical and non-





Figure 15: FA storage into neutral lipids in dHepaRG with deficiencies in canonical and non-
canonical NF-ĸB signalling, determined by LipidTOX green / Hoechst staining.  
Non-targeting control (NTC), IKKß knock out (IKKß KO), NIK knock out (NIK KO) and IKKß-NIK double knock out 
(IKKß NIK KO) dHepaRG cells were, untreated, FA treated and FA plus cytokine treated (FA + BS1, FA + LIGHT, 
FA + IL-17A, FA + TNF-α, FA + Cytokine Combination) for 24h. (A) Representative fluorescence pictures of 
LipidTOX green / Hoechst stained dHepaRG cells, to visualize lipid accumulation and (B, C) LipidTOX green mean 
area was quantified by flow cytometry analysis. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; 
**: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
4.2. Cellular stress response to inflammation and lipids 
 
4.2.1. Mitochondrial morphology is affected by inflammation in a lipid-rich environment 
Mitochondria produce energy (ATP) by oxidative phosphorylation (e.g. by FAO), regulate major 
metabolic pathways, and are critically involved in cell death control. Mitochondria cannot be 
formed de novo, therefore constant fission and fusion events are taking place. Fission- and 
fusion-deficiencies promote mitochondrial dysfunction, diminish ATP production, and decrease 
mitochondrial membrane potential and respiratory chain enzyme activity 68. 
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To investigate the involvement of FAs and inflammatory cytokines on mitochondrial 
morphology, dHepaRG cells were stimulated with lipids and cytokines, and mitochondria were 
visualized by MitoTrackerRed staining. 
Mitochondria of unstimulated and FA stimulated cells showed a similar morphology (Figure 
16). Cells that were simultaneously treated with lipids and inflammatory cytokines displayed 
changes in mitochondrial morphology. FA plus BS1 or LIGHT treatment induced a breakup of 
the mitochondrial network leading to small, independent organelles (presumably induced by 
mitochondrial fusion deficiency). FA plus IL-17A and TNF-α more likely promoted mitochondrial 
fusion events which resulted in a highly interconnected network (showing fission-deficiency). 
Mitochondrial staining showed that inflammatory cytokines affect mitochondrial morphology. 
 
Figure 16: Mitochondrial morphology is affected by inflammation in a lipid-rich environment. 
Mitochondrial staining of dHepaRG cells by MitoTracker red. 
dHepaRG cells were untreated, stimulated with FAs alone and in combination with inflammatory cytokines (FA + 
BS1, FA + LIGHT, FA + IL-17A and FA + TNF-α) for 24h. Mitochondria were visualized by MitoTracker Red staining 
and fluorescence microscopy. Representative images are shown. 
 
4.2.2. Inflammatory cytokines interfere with mitochondrial polarization and function  
Mitochondrial ATP synthesis is induced by the generation of an electrochemical gradient where 
protons (H+) are pumped from the mitochondrial matrix to the inner membrane space by 
oxidative phosphorylation complexes, leading to the formation of a transmembrane potential 
and ROS. Downregulation of genes that regulate FAO or antioxidation processes promotes 
mitochondrial depolarization, increases ROS production, and induces functional impairment of 
mitochondria, by arresting oxidative phosphorylation. In addition, mitochondrial depolarization 
can interfere with proteins that regulate cellular apoptosis which further increases 
mitochondrial permeabilization, caspase activation, and cell death. Inflammatory cytokines, 
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such as TNF-α, can depolarize mitochondrial membranes and can thereby induce 
mitochondrial dysfunction, however underlying mechanisms are not known in detail yet 195. 
To explore the influence of inflammatory cytokines and FAs on mitochondrial function over 
time (24h, 48h), cells were stained with the JC-1 dye to monitor mitochondrial membrane 
potential. 
JC-1 accumulation in the mitochondria is shown by a fluorescence emission shift from JC-1 
green monomers in the cytoplasm (mitochondrial depolarization, unhealthy) to JC-1 red 
aggregates (healthy, JC-1 dye trapped in the mitochondria). Pre-apoptotic cells display 
hyperpolarized mitochondria, whereas apoptotic cells show depolarized mitochondria 196.  
The JC-1 ratio of healthy mitochondria in dHepaRG was determined in untreated control cells 
(Figure 17A, B). As positive control (for mitochondrial depolarization), cells were subjected to 
the mitochondrial uncoupler, CCCP, which led to a decrease in mitochondrial membrane 
potential, indicated by a reduced red to green fluorescence ratio when compared to healthy 
untreated control cells (Figure 17A, B). FA treatment did not influence the mitochondrial 
membrane potential after 24h, shown by a similar JC-1 red to green ratio when compared to 
unstimulated cells. FA plus BS1, LIGHT, and TNF-α increased the mitochondrial 
depolarization, indicative for mitochondrial dysfunction and presumably apoptotic cell death. 
FA stimulation together with IL-17A and the combination of all cytokines induced mitochondrial 
hyperpolarization, shown by a significant increase in the JC-1 red to green ratio, displaying 
early-phase of apoptosis (Figure 17A, B).  
After 48h of stimulation with FAs the JC-1 red to green ratio was decreased, displaying that 
pro-longed / chronic lipid stimulation reduced mitochondrial polarization, probably by 
lipotoxicity induced-stress response and ROS production (Figure 17C, D). Exposure to FAs 
plus BS1, LIGHT, IL-17A, TNF-α, and the cytokine combination further intensified 
mitochondrial depolarization. Cells that were subjected to BS1, LIGHT, TNF-α and the cytokine 
combination without lipids also displayed mitochondrial depolarization (Figure 17E, F). This 
demonstrates that the activation of inflammatory signalling pathways can induce mitochondrial 
dysfunction. In contrast, dHepaRG stimulation with the inflammatory cytokine IL-17A alone did 
not affect mitochondrial functions. These results revealed that inflammatory mediators 
promoted mitochondrial dysfunction which is dependent on the primary signalling pathway 
activation and the duration of exposure to the different cytokines and lipids. Inflammation can 
induce mitochondrial dysfunction and presumably apoptotic cell death either directly (after 24 
hours), or induce a pre-apoptotic phenotype which can shift to apoptosis after prolonged 
treatment for after 48h. Thus, lipid excess in combination with an activated immune signalling 







Figure 17: Inflammatory cytokines interfere with mitochondrial morphology and function.  
JC-1 staining to monitor mitochondrial membrane potential in dHepaRG cells. 
dHepaRG were untreated, were stimulated with inflammatory mediators (BS1, LIGHT, IL-17A, TNF-α, Cytokine 
Combination) alone, were FA treated, and were treated with FAs plus inflammatory mediators (FA + BS1, FA + 
LIGHT, FA + TNF-α, FA + Cytokine Combination) for (A, B) 24h and (C-F) 48h. Cells were stained with JC-1 dye to 
determine mitochondrial polarization, by flow cytometry analysis and quantification of the ratio of the JC-1 red mean 
area and the JC-1 green mean area. (A, B) As positive control cells were subjected to the mitochondrial uncoupler 
CCCP. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 
0.001; ns: not significant. 
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4.2.3. Mitochondrial dysfunction is induced by specific inflammatory cytokines 
Exposure to the cytokine IL-4 did not influence FA storage in dHepaRG cells. To study the 
effect of IL-4 on mitochondrial membrane potential dHepaRG cells were stained with JC-1 dye. 
FA treatment reduced JC-1 red to green ratio, indicating mitochondrial depolarization. 
Additional BS1 stimulation further intensified this effect (Figure 18A, B). FA plus IL-4 
stimulation did not induce mitochondrial dysfunction, as shown by a similar JC1 red to green 
ratio when compared to the FA condition. 
These results demonstrate that only specific inflammatory cytokines promote mitochondrial 
dysfunction. 
 
Figure 18: Mitochondrial dysfunction is induced by specific inflammatory cytokines. 
JC-1 staining to monitor mitochondrial membrane potential in dHepaRG cells. 
(A, B) dHepaRG were, untreated, FA treated, and treated with FAs plus cytokines (FA + BS1, FA + IL4) for 24h. 
Staining with JC-1 dye to determine mitochondrial polarization by flow cytometry analysis, by quantification of the 
ratio of JC-1 red mean are and JC-1 green mean area. As positive control cells were additionally treated with the 
mitochondrial uncoupler, CCCP. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; 
***: p < 0.001; ****: p < 0.001; ns: not significant. 
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4.2.4. Inflammatory cytokines affect mitochondrial function via NF-ĸB signalling 
Inflammatory cytokines can signal via NF-ĸB, and interference with the NF-ĸB pathway 
prevented aberrant lipid storage. Thus, to investigate the influence of NF-ĸB on inflammation 
induced mitochondrial dysregulation, cells were treated with the IKKβ inhibitor, TPCA-1, and 
then stained with the JC-1 dye. 
FA plus cytokine stimulation decreased mitochondrial membrane potential (Figure 19A, B). 
Simultaneous treatment with the IKKß inhibitor, TPCA-1 prevented the cytokine induced 
mitochondrial dysfunction (Figure 19B). This shows that inhibition of NF-ĸB signalling via 
TPCA-1 prevented mitochondrial depolarization. 
 
Figure 19: Inflammatory cytokines affect mitochondrial function via NF-ĸB signalling. 
JC-1 staining to monitor mitochondrial membrane potential in dHepaRG cells. 
(A, B) dHepaRG cells, FA treated, and treated with FAs plus inflammatory mediators (FA + BS1, FA + LIGHT, FA 
+ TNF-α, FA + Cytokine Combination), with and without the IKKß inhibitor TPCA-1, for 48h. Staining with JC-1 dye 
to determine mitochondrial polarization, by flow cytometry analysis, by quantification of the ratio of JC-1 red mean 
area and JC-1 green mean area. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; 
***: p < 0.001; ****: p < 0.001; ns: not significant. 
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4.2.5. Fatty acids and inflammatory cytokines increase reactive oxygen species production, 
induce cell- apoptosis, proliferation and trigger replication stress and DNA damage 
NF-ĸB activation by inflammatory cytokines increased lipid accumulation and affected 
mitochondrial function. To address the effect of inflammation and lipid induced cellular stress 
response, I determined mitochondrial superoxide production, apoptotic cell death, cell 
proliferation, and DNA replication dynamics.  
FA stimulation induced lipid accumulation and mitochondrial superoxide production, shown by 
red mitochondrial superoxide staining which correlated with the green lipid staining (Figure 
20A). This indicates that high intracellular lipid concentrations promoted mitochondrial 
superoxide generation. Exposure to FAs and the cytokine combination intensified both, ROS 
production and neutral lipid accumulation, which also correlated with each other. Interference 
with ROS generation, by additional treatment with N-acetylcysteine, only slightly reduced lipid 
storage in both, FA, and FA plus inflammatory cytokine stimulated cells (Figure 20B). Elevated 
mitochondrial superoxide generation and intensified lipid accumulation induced by high lipid 
storage was prevented by simultaneous treatment with the IKKß-inhibitor, TPCA-1 (Figure 
20A, B). This analysis demonstrates that inflammatory cytokines intensify lipid accumulation 
and promote, probably as secondary effect, increased ROS production.  
To address the influence of inflammation and lipids on apoptosis, cells were stained with 
cleaved caspase 3 and annexin V antibodies. In the FA stimulated condition, only few cells 
were positive for red cleaved caspase 3 staining (Figure 20C), and the annexin V mean area 
was increased when compared to untreated cells (Figure 20D). FA plus inflammatory cytokine 
treatment exacerbated the number of red cleaved caspase positive cells and highly increased 
lipid levels (Figure 20C). Inhibition of apoptosis by the pan-caspase inhibitor Z-VAD-FMK, 
reduced apoptotic cell death in FA and FA plus inflammatory cytokine stimulated cells (Figure 
20D). Lipid levels were not affected by the inhibition of apoptosis (Figure 20E). This revealed 
that elevated FA storage induced by inflammation intensified apoptotic cells death. 
To determine cellular proliferation, cells were treated and stained with bromodeoxyuridine 
(BrdU). FA treatment mildly induced cell proliferation, shown by positive green nuclear staining, 
when compared to untreated control cells (Figure 20F, G). Additional treatment with 
inflammatory cytokines further increased the number proliferating cells. Simultaneous 
exposure to the IKKß inhibitor, TPCA-1 prevented increased cell proliferation (Figure 20F), 
indicating that cell proliferation was promoted by lipid stimulation and intensified by 
inflammatory NF-ĸB-signalling activation. 
Inflammatory stress response, apoptosis and compensatory proliferation can affect DNA 
replication. To study the influence of lipids and inflammatory cytokines on replication stress, 
protein levels of DNA double strand break markers and replication fork speed was determined. 
DNA double strand break marker (gH2Ax, 53BP1) levels were elevated by FA treatment and 
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were further increased by additional inflammatory cytokine exposure (Figure 20H, I). 
Replication dynamics by DNA combing demonstrated significant reduced replication fork 
speed in FA plus inflammatory cytokine stimulated cells when compared to FA treated cells, 
indicative of replication stress (Figure 20J).  
This showed that inflammatory cytokines and FAs induce double strand breaks, replication 










Figure 20: Mitochondrial superoxide production, lipid accumulation, apoptotic cell death, 
proliferation, and replication stress in dHepaRG cells. 
dHepaRG cells were either untreated, treated with FAs alone and in combination with inflammatory cytokines (FA 
+ Cytokine Combination, FA + BS1, FA + LIGHT, FA + IL-17A, FA + TNF-α), with and without the IKKß inhibitor 
TPCA-1, the ROS inhibitor N-acetylcystein, and the pan-caspase inhibitor Z-VAD-FMK, for 24h. (A) dHepaRG cells 
were stained with MitoSOX red and LipidTOX green, to visualize mitochondrial superoxide production and neutral 
lipid accumulation. Representative fluorescence pictures are shown. (B, E) dHepaRG were stained with LipidTOX 
green to quantify neutral lipid accumulation, analyzed by flow cytometry. Cells were additionally treated with (B) the 
IKKß inhibitor TPCA-1, the ROS inhibitor N-acetylcystein, and (E) the pan-caspase inhibitor Z-VAD-FMK. (C) 
Cleaved caspase 3 antibody staining, to quantify apoptotic cell death in combination with LipidTOX green stain, to 
visualize lipid accumulation by fluorescence microscopy. Representative images are shown. (D) Annexin V staining 
to quantify cell apoptosis by flow cytometry. Determination of the annexin V mean area (fluorescence). (F, G) Cell 
proliferation was determined by BrdU staining, by fluorescence microscopy and flow cytometry. (F) Representative 
pictures of BrdU stained dHepaRG (G) BrdU (fluorescence) mean area was determined by flow cytometry (H) 
Immunoblot analysis of the DNA damage (double strand break marker), gH2Ax. (I) quantification of the 
immunofluorescence staining, of DNA double strand break marker 53BP1, analyzed by imageJ (J) Replication 
dynamics determination by DNA combing to analyze replication fork speed. (H-J) Immunoblot analysis of gH2Ax, 
immunofluorescence analysis of 53BP, and the determination of replication fork speed assay was performed by 
Romain Donne, MSc, in a collaboration with Dr. Chantal Desdouets, Statistical analysis was performed by one-way 
ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
4.3. NF-ĸβ signalling – PPAR-α signalling  
 
4.3.1. Inflammatory cytokines affect gene and protein levels of PDK4  
Aberrant FA storage is induced by inflammation due to lipid catabolic deficiencies. The nuclear 
hormone receptor, PPARA, regulates major lipid metabolic pathways in hepatocytes including 
FA- uptake, storage, and oxidation 197. The PPARA target gene PDK4 is critically involved in 
the regulation of glucose- and FAO by phosphorylation of Pyruvate dehydrogenase complex 
(PDC) 74.  
The effect of inflammatory cytokines and lipids on genes and protein levels implicated in NF-
ĸB- and PPAR-α signalling was determined.  
Inflammatory cytokine stimulation upregulated NFKB2 (Figure 21A). PPAR-α gene and 
protein levels remained unchanged by FA, and additional cytokine treatment (Figure 21B, D). 
Lipid stimulation elevated PDK4 levels, additional exposure to inflammatory cytokines 
74 
 
downregulated PDK4 (Figure 21C, E). FA stimulation intensified phosphorylation of PDC when 
compared to untreated and FA plus Cytokine Combination (Figure 21F). Showing that 






Figure 21: Gene expression analysis and immunofluorescence stainings of dHepaRG cells, 
stimulated with FAs and cytokines. 
dHepaRG cells were, untreated, FA treated, and FA plus inflammatory cytokine (FA + Cytokine Combination) 
stimulated, for 24h. (A-C) Gene expression analysis of PPARA, PDK4 and NFKB2, by RT-PCR. 
Immunofluorescence staining against (D) PPAR-α, (E) PDK4, and (F) Phospho-PDC, representative images are 
shown. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 
0.001; ns: not significant. 
 
4.3.2. PPAR-α and PDK4 are not involved in inflammation-triggered elevated lipid 
accumulation 
To investigate the effect of PPAR-α and PDK4 on inflammation-mediated downregulation of 
lipid metabolic processes, si-RNA mediated PPAR-α and PDK4 knock down (KD) experiments 
were performed.  
FA treatment induced FA storage into neutral lipids and simultaneous stimulation with 
inflammatory cytokines further elevated lipid accumulation in NTC cells (Figure 22A). Si-RNA 
mediated PPAR-α KD in cells that were exposed to FAs, with and without inflammatory 
cytokines, revealed comparable lipid levels. Inflammation triggered aberrant lipid accumulation 
was not affected by loss of PDK4 (Figure 22A). Although, gene expression analysis displayed 
that si-RNA mediated PDK4 KD was efficient (Figure 22B). 
This showed that increased FA storage upon PPAR-α deficiency is an inflammation 
independent mechanism and that the PPAR-α-PDK4 axis is not critical for inflammation 




Figure 22: FA storage into neutral lipids in hepatocytes (dHepaRG) determined by LipidTOX 
green staining. 
dHepaRG cells, siRNA-mediated non-targeting control (NTC), PPARA KD and PDK4 KD, cells were untreated, FA 
treated, and treated with FA in combination with all cytokines (FA + Cytokine Combination) for 24h. Lipid 
accumulation was quantified by LipidTOX green staining and flow cytometry, by determination of LipidTOX green 
mean area. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p 
< 0.001; ns: not significant. 
 
4.4. Transcriptome profiling by RNA sequencing  
 
4.4.1. Inflammatory cytokines are the major regulators of overall gene expression in a lipid-rich 
environment in human dHepaRG cells 
Inflammatory mediators induced increased lipid accumulation in hepatocytes, driven by 
catabolic deficiencies. To explore whether these mechanisms are regulated by gene 
expression, RNA sequencing analysis was performed to disentangle differences between gene 
regulations induced by inflammatory mediators, by FAs and by cytokines in combination with 
FAs. 
On average, about 13.579 genes where detected per sample (Figure 23A). To address 
similarities and differences between all conditions the samples were clustered by principal 
component analysis (PCA) (Figure 23B) and euclidean distance matrix (tSNE) (Figure 23C), 
using normalized counts of all genes. These results displayed that untreated control cells and 
FA stimulated cells clustered closely nearby, showing that their gene expression profile is 
similar. BS1 and LIGHT treated samples with and without FAs were grouping together, 
revealing a similar gene regulation, induced by LTßR signalling activation. In addition, IL-17A 
stimulated samples in presence and absence of FAs clustered together. Additional stimulation 
with the IKKß inhibitor TPCA-1, of FA and IL-17A treated cells, spatially separated the samples 
(within the PCA plot) from the other ones, showing that NF-ĸB inhibition interfered with gene 
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expression induced by IL-17A. Cells that were stimulated with TNF-α, or the cytokine 
combination alone and together with FAs, formed groups separately from the other ones. RNA 
sequencing based sample clustering revealed that inflammatory mediators are the main 





Figure 23: RNA sequencing analysis; general numbers of detected genes, sample clustering by 
principal component analysis (PCA), and euclidean distance matrix (tSNE). 
Human dHepaRG cells were left untreated, were treated with inflammatory mediators (BS1, IL-17A, TNF-α, LIGHT, 
Cytokine Combination (Combo)) alone, were treated with FAs alone and together with inflammatory mediators (FA 
+ BS1, FA + IL-17A, FA + LIGHT, FA + TNF-α and FA + Combo) for 24h. FA plus IL-17A stimulated cells were 
additionally treated with the IKKß-inhibitor TPCA-1 (FA + IL-17A + TPCA1). For differential expression (DE) analysis 
genes were ranked based on their log2foldchange (log2FC≥1) and adjusted p value (padj<0.05) and normalized 
counts of all genes, raw counts (count < 2), were used. (A) Total number of genes detected by RNA sequencing. 
Sample clustering shown by (B) PCA and (C) tSNE. Genes and proteins were described by using 
ProteinDomainVisualizer. 
 
4.4.2. Fatty acid stimulation promotes upregulation of genes involved in lipid metabolic 
processes and proliferation 
Differential expression (DE) analysis was performed to discover gene regulations induced by 
FAs when compared to untreated controls. Lipid stimulation upregulated PPAR-α target genes 
e.g. ANGPTL4, FABP4, PDK4, FABP1, PLIN2, implicated in lipid uptake-, transport-, storage 
and catabolism (Figure 24A, B). In addition, FA treatment led to elevated expression of genes 
involved in other metabolic processes such as ketogenesis (HMGCS2) and peroxisomal 
biosynthesis (PEX11A) and increased levels of genes essential for cell cycle regulation 
including CCNF (CyclinF, regulates cell cycle transitions), CDCA3 (required for entry into 
mitosis), DCD20 (essential regulator during cell division, and for activation of anaphase), 
NUSAP1 (promotes the organization of mitotic spindle microtubules), and RRM2 (involved in 
biosynthesis of deoxyribonucleotides, thus for DNA synthesis).  
Exposure to FAs downregulated genes implicated in the regulation of apoptotic cell death 
including ANKRD1 (shows increased levels during apoptosis) and TNFRSF11B (can interfere 
with apoptosis) (Figure 24A, B). Gene set enrichment analysis (GSEA) displayed a higher 
expression of genes involved cell proliferation, including following terms, DNA strand 
elongation and activation of ATR in response to replication, cell cycle, and M-phase in FA 
treated cells (Figure 24C, D). In untreated cells, expression of genes implicated in extracellular 
matrix organization, post-translational protein phosphorylation and insulin-like growth factor 
(IGF) modification was increased. DE analysis showed that FA treatment affected expression 













Figure 24: RNA sequencing analysis, volcano plot, heatmap, and gene set enrichment analysis 
(GSEA), comparing FA treated and untreated dHepaRG cells. 
DE analysis (gene ranking based on log2foldchange (log2FC≥1) and adjusted p value (padj<0.05), (A) Volcano plot 
(based on DE analysis) illustrates genes that are up-and downregulated by FA stimulation in dHepaRG cells. (B) 
Heatmap showing significant (padj<0.05) up- and down regulated genes, ranked by log2foldchange (log2FC) (C, 
D) GSEA ranked by log2 fold change with padj<0.05 or padj<0.05. Genes and proteins were described by using 
ProteinDomainVisualizer. 
 
4.4.3. Lymphotoxin ß receptor signalling activators affect the expression of genes essential for 
the regulation of inflammation, proliferation, apoptosis, and metabolic processes  
To address the influence of LTßR signalling activation on the regulation of the whole gene 
expression in dHepaRG cells, DE analysis was performed comparing untreated control cells 
with cells that were exposed to the LTßR agonist BS1, or the inflammatory cytokine LIGHT. In 
addition, FA stimulated cells were compared with FA plus BS1 or LIGHT treated cells.  
DE analysis showed that BS1 stimulation in presence and absence of FAs induced a similar 
gene expression pattern (Figure 25A, B). Exposure to BS1 increased levels of genes 
implicated in the regulation of inflammatory response, cell proliferation and apoptosis. 
Upregulated genes by BS1 included BIRC3 (regulates apoptotic cell death, inflammatory 
signalling and cell proliferation), MMP7 and MMP9 (metalloproteases, break down extracellular 
matrix), TRAF1 and TRAF2 (involved in TNFR signalling, regulate mitogen-activated protein 
kinase (MAPK), c-Jun N-terminal kinase (JNK), NF-ĸB signalling, and apoptosis), VCAM1 and 
ADGRE1 (regulate cell-cell interactions) (Figure 25A, B). Downregulated genes by BS1 
stimulation included IGFBP5 (can regulate cell growth), KCNJ16 (regulates cellular fluids and 
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maintains the pH balance), HMGCS2 (catalyses the first reaction of ketogenesis), CA9 (a 
metalloenzyme, catalyzes the hydration of carbon dioxide), (KRT19 (a biliary cell marker) and 
GSTA1 (a detoxification enzyme). DE analysis showed that BS1 stimulation in presence and 
absence of FAs decreased genes involved in the regulation of metabolic processes including 
enzymes essential for anabolic and catabolic processes, oxidation, and cell differentiation.  
GSEA, by Kyoto Encyclopaedia of Genes and Genomes (KEGG), showed elevated 
enrichment of genes in BS1 stimulated cells, with and without FAs, were involved in cell 
proliferation and cellular stress response including following KEGG terms DNA Replication, 
Homologous Recombination Mismatch Repair, Proteasome, Primary Immunodeficiency, Base 
Excision Repair, Nucleotide Excision Repair, Oocyte Meiosis and Pyrimidine Metabolism 
(Figure 25C).  
GSEA analysis displayed reduced levels of genes essential for homeostasis of major metabolic 
processes involved in following KEGG terms, Drug Metabolism - cytochrome P450, (CYPs), 
Metabolism of Xenobiotics, Complement and Coagulation Cascades, Retinol Metabolism, 
Steroid Hormone Biosynthesis, Hypertrophic Cardiomyopathy (HCM) and Tight Junction, Type 
II Diabetes Mellitus, Glycolysis Gluconeogenesis, Peroxisome, Axon Guidance and Calcium 
Signalling Pathways (Figure 25C).  
DE analysis comparing LIGHT with untreated control cells and LIGHT plus FAs with FA treated 
cells, revealed a similar gene expression profile as BS1 treated cells (Figure 25D, E). 
Exposure to LIGHT, with and without FAs, increased expression of genes involved in cellular 
inflammatory stress-response and regulation of proliferation and apoptosis. Upregulated 
genes comprised e.g. MMP9, IL34 (inflammation), TRAF1, VCAM1, TNFRSF9 (TNFR 
signalling), and CCNF. Downregulated genes by LIGHT treatment in presence and absence 
of FAs were implicated in homeostasis of metabolic processes including e.g. IGFBP5, CYP24 
(mitochondrial monooxygenase), CA9, GSTA1, KRT19, and HMGCS. KEGG pathway analysis 
revealed an enrichment of genes implicated in following KEGG terms, DNA replication, 
Proteasome, Base Excision Repair, Oocyte Meiosis, Progesterone Mediated Oocyte 
Maturation, and Pyrimidine Metabolism (Figure 25F). Genes involved in several metabolic 
processes were decreased by LIGHT treatment, included in following terms, Complement and 
Coagulation Cascades, Drug Metabolism by Cytochrome P450, Metabolism of Xenobiotics by 
Cytochrome P450, Hypertrophic Cardiomyopathy HCM, Valine Leucine and Isoleucine 
Degradation, Arrhythmogenic Right Ventricular Cardiomyopathy ARVC, Retinol Metabolism, 
Steroid Hormone Biosynthesis, ECM Receptor Interaction and Fatty Acid Metabolism (Figure 
25F). 
RNA sequencing analysis showed that BS1 and LIGHT treatment induced a cellular 
inflammatory stress response and interfered with genes essential for several metabolic and 
oxidative processes. Lipid exposure showed a negligible effect on the whole gene expression 
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regulation, indicating that an inflammatory microenvironment mainly determines the gene 










Figure 25: RNA sequencing analysis, volcano plot, heatmap, and gene set enrichment analysis 
(GSEA), comparing BS1 and LIGHT, with and without FAs, with untreated and FA treated 
dHepaRG cells. 
DE analysis (genes ranked by log2 fold change (log2FC≥1) and adjusted p value (padj<0.05)), (A, D) Volcano plot 
(based on DE analysis) illustrates genes that are up-and downregulated by BS1/LIGHT +/- FA stimulation, when 
compared to untreated and FA treated cells. (B, E) Up- and downregulated genes, ranked by log2FC and padj<0.05, 
(C, F) GSEA, KEGG pathway analysis shows gene enrichment ranked by the normalized enrichment score (NES) 
and padj<0.05. Genes and proteins were described by using ProteinDomainVisualizer. 
 
4.4.4. IL-17A stimulation elevates the expression of genes involved in the regulation of 
inflammation and immune response and reduces expression of genes essential for metabolic 
regulations, NF-ĸB signalling prevents gene regulations induced by IL-17A 
To address the impact of IL-17A on overall gene expression in hepatocytes, DE analysis was 
performed comparing dHepaRG cells that were treated with IL-17A with untreated control cells 
and FA plus IL-17A with FA stimulated cells. In line with the results obtained by DE analysis of 
BS1 and LIGHT, IL-17A treatment primarily regulated gene levels with a minor effect induced 
by additional FA stimulation (Figure 26A, B). Genes that were significant elevated upon IL-
17A stimulation included genes critical for the regulation of inflammatory response, such as 
chemokines, acute-phase proteins, and pro-inflammatory mediators e.g. LCN2 (sequesters 
iron, thereby limiting bacterial infections), CXCL1 (chemokine), SOD2 (clears mitochondrial 
ROS), CRP, SAA4 and LBP (acute-phase proteins), SLC43A2 (amino acid transporter), 
SERPINB4 (protease inhibitor) and VNN3 (pantetheinase associated with inflammation). 
Exposure to IL-17A downregulated genes implicated in metabolic, oxidant related processes 
and biliary cell differentiation markers including GSTA1, KRT19, CA9, CYP3A4 (oxidizes 
xenobiotics), NAT8 (involved in detoxification), CD36 (FA uptake protein), FABP1 (FA binding 
protein), HMGCS2,  RGS4 (GTPase activating protein), and ATP1A2 (Na+/K+ ATPase).  
GSEA revealed elevated levels of genes involved in proliferation and inflammation included in 
following KEGG terms, Cell Cycle, DNA Replication, NOD-like Receptor Signalling Pathway, 
Oocyte Meiosis and Cytokine-Cytokine Receptor Interaction (Figure 26C). IL-17A treatment 
reduced expression of genes linked to following KEGG terms,  Drug Metabolism - Cytochrome 
P450, Metabolism of Xenobiotics by Cytochrome P450, Extracellular Matrix (ECM) Receptor 
Interaction, Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), Dilated 
Cardiomyopathy, Valine Leucine and Isoleucine Metabolism, Cardiac Muscle Contraction, 
Complement and Coagulation Cascades, and Tight Junction. 
In line with the RNA Sequencing data from BS1 and LIGHT stimulated cells, IL-17A exposure 
promoted gene expression involved in cellular response to inflammation and downregulated 
genes essential for the regulation of metabolic processes. IL-17A stimulation induced a specific 
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gene expression profile in dHepaRG cells, whereas the effect of additional FA treatment was 
minor.  
Additional TPCA-1 stimulation interfered with the upregulation of genes involved in 
inflammatory response e.g. CXCL1 and CXCL2, SOD2, SAA, LBP, and VNN (Figure 26D). 
Simultaneous TPCA-1 treatment did not influence the downregulation of the biliary cell marker 
KRT19, or CA9, induced by IL-17A, indicating that the downregulation of these enzymes is 
independent on canonical NF-ĸB signalling. FA stimulation with IL-17A plus TPCA-1 
upregulated several metabolic associated genes including SEC11 (removes signal peptides 
from nascent proteins), AFR2 (during regeneration and tumorigenesis), GARS (charge tRNAs 
with their cognate amino acids), CYP1A1 and CYP1B1. In addition, it downregulated STMN1 
(regulates of the cell cytoskeleton), HMGB2 (chromatin-associated non-histone protein 
involved in transcription, chromatin remodeling and V(D)J recombination), RRM2 (catalyzes 
the formation of deoxyribonucleotides) (Figure 26D).  
GSEA analysis showed that additional TPCA-1 stimulation upregulated genes involved in 
metabolic processes included in following KEGG terms Aminoacyl-tRNA Synthesis, Protein 
Export, Metabolism of Xenobiotics by Cytochrome P450, Retinol Metabolism, Axon Guidance. 
Downregulated genes were involved in replication included in following KEGG terms, Cell 
Cycle, DNA Replication, and Oocyte Meiosis. This demonstrated that TPCA-1 prevents 
inflammatory signalling, induced by IL-17A, and the downregulation of metabolism, showing 











Figure 26: RNA sequencing analysis, volcano plot, heatmap, and gene set enrichment analysis 
(GSEA), comparing untreated and IL-17A, and FA plus IL-17A (+/- TPCA-1) treated and FA treated 
HepaRG cells.  
DE analysis (genes ranked by log2 fold change (log2FC≥1) and adjusted p value (padj<0.05), (A,D) Volcano plot 
illustrates genes that are up-and downregulated by (A) IL-17A and FA plus IL-17A (D) and FA plus IL-17A in 
combination with TPCA-1 vs FA. (B) Up- and downregulated genes, ranked bylog2foldchange (log2FC) and 
padj<0.05 (C, E) GSEA, KEGG pathway analysis shows gene enrichment based on the NES and padj<0.05. Genes 
and proteins were described by using ProteinDomainVisualizer. 
 
4.4.5. The pro-inflammatory cytokine TNF-α regulates gene expression of various genes 
critical for inflammation, anti-viral response, and metabolic processes.  
To investigate the involvement of TNF-α on the regulation of gene expression in presence and 
absence of FAs, DE analysis was performed comparing TNF-α with untreated cells and FA 
plus TNF-α with FA stimulated cells (Figure 27A). In line with the DE analysis from the other 
cytokines (BS1, LIGHT, IL-17A) additional lipid stimulation showed a negligible effect on the 
whole gene expression regulation induced by TNF-α (Figure 27A, B). 
Upregulated genes upon TNF-α treatment included genes involved in regulating immune cell 
response, anti-viral response, inflammation, proliferation, and apoptosis. e.g. ISG15, IFIT3, 
IFI6, OAS3 and RSAD2 (associated with type I interferon (IFN) signalling), CXCL10, CXCL11 
and CCL2 (chemokines), IL4I1 (L‐amino acid oxidase enzyme, having an immunomodulatory 
function), MMP9, and ICAM (adhesion molecule). Genes that were significantly downregulated 
by TNF-α treatment included genes involved in several metabolic and oxidant processes, e.g. 
GSTA1, ALDH1 (aldehyde dehydrogenases), CA9, KRT19, IGFBP5, ANGPTL3 (inhibitor of 
lipases), CDH1 (regulates cell adhesion), ANXA9 (phospholipid binding protein), FABP4 and 
FABP1, CYP3A4, and HMGCS2.  
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GSEA revealed increased enrichment of genes implicated in following KEGG terms, 
Proteasome, DNA Replication, Cytosolic DNA Sensing Pathway, RIG I Like Receptor 
Signalling Pathway, NOD Like Receptor Signalling Pathway, Antigen Processing and 
Presentation, Systemic Lupus Erythematosus, Cytokine-Cytokine Receptor Interaction,  
Homologous Recombination, Base Excision Repair, Toll Like Receptor Signalling Pathway, 
Mismatch Repair, Pyrimidine Metabolism, Oocyte Meiosis, RNA Degradation, Apoptosis, 
Chemokine Signalling Pathway, and Small Cell Lung Cancer (Figure 27C). TNF-α treatment 
reduced the expression of genes included in following KEGG terms, Metabolism of Xenobiotics 
by Cytochrome P450, Retinol Metabolism, Drug Metabolism Cytochrome P450, Steroid 
Hormone Biosynthesis, Complement and Coagulation Cascades, Fatty Acid Metabolism 
Vascular Smooth Muscle Contraction, Glycolysis and Gluconeogenesis, and Butanoate 
Metabolism (Figure 27C).  
RNA sequencing based DE analysis showed that TNF-α in presence and absence of lipids 
upregulated genes involved in regulation of immune cell response, anti-viral response (type I 
interferon signalling), proliferation, and apoptosis, and downregulated genes critical for 







Figure 27: RNA sequencing analysis, volcano plot, heatmap, and gene set enrichment analysis 
(GSEA), comparing untreated and TNF-α and FA plus TNF-α treated and FA treated HepaRG cells.  
DE analysis (genes ranked by log2 fold change (log2FC≥1) and adjusted p value (padj<0.05),(A) Volcano plot 
illustrates genes that are up-and downregulated by TNF-α and FA plus TNF-α. (B) Up- and downregulated genes, 
ranked by  log2foldchange (log2FC) and padj<0.05, (C) GSEA, KEGG pathway analysis shows gene enrichment 
based on the NES and padj<0.05. Genes and proteins were described by using ProteinDomainVisualizer. 
 
4.4.6. Inflammatory mediators affect expression levels of genes essential for cellular 
inflammatory response, proliferation, apoptosis, and regulations of major metabolic processes. 
To mimic the in vivo situation during NAFLD to NASH progression, human HepaRG cells were 
stimulated with a combination of inflammatory mediators elevated and known to contribute to 
NASH development and progression to NASH-derived HCC 88. 
DE analysis revealed that the combination of inflammatory cytokines (BS1/LIGHT, IL-17A and 
TNF-α) in presence and absence of FAs, increased genes involved in inflammation, immune 
response, TNF-α target genes and Type I IFN genes (associated with an anti-viral response), 
comprising G20S (involved in cell cycle regulation), NFKBIA (IκBα, inhibits NF-ĸB pathway 
activation), BIRC3, IL6 (pro-inflammatory cytokine), IFIT1, TNFAIP6 (a TNF signalling target 
gene), MMP1 and MMP12, CXCL5, CCL8, and CSF3 (Figure 28A, B). In addition, stimulation 
with the cytokine combination led to downregulation of genes necessary to maintain major 
metabolic processes and cell differentiation markers, e.g. GSTA1, KRT18 (hepatocyte and 
biliary cell marker), KRT8 (biliary cell marker), ALDH1A1, ANXA13, IGFBP5, HMGCS2, and 
FABP4.  
GSEA displayed increased enrichment of genes implicated in inflammation-induced cellular 
stress response, proliferation, and apoptosis in cells that were treated with the cytokine 
combination. GSEA included following KEGG terms, Cytokine-Cytokine Receptor Interaction, 
NOD Like Receptor Signalling Pathway, Proteasome, Chemokine Signalling Pathway, 
Leishmania Infection, RIG I Like Receptor Signalling Pathway,  DNA Replication, Cytosolic 
DNA Sensing Pathway, JAK STAT Signalling Pathway, Toll-Like Receptor Signalling Pathway, 
Hematopoietic Cell Lineage, Homologous Recombination, Antigen Processing and 
Presentation, Systemic Lupus Erythematosus, Intestinal Immune Network For IgA Production, 
Oocyte Meiosis, Pyrimidine Metabolism, and Apoptosis (Figure 28C). Genes involved in 
overall metabolic processes were decreased by cytokine combination stimulation, included in 
following KEGG terms, Drug Metabolism Cytochrome P450, Metabolism of Xenobiotics by 
Cytochrome P450, Retinol Metabolism, Butanoate Metabolism, Histidine Metabolism, Tyrosine 
Metabolism, Valine Leucine and Isoleucine Metabolism, Dilated Cardiomyopathy, 
Complement and Coagulation Cascades, Fatty Acid Metabolism, Melanoma, Axon Guidance 
and Vascular Smooth Muscle Contraction (Figure 28C).  
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This analysis showed that the stimulation with the cytokine combination in presence and 
absence of lipids highly upregulated genes critically involved in activation of several 
inflammation-linked pathways and cellular stress response. Several genes essential for the 
regulation of main metabolic pathways were significantly decreased. RNA sequencing data 
clearly demonstrated that the whole gene expression profile is primarily driven by presence or 
absence of an inflammatory mediator inducing similar gene up- and downregulations. 







Figure 28: RNA sequencing analysis, volcano plot, heatmap, and gene set enrichment analysis 
(GSEA), comparing untreated and cytokine combination, and FA plus cytokine combination 
treated and FA treated HepaRG cells. 
DE analysis (genes ranked by log2 fold change (log2FC≥1) and adjusted p value (padj<0.05) (A) Volcano plot 
illustrates genes that are up-and downregulated by cytokine combination and FAs plus cytokine combination. (B) 
Up- and downregulated genes, ranked by log2foldchange (log2FC) and padj<0.05, (C) GSEA, KEGG pathway 
analysis shows gene enrichment based on the NES and padj<0.05. Genes and proteins were described by using 
ProteinDomainVisualizer. 
 
4.4.7. The overall gene expression is primarily regulated by absence or presence of an 
inflammatory mediator 
DE analysis demonstrated that gene regulation driven by inflammatory mediators (Figure 29). 
The gene expression profile of untreated control cells and cells that were exposed to FAs was 
similar, displayed by a comparable expression pattern. The gene expression profile of cells 
stimulated with BS1 or LIGHT with or without FAs more closely resembled the expression 
profiles of untreated and FA treated cells, whereas IL-17A, TNF-α or cytokine combination 
stimulated cells showed distinct profiles. The expression pattern of cells treated with IL-17A 
with and without FAs was distinct compared to the expression profiles induced by the other 
inflammatory mediators. TPCA-1 treatment prevented up- and down regulation of genes 
induced by IL-17A, showing that, NF-ĸB inhibition prevented gene expression regulations 
driven by IL-17A. The expression pattern of cells stimulated with TNF-α and the cytokine 






Figure 29: RNA sequencing based differential expression (DE) analysis in dHepaRG cells. 
DE analysis (gene ranking based on log2foldchange (log2FC≥1) and adjusted p value (padj<0.05). (A) A heatmap 
that illustrates genes that are up- and downregulated was divided into subclasses Class 1 (C1) – Class 9 (C9), 
displaying specific gene set up- and down regulations, in unstimulated, FA stimulated, and inflammatory mediator 
stimulated cells. Heatmap was separated into different genes classes (C), including following genes C1, TOP2A, 
PLK1, CDC20, PCLAF, NUSAP1, CENPF, CDK1, BIRC5, SFN, MKI67, HIST1H1E, CENPU, TK1, ANLN, PTTG1, 
TPX2, C2, NNMT, IFIT3, MX1, IFI6, OAS1, OAS3, ISG20, IFIT2, IFITM1, IFIT1, TRAF1, PLAUR, ITGA2, IL15RA, 
IFI35, PARP14, SAMD9L, NT5E, TYMP, C19orf66, IRF1, H1F0, EIF2AK2, BIRC3, LGALS1, TNIP1, BID, WARS, 
ICAM1, UBE2L,6 TNFAIP2, CD82, CD47, TNFSF10, PLSCR1, LAP3, SP100, RNF213, PML, APOL1, SQOR, 
PMAIP1, C3, EBI3, HELZ2, XAF1, CXCL11, MX2, OAS2, OASL, EPSTI1, TNFAIP3, CTSS, SAMHD1, IFI44, 
SAMD9, SP110, HERC5, IFI44L, HERC6, DDX58, GBP4, PARP9, GBP1, DDX60L, IFIH1, SELENOP, C4, CSF1, 
TNC, MT1X, SLC39A8, BPGM, WFDC21P, PI3, SGK1, PID1, CCL8, IL6, SERPINB4, TNIP3, TNFAIP6, CSF3, 
IL1B, PTGS2, TNFSF13B, MMP13, EBI3, HELZ2, XAF1, CXCL11, C5, SPINK1, AC025423.4, PSAT1, CYP1B1, 
PDK4, THBS1, AGR2, DDIT4, C6, TYMS, KPNA2, PSME1, STMN1, HMGB2, H2AFZ, TUBB4B, STAT1, NFKBIA, 
TFPI2, SERPINE2, MT1E, CKS2, RRM2, BTG3, RAC2, OPTN, PSME2, HMGA1, ANGPTL4, C7, IFITM3, SAA1, 
GDF15, ORM1, CXCL2, CXCL3, CCL2, C15orf48, CXCL8, LCN2, PDZK1IP1, KYNU, G0S2, ZC3H12A, VNN1, 
LBP, ACSL4, SLC43A3, SDC4, S100A9, C9orf16, NAMPT, CXCL10, ISG15, C8, PLIN2, KRT19, AKR1C3, 
AKR1B10, ANXA2, TUBA1B, C9, MT2A, IFITM3,SOD2.  
 
4.5. Proteomics analysis 
 
4.5.1. Inflammatory cytokines affect abundance of proteins implicated in the regulation of 
inflammation induced cellular stress response and metabolic processes 
Whole gene expression analysis, by RNA sequencing, demonstrated that inflammatory 
mediators induced specific expression profiles in hepatocytes with a minor effect by additional 
FA stimulation. To investigate the involvement of inflammation, in presence and absence of 
FAs, on overall protein levels proteomics analysis was performed. About 4.144 proteins were 
identified per sample (Figure 30A). tSNE plot revealed clear differences between the distinct 
treatment conditions (Figure 30B). Proteomics clustering analysis showed similar sample 
grouping as observed by RNA sequencing clustering analysis. Untreated, and FA treated 
samples clustered closely together, indicating a similar protein profile. BS1 and LIGHT 
samples were grouping and FAs plus BS1 and LIGHT formed groups, revealing that these two 
inflammatory mediators similarly affect protein levels. The formation of the other clusters was 
induced by IL-17A or TNF-α alone and in combination with FAs, revealing that the induction of 
a specific proteome was mainly driven by an inflammatory mediator. The additional presence 





Figure 30: Proteomics analysis of dHepaRG cells stimulated with inflammatory mediators and 
FAs. Numbers of detected proteins, sample clustering by Euclidean distance matrix (tSNE). 
Proteomics analysis of human dHepaRG cells that were left untreated, were treated with inflammatory mediators 
(BS1, IL-17A, TNF-α, LIGHT), stimulated with FAs, and with FAs in combination with inflammatory mediators (FA 
+ BS1, FA + IL-17A, FA + LIGHT, FA + TNF-α) for 24h. DE analysis (protein ranking based on log2foldchange 
(log2FC≥1). (A) On average 4.144 proteins were detected per sample, with at least 2 counts. (B) Normalized counts 
of proteins were used for sample clustering shown by tSNE. Proteomics analysis filtered data using for at least 2 
identified unique peptides.  
 
4.5.2. Fatty acid stimulation leads to elevated levels of proteins implicated in lipid metabolism 
and proliferation 
To examine proteome regulations induced by FAs, inflammatory mediators, and inflammatory 
mediators in combination with FAs, DE analysis was performed. The regulations driven by FAs 
were investigated when compared to untreated (UT) control samples (Figure 31A, B). In line 
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with the RNA sequencing DE analysis, lipid stimulation influenced levels of proteins involved 
in FA metabolism and proliferation. Significantly upregulated proteins included PLIN2 (lipid 
droplet binding protein that regulates neutral lipid storage), MYO5C (involved in actin-based 
membrane trafficking) and PDK4 (regulates glucose and fatty acid oxidation). Significant 
downregulated proteins included TUBB3 (regulates microtubule formation), LMBRD1 
(lysosomal cobalamin (Vitamin B12) transporter), HIST2H2BE (core component of 
nucleosomes, thereby involved in transcription regulation, DNA repair, DNA replication, and 
chromosomal stability), and MT-CYB (component of the ubiquinol-cytochrome c reductase 
complex (complex III) of the mitochondrial respiratory chain). 
GSEA showed an elevated enrichment of proteins involved in the regulation of proliferation in 
FA stimulated cells (Figure 31C), involved in following KEGG terms, DNA Replication, Protein 
Export (sec-dependent protein translocation), and Ribosome (including assembly / 
biogenesis). In addition, proteins essential for cytokine-cytokine receptor signalling (KEGG 
term, Systemic Lupus Erythematosus) MAPK-, phosphatidylinositol- and calcium signalling 
(KEGG term, GAP Junctions), and lysosomal mechanisms (KEGG Term Lysosome) were 





Figure 31: Proteomics analysis, volcano plot, heatmap, gene set enrichment analysis (GSEA), by 
Kyoto Encyclopedia of Genes and Genomes (KEGG), comparing FA treated and untreated 
dHepaRG cells. 
DE analysis (protein ranking by log2foldchange (log2FC≥1) and adjusted p value (padj<0.05) displayed by (A) 
Volcano plot. (B) Heatmap shows up- and downregulated proteins by FA stimulation, ranked by log2FC≥1 with 
padj<0.05 (C) GSEA by KEGG (ranked by NES≥1) with p.adj<0.05) (D) GSEA proteins ranked by p.adj<0.05. Genes 
and proteins were described by using ProteinDomainVisualizer. 
 
4.5.3. Exposure to the inflammatory mediators BS1 and LIGHT affects levels of proteins 
essential for the regulation of inflammation, proliferation, and metabolic processes 
To investigate protein regulations induced by BS1 or LIGHT in presence and absence of FAs, 
DE analysis was performed comparing BS1 or LIGHT stimulated cells with untreated control 
cells, and FA plus BS1 or LIGHT treated cells with FA treated cells. DE analysis revealed that 
BS1 and LIGHT stimulation mainly regulated protein levels with a minor effect by additional 
lipid stimulation (Figure 32A, B, D, E). Upregulated proteins by BS1 included GBP4 
(hydrolyzes GTP), MX1 (an interferon-induced GTP-binding protein), SAMD9L (regulates cell 
proliferation and anti-viral response), MCM2, MCM4, and MCM6 (DNA helicases, essential for 
replication), RRM2 (involved in the generation of deoxyribonucleotides), HMGCS1 (involved in 
cholesterol synthesis), NFKB2 (NF-ĸB p100 precursor of p52), and DPYSL3 (involved in 
cytoskeleton remodeling). Downregulated proteins included PDK4, CLTB (main component of 
clathrin coated pits), PLIN2, RAP1GAP (GTPase activating protein), and PTS (involved in 
folate, vitamin B metabolism).  
KEGG pathway revealed enhanced enrichment of proteins implicated in following KEGG 
terms, DNA Replication, Cell Cycle, Systemic Lupus Erythematosus, and Ribosome (Figure 
32C). Downregulated proteins by BS1 included proteins and enzymes regulating e.g. 
endocytosis, autophagy and mechanisms essential for lysosomal processes (KEGG term, 
Lysosome), calcium signalling (KEGG term, cardiac muscle contraction), and proteins involved 
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in oxidative phosphorylation (KEGG term oxidative phosphorylation), insulin- and calcium 
signalling, and Wnt- signalling pathway (KEGG Alzheimer disease), oxidative phosphorylation 
(KEGG term, Oxidative Phosphorylation), and KEGG Term and Drug Metabolism Cytochrome 
P450 (Figure 32C).  
DE analysis comparing LIGHT and LIGHT plus FA stimulated with untreated and FA stimulated 
cells showed increased proteins levels comprising e.g. MCM4, MCM5 and MCM7 , GBP4, 
DPYSL3, KPNA2 (nuclear export protein), SAMD9L, HMGCS1, RRM2, and NFKB2 (Figure 
32D, E). Decreased proteins by LIGHT treatment included PDK4, PLIN2, AHNAK2 
(nucleoprotein), PDCD4 (localized to the nucleus in proliferating cells), FGG and FGA (form 
fibrin a matrix, components of blood clots), RAP1GAP, AGT (peptide hormone), and LCN2.  
KEGG pathway analysis revealed enhanced protein enrichment implicated in cell proliferation 
e.g. involved in ribosome assembly / biogenesis (KEGG term, Ribosome), cell cycle 
regulations, MAPK signalling and DNA biogenesis (KEGG term, Cell Cycle), nucleobase 
biosynthesis (KEGG term, Pyrimidine Metabolism), DNA replication (KEGG term, DNA 
Replication), and nucleotide excision repair (KEGG term, Nucleotide Excision Repair) (Figure 
32F). Downregulated proteins were implicated in e.g. regulation of lysosomal processes 
(KEGG term, Lysosome), amino acid catabolism (KEGG term, Valine Leucine, and Isoleucine 
Degradation), fatty acid synthesis and catabolism (KEGG term, Fatty Acid Metabolism), and 
oxidative phosphorylation (KEGG term, Oxidative Phosphorylation) (Figure 32F).  
Proteomics analysis showed that protein levels were primarily regulated by absence or 
presence of an inflammatory mediators (BS1 or LIGHT). In line with the results obtained by 
RNA sequencing analysis, BS1 and LIGHT exposure increased the abundance of proteins 
involved in inflammatory stress response and proliferation and reduced levels of proteins 










Figure 32: Proteomics analysis, volcano plot, heatmap, gene set enrichment analysis (GSEA), by 
Kyoto Encyclopedia of Genes and Genomes (KEGG), comparing BS1 or LIGHT and FA plus BS1 
or LIGHT with FA and untreated dHepaRG cells.  
DE analysis (proteins ranked by log2 fold change (log2FC≥1) and p value adjusted (padj<0.05) (A, D) Volcano plot 
illustrates proteins that are up-and downregulated by FAs and BS1 or LIGHT. (B, E) Up- and down regulated 
proteins, ranked by log2FC and padj<0.05. (C, F) GSEA, KEGG pathway analysis shows protein enrichment based 
on the NES and padj<0.05. Genes and proteins were described by using ProteinDomainVisualizer. 
 
4.5.4. IL-17A stimulation affects abundance of proteins essential for the regulation of 
inflammation, proliferation, and metabolic processes. 
To further address the influence of IL-17A in presence and absence of lipids on overall protein 
levels, DE analysis was performed comparing IL-17A with untreated and FA plus IL-17A with 
FA treated cells (Figure 33A, B). DE analysis displayed a similar protein regulation as 
observed by RNA sequencing based DE analysis. Upregulated proteins included LCN2, 
SERPINB3 and SERPINB4, ORM1, CFB and HP (acute phase proteins), VNN1, and KYNU 
(kynureninase, associated with inflammation). Down regulated proteins included H2AFY and 
HIST1H4A (histone proteins), UQCRB (component of mitochondrial complex III subunit), 
AHNAK2 and MARCKSL1 (calcium signalling and cytoskeleton regulation), TUBB3, FABP5, 
and PDK4. 
KEGG pathway analysis displayed elevated abundance of proteins in IL-17A treated cells 
involved in cell proliferation and general inflammatory response including following KEGG 
terms, DNA Replication, Protein Export and Cytosolic DNA Sensing Pathway (Figure 33C). 
GSEA showed an up regulation of proteins involved in oxidative stress induced senescence, 
NF-ĸB associated proteins (e.g. IKBKG, TNFAIP8) and several histone proteins. 
Downregulated proteins by IL-17A stimulation were implicated in metabolic processes included 
in following KEGG terms, Beta Alanine Metabolism, Cardiac Muscle Contraction, Valine 
Leucine Isoleucine Metabolism, Oxidative Phosphorylation, Lysosome, Huntington’s Disease, 
Propanoate Metabolism, Small Cell Lung Cancer, Retinol Metabolism, Butanoate Metabolism 
and Pyruvate Metabolism (Figure 33C).  
Overall, cell exposure to IL-17A increased the abundance of proteins involved in inflammatory 
stress response, proliferation and reduced levels of proteins involved in metabolic processes 







Figure 33: Proteomics analysis, volcano plot, heatmap, gene set enrichment analysis (GSEA), by 
Kyoto Encyclopedia of Genes and Genomes (KEGG), comparing untreated and IL-17A, and FA 
plus IL-17A with FA treated dHepaRG cells,  
DE analysis (proteins ranked by log 2 fold change (log2FC≥1) and p value adjusted (padj<0.05) (A) Volcano plot 
illustrates proteins that are up-and downregulated by FA and IL-17A. (B) Up- and down regulated proteins, ranked 
by log2FC and padj<0.05, (C) GSEA, KEGG pathway analysis shows protein enrichment based on the NES and 
padj<0.05. Genes and proteins were described by using ProteinDomainVisualizer. 
 
4.5.5. TNF-α stimulation increases abundance of proteins critical for the regulation of 
inflammation and anti-viral response and decreases proteins levels implicated in metabolic 
processes 
To examine the influence of TNF-α in presence and absence of FAs on overall protein levels 
DE analysis was performed comparing TNF-α treated with untreated cells, and FA plus TNF-
α with FA treated cells (Figure 34A, B). 
DE analysis showed that TNF-α upregulated e.g. MX, OAS1 and OAS2, HELZ2 (co-activator 
of PPARA), IFIT3, IFIT1 and IFIT2, GBP4, and DDX58 (involved in anti-viral response). 
Downregulated proteins included PDK4, PDCD4, FGG, SORT1 (regulates sorting and 
transport of intracellular proteins), FABP5, and PLIN2. KEGG pathway analysis revealed 
elevated protein enrichment involved in cell proliferation and inflammation including following 
KEGG terms, DNA Replication, Antigen Processing and Presentation, Leishmania Infection, 
Proteasome, Pancreatic Cancer, Cell Adhesion Molecules Cams and Cytosolic DNA Sensing 
Pathway (Figure 34C). In addition, abundance of proteins was reduced that were implicated 
in regulation of oxidative phosphorylation, vitamin, and drug metabolism, included in following 
KEGG terms, Oxidative Phosphorylation, Retinol Metabolism and Metabolism of Xenobiotics 
by Cytochrome P450 and Huntingtons Disease (Figure 34C). 
Proteomics analysis showed that inflammatory cytokine stimulation increased the abundance 
of proteins involved in inflammation, immune- and cellular stress response and reduced levels 
of proteins involved in metabolic processes, similar to RNA sequencing-based gene 







Figure 34: Proteomics analysis, volcano plot, heatmap, gene set enrichment analysis (GSEA), by 
Kyoto Encyclopedia of Genes and Genomes (KEGG), comparing untreated and TNF-α, and FA 
plus TNF-α with FA treated dHepaRG cells.  
DE analysis (proteins ranked by log 2 fold change (log2FC≥1) and p value adjusted (padj<0.05) (A) Volcano plot 
illustrates proteins that are up-and downregulated by FAs and TNF-α. (B) Up- and down regulated proteins, ranked 
by log2FC and padj<0.05, (C) GSEA, KEGG pathway analysis shows protein enrichment based on the normalized 
enrichment score (NES) and padj<0.05 (F)(G) Gene ontology (GO) analysis (DE). Genes and proteins were 
described by using ProteinDomainVisualizer. 
 
4.6. Phosphoproteomics analysis 
 
4.6.1. Inflammation affects phosphorylation of proteins involved in the regulation in 
programmed cell death and DNA damage response 
To investigate the effect of inflammation in a lipid rich environment on signalling pathway 
regulation, phosphoproteomics analysis was performed comparing FA with FA plus 
inflammatory cytokine treated cells. Previously acquired proteomics data were used to 
distinguish between regulations in the phosphoproteome and changes in the total proteome 
(Figure 35A, B). 
Data were normalized and samples were clustered by tSNE, displaying a clear separation of 
FA and FA plus cytokine stimulated cells (Figure 35C). DE analysis showed several significant 
different phosphorylation sites in FA plus cytokine treated cells when compared to FA treated 
cells (Figure 35B, D). To determine phospho site changes that are not correlating with 
abundance changes in the total proteome, DE analysis was performed comparing proteome 
and phosphoproteome (Figure 35D). Proteomics analysis showed elevated levels of proteins 
in FA and cytokine stimulated cells involved in type I interferon signalling (IFIT1, IFIT2 and 
IFIT3, ISG15), anti-bacterial response (LCN2), transcriptional co-activator of PPARs (HELZ2), 
and inflammatory mediators (TNFAIP2 and TNFAIP8). Downregulated protein where involved 
in blood coagulation (FGA and FGG), and cell migration (AHNAK) (Figure 35A). 
Several phosphorylation sites were significantly changed independently of total protein 
abundance (Figure 35D). On the phospho-level, an elevated enrichment of proteins involved 
in apoptotic process regulation, DNA damage response, and inflammation were determined, 
including following significant increased phospho proteins,  ACBD5 (acetyl-CoA binding 
protein), ACSL5 (acetyl-CoA synthetase, activates long-chain fatty acids and regulates 
programmed cell death), API5 (antiapoptotic protein), CLIP1 (cytoskeleton protein involved in 
intracellular vesicle transport), DNMT1 (DNA methyltransferase), EGFR (associated with 
proliferation and  negative regulation of apoptosis), MAP2K4 and MAPK24  (associated with 
programmed cell death regulation), MARCKS (substrate for protein kinase C, binds 
calmodulin, actin and synapsin), NCL (regulates endocytosis and is associated with liver 
regeneration and negative regulation of apoptosis), PALLD (involved in cell migration), RBBP5 
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(responses to DNA damage), RSL1D1 (involved in the regulation of apoptotic cell death), 
SMARCA5 (associated with chromatin remodeling and regulation of gene expression), 
TNKS1BP1 (regulates DNA damage response), and XRCC1 (regulates DNA damage repair). 
Decreased phosphoproteins included, ARHGEF12 (positive regulator of apoptotic cell death), 
BIN1 (regulates cell proliferation, lipid tube assembly and positive regulator of apoptotic 
process), HCFC1 (cell cycle regulator), MYO18A (negative regulator of apoptotic processes), 







Figure 35: Phosphoproteomics analysis, volcano plot, and tSNE plot, comparing FA with FA plus 
inflammatory cytokine treated dHepaRG cells.  
DE analysis of proteomics, proteins were ranked by log 2 fold change (log2FC≥1, and p value adjusted (padj<0.05), 
and phospho proteomics, phosphoproteins were ranked by p value adjusted (padj< 0.1, with a logFC > 1). (A, B) 
Volcano plot illustrates proteins / phospho sites that are up-and downregulated by FA and cytokine combination 
treatment. (C) tSNE based on DE analysis. (D) Total proteome versus phospho proteome. Genes and proteins 
were described by using ProteinDomainVisualizer. 
 
4.7. Proteome based complex analysis 
 
4.7.1. Inflammatory cytokines downregulate and destabilize proteins that regulate 
carbohydrate metabolism  
To investigate the impact of protein-protein interaction and protein complex formation on the 
regulation of metabolic and inflammatory processes, protein abundance and protein stability 
were determined by thermal proteome profiling.  
Untreated, cytokine stimulated, FA stimulated, and FA plus inflammatory cytokine stimulated 
dHepaRG cells were prepared for proteome-based complex analysis. Samples were clustered 
by tSNE based on abundance scores (Figure 36A) and on stability scores (Figure 36B). tSNE 
plot based on protein levels showed a clear group formation according to the different 
conditions, FA treated samples clustered together and cytokines in presence and absence of 
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FAs clustered together (Figure 36A). In contrast, tSNE plot based on protein stability did not 
display clear separations between the conditions (Figure 36B).  
One-sample Limma analysis was performed to compare abundance and stability scores 
between the different conditions. FA stimulation significantly elevated PLIN2 abundance 
(Figure 36C), whereas protein stability was not significantly affected by FA treatment when 
compared to untreated control samples (Figure 36D). Cytokine stimulation, in absence and 
presence of FAs, affected protein abundance (Figure 36E, G) and thermal stability (Figure 
36F, H) of several proteins, when compared to control. FAs in combination with inflammatory 
cytokines influenced protein stability less significantly than cytokine stimulation alone (Figure 
36H).  
To distinguish between regulations that influence protein abundance and stability, induced by 
FA alone, cytokines alone, and FA plus cytokines, the distinct conditions were compared with 
each other.  
FA treatment alone showed a minor effect as only PLIN2 was significantly upregulated (up on 
the x-axis) (Figure 36I). Inflammatory cytokines affected abundance of various proteins 
(several up- and down regulated protein along the y-axis). The combination of FA and 
cytokines further enhanced or diminished the regulations induced by cytokine only (Figure 
36I). Inflammatory cytokine treatment upregulated several proteins involved in inflammatory 
response, which was reduced by additional FA stimulation. Protein levels up-regulated by 
cytokine stimulation (up on y-axis) (FA-diminished cytokine up-regulation (upper left square, x 
<= -1, y >= 1)) included SERPINB3 (Figure 36K) and SERPINB4, MX1, CTSS (protease, 
regulates adaptive immune response, antigen processing and presentation), IFIT3, ITGA2 (cell 
adhesion protein), and SAMD9 (Figure 36I) (downstream target of TNF-α signalling). 
Inflammatory cytokine stimulation increased protein levels involved proliferation which was 
further elevated by simultaneous lipid stimulation, (up on x-axis) (FA-enhanced cytokine up-
regulation (upper right square, x >= 1, y >= 1)) included TK1 (Figure 36L) (involved in 
regulation of proliferation, DNA biosynthetic process), TOP2A (DNA topoisomerase, essential 
during mitosis and meiosis for proper segregation of daughter chromosomes) and MRPL2 ( 
involved in mitochondrial translation). Cytokine treatment downregulated proteins essential for 
carbohydrate metabolism which was enhanced by simultaneous FA treatment (down on y-
axis) (FA-enhanced cytokine down-regulation (lower left square, x <= -1, y <= -1)) included 
UGT2B15 (Figure 36M) (involved in the elimination of xenobiotics and endogenous 
compounds), SLC2A2 (GLUT-2, glucose transporter), GUSB (involved in carbohydrate 
metabolic process), DPP4 (induces T-cell proliferation and NF-ĸB activation) and HSD17B11 
(estradiol dehydrogenase, involved in steroid metabolism). Inflammatory cytokine treatment 
downregulated protein essential for drug metabolism and glycolysis. Proteins that were 
decreased (FA-diminished cytokine down-regulation (lower right square, x >= 1, y <= -1)) 
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included CYP2C8 (Figure 36N) (drug metabolism process), ALDOB (regulates glycolysis, 
fructose metabolism), OTC (regulates ammonia homeostasis, arginine biosynthesis, liver 
development), ADH1B (alcohol dehydrogenase), FABP4 (lipid transport protein), and PKLR 
(regulates glycolysis). 
Several proteins displayed increased or decreased stability induced by inflammatory cytokine 
stimulation which was further reduced or enhanced by FA plus inflammatory cytokine 
stimulation (Figure 36J).  
Increased protein stability induced by FA plus cytokine treatment when compared to FA alone 
(FA-diminished cytokine up-regulation (upper left square, x <= -1, y >= 1)) included, DNAJC9 
(Figure 36O) (a co-chaperone of HSP70 family and p53 target), and PRRC2C (Figure 35J).  
Stability of proteins enhanced in FA conditions and further up-regulated by additional cytokines 
stimulation (FA-enhanced cytokine up-regulation (upper right square, x >= 1, y >= 1)) included 
TST (Figure 36P) (regulates cyanate catabolic processes), NDUFA9 (NADH dehydrogenase, 
subunit of complex I of the respiratory chain), NDUFS1 (core subunit of the mitochondrial 
membrane respiratory chain, NADH dehydrogenase), MYO1B (Figure 37Q) (regulates actin 
filament based movement), GDAP1 (Figure 36R) (regulates the mitochondrial network by 
promoting mitochondrial fission), METTL7B (Figure 36S) (methyltransferase), DHRS7 (Figure 
36T), FMO5 (Figure 36U) (drug metabolizing enzyme, a and involved in carbohydrate 
metabolism), and YKT6 (Figure 36V) (implicated in vesicular transport between secretory 
compartments).  
Protein stability that was enhanced by FA stimulation and decreased by cytokines (FA-
enhanced cytokine down-regulation (lower left square, x <= -1, y <= -1)) included PGM1 
(Figure 36W) (catalyzes the transfer of phosphate between the 1 and 6 positions of glucose), 
CPQ (involved in the hydrolysis of circulating peptides), PSMC1 (26S protease involved in 
degradation of ubiquitinated proteins), GNAS (Figure 36X) (G-protein involved in GPCR 
signalling), TOLLIP (Figure 36Y) (involved in IL-1ß and TLR signalling, affects NF-ĸB 
activation), PARVA (involved in actin cytoskeleton organization and cell adhesion), VBP1 
(Figure 36Z) (regulates protein folding) and TALDO1 (regulates carbohydrate metabolism). 
Proteins that were further downregulated by cytokine stimulation (lower right square, x >= 1, y 
<= -1) included, RPS26 (ribosomal protein), CTPS1 ( involved in de novo synthesis of cytidine 
triphosphate CTP, important for phospholipids and nucleic acids biosynthesis), RPL9 (Figure 
36AA), RPL11, RPL30 and RPL35A (ribosomal proteins), and SPTBN2 (Figure 36AB) 
(regulates actin filaments and antigen processing). 
Proteome-based complex analysis showed that inflammatory cytokine treatment upregulated 
several proteins including proteases, which was reduced by additional FA stimulation. Cytokine 
stimulation increased protein levels involved in DNA-dependent proliferative processes and 
stabilized proteins involved in drug metabolism and the regulation of cytoskeleton organization, 
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which was further enhanced by additional FA stimulation. Cytokine treatment alone 
downregulated and destabilized proteins essential for carbohydrate metabolism which was 
enhanced by simultaneous FA treatment. Inflammatory cytokine treatment downregulated 
protein essential for drug metabolism and glycolysis and destabilized several ribosomal 





























Figure 36: Proteome-based complex analysis of dHepaRG cells stimulated with inflammatory 
mediators and FAs.  
Thermal proteome profiling in human dHepaRG cells which were untreated, treated with inflammatory mediators 
(BS1, IL-17A, TNF-α, LIGHT), stimulated with FAs and FAs in combination with inflammatory mediators (FA + BS1, 
FA + IL-17A, FA + LIGHT, FA + TNF-α) for 24h. (A, B) Normalized counts of proteins were used for sample 
clustering, shown by tSNE, based on (A) protein abundance or (B) protein stability. (C-J) One-sample Limma 
analysis to compare abundance and stability scores between the different conditions. (K-AB) Abundance and 




















There has been a pandemic rise in the prevalence of obesity and metabolic syndrome, which 
is associated with an increase in NAFLD, the most common chronic liver disease, affecting 
about 25% of the population globally 10,140. NAFLD includes a continuum of liver diseases and 
ranges from hepatic steatosis, a non-alcoholic fatty liver (NAFL), to the more severe form of 
disease, steatohepatitis, NASH, which can progress to cirrhosis and HCC 10,147,152. Today, we 
know that not only NASH but the combination of ASH and NASH (BASH) also becomes more 
and more prevalent 88. 
Steatotic hepatocytes are in a reversible metabolic state of increased lipid accumulation and 
additional factors in the microenvironment such as pro-inflammatory cytokines and oxidative 
stress inducing steatohepatitis. The latter is characterized by exacerbated lipid storage, 
hepatocyte cell death, and compensatory proliferation, which promotes disease progression 
168. Therefore, the essential step in NAFLD development is the progression from simple 
steatosis to inflammation-induced steatohepatitis, including high prevalence of 
necroinflammation, and most likely also DNA damage. Since current treatment options are far 
from being efficient, the generation of a better understanding of NAFLD development is of high 
clinical importance.  
Thus, I established an in vitro NASH model to discover molecular mechanisms underlying the 
transition from steatosis to steatohepatitis in human hepatocytes, dHepaRG cells.  
Using this in vitro NASH model, I observed that hepatocytes take up and store FAs in LDs 
which induced a steatotic phenotype. The stimulation of hepatocytes with FAs and specific 
inflammatory mediators further increased FA storage, which was leading to intensified 
accumulation of intracellular LDs. This demonstrated that an inflammatory microenvironment, 
generated by pro-inflammatory cytokines, affected the lipid metabolic state of hepatocytes. 
FA uptake and storage was induced within 1h of treatment, and further continued when 
stimulation was prolonged. After 24h of cell exposure to FAs, intracellular neutral lipid levels 
increased about threefold. At the same time FAs were used as energy source by fatty acid 
oxidation (FAO), observed after 3h and 24h of lipid stimulation. This revealed that FAs are 
constantly metabolized (FAs are taken up, are stored, and are oxidized) under normal and 
non-inflammatory conditions. 
Further, pro-inflammatory cytokines affected FA uptake and storage immediately after 1h, 
observed by a significant decrease of intracellular FA levels. After 3h of stimulation the lipid 
levels were comparable to FA treated cells, presumably due to lipid catabolic deficiencies, 
determined by reduced FAO. The deficiency of FAO after 24h was further increased, which 
was reflected by exacerbated lipid accumulation of about six-fold, when compared to the 1h 
time point. Moreover, the reduced FA uptake, triggered by inflammatory cytokines, sufficed to 
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promote intensified lipid accumulation, showing that interference with FA catabolic processes 
is decisive and drives the increased steatotic phenotype in hepatocyte.  
In primary mouse hepatocytes, inflammatory mediators not only affected neutral lipid levels 
but also the size of LDs, observed by an increase of very large (1.5-2um) LDs, which induced 
a macrovesicular phenotype. In contrast, in dHepaRG cells this macrovesicular phenotype was 
markedly lower, indicating that freshly isolated primary mouse hepatocytes better recapitulate 
the in vivo situation during NASH, as a differentiated cultured cell line. However, the process 
of primary hepatocyte isolation and in vitro culture can interfere with their function, and their 
metabolic gene expression profile is not maintained over time, both, in murine and human 
hepatocytes. Therefore primary hepatocytes are only suitable for short-term metabolic 
experiments 198. dHepaRG cells were used in several studies as in vitro steatosis and drug 
metabolism model, which showed that their metabolic gene expression profile is stable and 
maintained, also during long-term experiments comparable to hepatocytes in vivo 199–203. 
These features designate dHepaRG cells as perfect tool to study lipid metabolism in 
hepatocytes.  
FFAs can induce lipotoxicity in cells, thus FA storage in form of TGs in LDs was reported as 
protective cellular mechanism 4,175. It has been suggested that lipotoxicity is not only dependent 
on intracellular lipid levels but also on the lipid composition 16. 
Based on this, I addressed whether inflammatory cytokines induce a distinct lipid metabolic 
state, not only by increasing lipid levels but also by affecting the lipid composition, when 
compared to FA stimulated cells. 
Lipidomic analysis demonstrated that FAs were mainly stored in TGs, but also in other lipid 
classes including, DGs, PLs, and GPEtns, which was further intensified, and not changed, by 
additional exposure to inflammatory mediators. This showed that the lipid concentration, but 
not the lipid composition, was affected by inflammatory mediators in hepatocytes.  
Moreover, only specific, pro-inflammatory cytokines (BS1/LIGHT, IL-17A) that are elevated 
during NASH 139,144 indeed induced aberrant lipid accumulation in hepatocytes. Whereas 
inflammatory mediators that regulate an anti-inflammatory immune response including IL-4, or 
control anti-viral immune responses, including IFN-γ, did not promote intensified FA storage. 
Inflammation contributes to NAFLD development 204 and the pro-inflammatory cytokines used 
in this study activated the canonical (BS1/LIGHT, IL-17A and TNF-α) and non-canonical 
(BS1/LIGHT, TNF-α) NF-ĸB signalling pathway. Therefore, I investigated the influence of 
inflammatory cytokine induced NF-ĸB activation on the lipid metabolic state in hepatocytes. 
The interference with canonical and non-canonical NF-ĸB signalling by treatment with the IKKß 
inhibitor TPCA-1, or by CRISPR-Cas mediated loss of IKKß or NIK, prevented exacerbated 
lipid accumulation in hepatocytes and demonstrated that the NF-κB signalling pathway affects 
lipid metabolism in hepatocytes by promoting FA storage into neutral lipids. This highlights the 
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critical role of a pro-inflammatory environment, and activation of inflammatory pathways (NF-
ĸB) on the development of steatohepatitis (NASH). 
Mitochondria are key metabolic organelles for ATP production by oxidization of lipids, through 
oxidative phosphorylation. During ATP synthesis an electrochemical gradient is generated, 
resulting in the formation of a transmembrane potential and ROS 68. 
Mitochondria are critically involved in NAFLD development 182,183. To adjust to elevated 
intracellular lipid levels during disease development, mitochondria increase FAO, which is 
associated with elevated ROS production. Increased ROS decreases respiratory chain 
function, and ATP-synthesis and is leading to incomplete FAO, which results in accumulation 
of toxic lipid intermediates, and can induce apoptotic cell death, associated with decreased 
transmembrane mitochondrial potential 185–187. 
Thus, I investigated the influence of FAs and pro-inflammatory cytokines, on mitochondrial 
morphology, function, and superoxide production.  
I demonstrated that FA stimulation alone did not influence mitochondrial morphology when 
compared to untreated control cells after 24h of stimulation. However, intracellular lipid 
accumulation in FA treated cells, correlated with elevated mitochondrial superoxide production. 
In addition, mitochondrial function was influenced by pro-longed (48h) FA stimulation, which 
was determined by decreased mitochondrial membrane potential. This showed that chronic 
FA exposure increased lipid levels, FAO, and ROS production, which then affected 
mitochondrial membrane potential, and induced mitochondrial depolarization. 
In addition, the pro-inflammatory cytokines (BS1/LIGHT and TNF-α), without FAs, also reduced 
mitochondrial membrane potential, revealing that FAs and inflammatory cytokines can 
independently interfere with mitochondrial function. The impact of FAs is presumably due to 
increased ROS production, induced by ongoing and elevated FAO, whereas inflammatory 
cytokines downregulate lipid catabolic genes and antioxidants, observed by gene expression 
analysis, which can also trigger elevated ROS. Further, pro-inflammatory cytokines (such as 
TNF-α) might directly induce pro-apoptotic TNFR signalling, which is also reflected by 
mitochondrial dysfunction. 
FAs in combination with inflammatory mediators decreased FAO and changed mitochondrial 
morphology, shown either by a breakup (BS1/LIGHT), or hyperfusion (IL-17A) of the 
mitochondrial network. Increased intracellular neutral lipid accumulation promoted 
mitochondrial superoxide production, which was both intensified by additional inflammatory 
cytokine stimulation. In addition, the stimulation with FAs and BS1, LIGHT and TNF-α, induced 
mitochondrial membrane depolarization after 24h and exposure of hepatocytes to FAs and IL-
17A or the cytokine combination promoted mitochondrial hyperpolarization. Pro-longed 
treatment for 48h with all inflammatory mediators promoted mitochondrial depolarization, 
showing that mitochondrial dysfunction is dependent on the primary signalling pathway 
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activation and the duration of exposure to the different cytokines and lipids. Thus, inflammation 
can induce mitochondrial dysfunction either directly (after 24 hours), and presumably apoptotic 
cell death, or a pre-apoptotic phenotype which can shift to apoptosis at prolonged treatment 
after 48h 205. This demonstrates that FAs and cytokines can independently trigger 
mitochondrial stress, which is exacerbated by their combination.  
In addition, simultaneous anti-ROS treatment did not prevent increased lipid storage, indicating 
that elevated ROS production is a secondary effect of elevated lipid storage. 
Further, only pro-inflammatory cytokines influenced mitochondrial polarization, the anti-
inflammatory cytokine IL-4 did not induce mitochondrial dysfunction.  
I tested the effect of inflammatory cytokine activated NF-ĸB signalling on mitochondrial 
function, which showed that interference with activation of the canonical NF-ĸB pathway 
prevented mitochondrial depolarization and ROS production. 
Mitochondrial dysfunction can trigger apoptotic cell death 186,187. Therefore, I studied the effect 
of FAs and inflammatory cytokines on apoptotic cell death and associated compensatory 
proliferation. Exacerbated inflammation-induced lipid storage triggered both apoptosis and 
proliferation, however inhibition of apoptosis by a pan-caspase inhibitor did not influence 
increased lipid storage.  
These data demonstrate that mitochondrial dysfunction, apoptotic cell death and 
compensatory proliferation are most likely a consequence of increased lipid accumulation, 
induced by inflammatory cytokines, in a NF-ĸB dependent manner. In addition, I determined 
that this lipid-induced cellular stress response further induced replication stress and increased 
DNA damage, mimicking NAFLD pathogenesis. 
Overall, the data indicate that the essential step in NAFLD development is the pro-
inflammatory cytokine-induced exacerbated lipid accumulation, which subsequently affects 
cellular physiology, metabolic functions, and cell viability. Thus, investigating the underlying 
molecular mechanisms of inflammation triggered aberrant lipid metabolism in hepatocytes is 
critical for the identification of potential treatment options. 
Therefore, I set out to perform transcriptomics and proteomics analysis to disentangle 
regulations in hepatocytes that were induced by FAs alone, by inflammatory cytokines, and by 
FAs in combination with pro-inflammatory cytokines.  
Whole gene expression analysis by RNA sequencing and proteomics analysis, demonstrated 
that FA stimulation regulated the expression of only few genes and proteins, when compared 
to untreated control cells. This can be partly explained by the fact that lipid metabolic processes 
are regulated by enzymes and gene or protein abundance is not reflecting the impact of FAs 
on enzyme function. Thus, the examination of enzyme phosphorylation, interaction with other 
enzymes or proteins, or quantification of their substrates and final product represents a more 
sensitive read out.  
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The expression of genes and proteins that are involved in metabolic processes, mostly PPAR-
α targets, including genes and proteins that regulate FA- uptake, transport, storage, oxidation 
and LD metabolism, was increased by FA stimulation, revealing on-going lipid metabolic 
processes in hepatocytes. In addition, FA treatment lead to an upregulation of genes and 
proteins that regulate cell proliferation. 
RNA sequencing analysis demonstrated that the overall gene expression was primarily 
regulated by respective inflammatory mediators (BS1/LIGHT, IL-17A, TNF-α, and the cytokine 
combination), whereas additional FA stimulation showed a negligible effect. 
Omics (transcriptomics and proteomics) analysis showed that all inflammatory cytokines used 
in this study induced similar gene- and protein up and downregulation. However, some 
regulations were also distinct and cytokine specific, revealing their primary pathway activation 
and subsequent target gene transcription.  
Heatmap- and sample clustering analysis (by tSNE and PCA) showed that gene regulations 
induced by BS1 and LIGHT were similar to FA treated and untreated cells. In contrast, the 
expression profile induced by IL-17A was distinct to the other conditions. TNF-α and cytokine 
combination treated cells showed a comparable expression profile. 
All pro-inflammatory cytokines alone or in combination with FAs induced the expression of 
genes and proteins involved in cellular stress response, inflammation, immune response, 
proliferation, and apoptosis.  
An analysis comparing transcriptomics and proteomics showed that most proteins which were 
significantly regulated on proteome level were also significantly regulated on expression level. 
However, on the transcriptome level, more genes showed significant differential expression. 
In addition, the up-regulations on proteome and transcriptome were more correlative than the 
downregulations. This analysis revealed that FA stimulation leads to a significant upregulation 
of PLIN2 and PDK4 on both, gene and on protein level, whereas all inflammatory cytokines 
induce the upregulation of NFKB2  
Further, the activation of LTβR signalling via BS1/LIGHT highly induced the upregulation of 
genes involved in inflammation, apoptotic cell death regulation and proliferation including 
BIRC3, TRAF1, and MMP7. IL-17A stimulation increased the expression of genes involved 
acute-phase response, including acute-phase proteins, SAA and LBP, in immune response, 
including chemokines such as CXCL1 and CXCL2, and general inflammatory response such 
as, VNN1, SOD2, and LCN2. The highest upregulated genes upon TNF-α treatment included 
genes associated with type I IFN signalling such as ISG15, IFIT3 and IFI6, but also chemokines 
such as CCL2. The cytokine combination clearly mirrored the gene expression of each single 
cytokine but also induced a distinct regulation and highly increased genes implicated in cell 
cycle regulation such as G02S, and regulators of NF-ĸB signalling including NFKBI. 
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I observed that inflammatory cytokine stimulation downregulated genes and proteins induced 
by FAs, including PPAR-α target genes such as PDK4, showing that inflammatory signalling 
interferes with lipid metabolic pathways in hepatocytes. Moreover, PPAR-α expression levels 
were not affected by FA stimulation, indicating that the reduction of PPAR-α target genes is 
not regulated by decreased levels of the transcription factor itself. 
Importantly, inflammatory cytokines not only affected regulations of genes and proteins 
associated with FA metabolism but also with genes and proteins essential for the regulation of 
overall metabolic processes, including genes and enzymes of the oxidant system, involved in 
oxidation of xenobiotics, ketogenesis, amino acid metabolism, vitamin metabolism, cholesterol 
metabolism, phospholipid metabolism, glucose metabolism and ethanol metabolism. Genes 
that were significantly downregulated by all cytokines (BS1/LIGHT, IL-17A, TNF-α, and the 
combination of all cytokines) included KRT19 (a biliary cell marker), GSTA1 (a detoxification 
enzyme), and CA9 ( a metalloenzyme, catalyses the hydration of carbon dioxide).  
This demonstrates that proinflammatory cytokines not only decrease the expression of 
metabolism associated genes and proteins but also of cellular differentiation markers such as 
keratins (KRT19), revealing that inflammatory cytokines also affect cellular differentiation. 
Phosphoproteomics showed an enrichment of phospho-proteins involved in apoptotic process 
regulation, DNA damage response, and inflammation. 
Inflammation influences whole cellular metabolism, and the gene expression of hepatocytes is 
rapidly changed (within hours) by inflammatory cytokines. After 90 minutes of inflammatory 
cytokine stimulation, hepatocytes showed elevated expression of inflammation-related genes 
(NFKB2) and downregulation of metabolic associated genes (PDK4). However, how metabolic 
genes in FA plus inflammatory cytokine treated cells are regulated, remains elusive. 
The overall downregulation of cellular metabolism upon inflammation hints towards a 
conserved mechanism because it affects several proteins and enzymes essential to maintain 
hepatic metabolism. 
One possible mechanism could be that the activation of the inflammatory pathway (NF-ĸB) 
interferes with the upregulation of metabolic genes, thus their expression levels are kept 
comparable to untreated cells. Further, the stimulation with inflammatory cytokines alone 
already decreases gene levels associated with cell metabolic regulations, indicating that 
downregulation of metabolic genes proteins must be an active mechanism. 
Decreased expression of metabolism-associated genes (including FAO, lipolysis and 
cholesterol metabolism) was also observed in a preclinical NASH mouse model 144, but the 
molecular regulations on how inflammation affects cellular metabolism remained unclear.  
One hypothesis is that activated inflammatory signalling pathways compete with metabolic 
signalling pathways. NF-ĸB and nuclear receptors such as PPARs are part of the family of 
primary, rapid acting transcription factors that are present in cells in an inactive state and do 
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not need to be newly synthesised for activation 104,206. This allows for a fast response to distinct 
stimuli 107. FA stimulation activated PPAR-α, and inflammatory cytokine stimulation activates 
the NF-ĸB pathway, therefore simultaneous activation of both signalling pathways might lead 
to a competition of e.g. DNA binding sites, co-activators, or co-transcription factors. Due to the 
ubiquitous presence in cells, primary and rapid acting transcription factors might interact with 
each other influencing their activation status. 
Ligand activated PPAR-α can regulate target gene transcription by direct binding to promoter 
site of target genes. Other mechanisms include binding to co-transcriptions factor that can 
activate target gene transcription or by interaction with other proteins that can induce signal 
transduction and can activate transcription factors that can then bind to target gene promoter 
sites 63. Thus PPAR-α target gene transcription can be influenced by several factors. One 
possibility is the inhibition of PPAR-α binding to promoter sites by either blocking the target 
site or by protein-protein interaction or protein complex formation. 
Based on this, I performed a protein-based complex analysis with untreated, FA stimulated 
and FA plus inflammatory cytokine stimulated cells. This protein thermal profiling demonstrated 
that inflammatory cytokines intensified FA increased stability of proteins involved in 
mitochondrial respiration and biosynthesis, proteins involved in drug metabolism and the 
regulation of cytoskeleton organization. In addition, FA-induced increased thermal stability of 
proteins was reduced by inflammatory cytokines. Cytokine treatment alone downregulated and 
destabilized proteins essential for carbohydrate metabolism, which was enhanced by 
simultaneous FA treatment, destabilizing several ribosomal proteins. However, protein 
interactions can have activating, or inhibitory functions and, thus they can be indicative for 
positive and negative downstream regulations. Proteome based-complex analysis data 
showed that there was no transcription factor interaction, however transcription factors are 
often thermally unstable. 
The specific targeting of enzymes critically involved in lipid metabolic processes was 
inconclusive and will need further detailed experimentation.  
For example, the loss of PPAR-α, induced by CRISPR-Cas mediated KO, did not affect lipid 
accumulation in FA and FA plus inflammatory cytokine stimulated cells (see in Appendix I.I). 
Interference with PPAR-α activation by additional treatment with an antagonist increased lipid 
accumulation comparable to FA and cytokine stimulated control cells. Thus, inactivation of 
PPAR-α promotes a similar lipid metabolic phenotype as induced by inflammatory cytokines. 
Thus PPAR-α activation status might be affected by inflammatory cytokine stimulation and 
interference results in downregulation of enzymes essential for FA uptake, transport, and 
importantly catabolic processes such as FAO. PPAR-α antagonization in FA and cytokine 
stimulated cells showed no additional effect, indicating that cytokine stimulation already inhibits 
PPAR-α activation and therefore simultaneous inactivation has no impact. However, PPAR-α 
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agonization did not prevent increased lipid levels in FA and inflammatory treated cells. Lipid 
levels in FA stimulated cells remained unchanged, indicating that FAs already activate PPAR-
α thus and additional agonization is non effective. This suggests that inflammation induced 
aberrant lipid storage is not regulated by PPAR-α activation (see in Appendix I.II). 
Loss of PPAR-α by si-RNA mediated KD also resulted in increased lipid levels in FA stimulated 
cells comparable to additional cytokine stimulation. FA plus inflammatory cytokine treated cells 
displayed comparable lipid levels as the control. PDK4 loss induced elevated neutral lipid 
accumulation in both FA and FA plus inflammatory cytokines indicating an additional effect. 
Omics analysis clearly demonstrated that not only genes and proteins involved in lipid 
metabolic processes are affected by inflammatory cytokines. Thus, molecular mechanisms 
that can influence the transcriptional activity of several metabolic genes in response to external 
and / or internal changes must be involved in this process, such as epigenetic regulations. 
The term epigenetics includes heritable changes in gene expression that are not mediated by 
alterations within the DNA. Changes in the environment can affect epigenetic regulations, and 
modifications 207. Main epigenetic mechanisms that regulate chromatin accessibility for 
transcription factors and RNA polymerase, and are associated with gene silencing include, 
DNA methylation, histone modification and non-coding RNAs 208,209. Inflammatory cytokines 
can influence epigenetic regulations in cancer 210. An inflammatory tumour microenvironment 
can activate NF-ĸB which then interacts with the epigenetic modifier histone deacetylase 1 
(HDAC1) to form a gene-silencing complex, affecting gene expression 211. Metabolic changes 
in cancer cells can be controlled by epigenetic mechanisms 212  
A recent study addressed the transcriptional regulation during liver regeneration, which 
demonstrated that chromatin accessibility in repopulating hepatocytes was increased in the 
regulatory regions of genes promoting proliferation and decreased in the regulatory regions of 
genes involved in metabolism 213. 
Thus, the hypothesis is that inflammatory cytokines might regulate gene expression in 
hepatocytes through epigenetic mechanisms.  
Based on this, I performed epigenetic experiments to investigate the influence of inflammatory 
cytokines on chromatin accessibility by H3K27ac-ChiPSeq analysis and ATAC-sequencing 
(data not shown). These experiments are ongoing and will pave the way whether epigenetic 
regulatory mechanisms are key to alter hepatocyte metabolism upon dyslipedemia and 
inflammation. 
In summary, I observed that hepatocytes take up FAs and primarily store them in form of TGs 
in LDs, and at the same time FAs are used as energy source by FAO. FA stimulation induced 
upregulation of genes and proteins that are involved in lipid metabolic processes and 
proliferation. This showed that FA treatment results in ongoing lipid metabolic processes. 
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In contrast, inflammatory cytokine treatment intensified FA storage by decreasing FA catabolic 
processes such as FAO, which exacerbated intracellular LD accumulation. Increased lipid 
accumulation induced lipotoxicity and mitochondrial dysfunction via direct and indirect effects 
of oxidative stress. The treatment of hepatocytes with inflammatory cytokines activated 
inflammatory - stress response (NF-ĸB signalling), induced cell death, compensatory 
proliferation, and replication stress and DNA damage and can thereby promote pathogenesis.  
The most critical finding was that the exposure to inflammatory cytokines alone and in 
combination with FAs downregulated the expression of genes involved in several metabolic 
processes, not specific for FA metabolism. Thus, to further study the effect of inflammation on 
transcriptional dysregulation in hepatocytes and to understanding the transcriptional control of 
metabolic genes will help to find possible treatment options for NAFLD / NASH. 
 
Figure 37: Illustration of molecular mechanisms contributing to NASH development 
(I) FA stimulation leads to the activation of PPAR-α, and transcription of genes involved in FA- uptake, transport, 
storage, and oxidation, and induces a steatotic phenotype (LD accumulation, yellow circles) in hepatocytes. (II) 
Additional inflammatory cytokine stimulation activates NF-ĸB signalling and downregulates genes essential for lipid 
metabolic processes and overall cellular metabolism. FA stimulation in combination with inflammatory cytokines 
induce exacerbated LD accumulation and hepatocyte changes and (III) promotes lipotoxicity which is associated 
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I.I. Inflammation induced increased lipid storage is independent of PPAR-α  
To address the role of PPAR-α during inflammation-triggered aberrant FA metabolism CRISPR 
Cas-mediated HepaRG NTC and PPAR-α KO cells were generated. 
FA treatment induced lipid storage which was further increased by additional cytokine 
stimulation in NTC and in PPAR-α KO cells (Figure IA), showing that increased lipid storage 
induced by inflammatory cytokines was independent on PPAR-α presence. Gene expression 
analysis showed reduced PPAR-α levels in PPAR-α KO cells when compared to NTC 
dHepaRG (Figure IB). However, PDK4 expression levels in PPAR-α KO cells were similar 
when compared to NTC dHepaRG (Figure IC). This indicates that reduced PPAR-α levels 
sufficed to induce PDK4 target gene transcription, or that PDK4 transcription was independent 
on PPAR-α. 
 
Figure I: Fatty acid storage into neutral lipids in hepatocytes (dHepaRG non-targeting control 
and PPARA knock out), LipidTOX green / Hoechst staining CRISPR Cas-mediated non-targeting control 
(NTC) and PPARA knock out (KO) dHepaRG cells, untreated (CTRL), treated FAs, and treated with FAs together 
with inflammatory cytokines for 24h. (A) neutral lipid stain by LipidTOX Green analysed by flow cytometry (B, C) 
Gene expression analysis by RT-PCR. Statistical analysis was performed by one-way ANOVA. *: p < 0.05; **: p < 
0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
I.II. Inflammation driven aberrant lipid accumulation is not regulated by PPAR-α activation 
To further study the role of PPAR-α on inflammation driven metabolic alterations, dHepaRG 
were exposed to the PPAR-α antagonist, GW-6471, and the PPAR-α agonist, WY-14643. 
Inflammatory cytokine exposure intensified lipid accumulation in NTC cells as well as in cells 
that were additionally exposed to the PPAR-α agonist, WY-14643 (Figure IIA). PPAR-α 
antagonization led to elevated lipid levels in FA stimulated cells, however, FA storage in 
cytokine stimulated cells was not affected (Figure IIB), showing that the increased lipid storage 
in FA stimulated cells is an additional, independent effect. These results show that 





Figure II: Fatty acid storage into neutral lipids in hepatocytes (dHepaRG), LipidTOXgreen 
staining 
dHepaRG cells, untreated (CTRL), FA treated, treated with FAs in combination with cytokines for 24h, in absence 
and presence of (A) PPARA agonist WY-14643 and (B) PPARA antagonist GW-6471. Lipid accumulation was 
quantified by LipidTOX Green staining and flow cytometry. Statistical analysis was performed by one-way ANOVA. 
*: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.001; ns: not significant. 
 
